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ABSTRACT
The present investigations were primarily aimed at defining the 
detoxicating capacity of the placenta, and then to a more general study 
of steroid and fatty acid metabolism. Concomitant studies were undertaken 
with foetal and maternal liver, plus certain other steroidogenic organs. 
Cytochrome P-450 was demonstrated both in the mitochondrial and micro­
somal fractions of human and rabbit placentae, but associated only with 
the microsomes in rat placenta. Evidence for rat and ferret testicular 
cytochrome P-450 has been presented. The placental CO-binding pigment 
responded similarly to that of maternal liver with regard to storage, 
deoxycholate treatment and the capacity of the reduced pigment to bind 
metyrapone. It did not prove possible to elicit binding spectra with 
various endogenous and foreign substrates normally metabolized by the 
hepatic microsomal mixed function oxidase system. Whereas enzyme inducing 
agents elevated foetal and maternal hepatic cytochrome P-450, they did 
not significantly alter such levels in the placenta.
The ability of placentae from humans, rats, rabbits and pigs to 
metabolize a variety of anutrients, including hydroxylation of biphenyl, 
benzo[a]pyrene and zoxazolamine, N-demethylation of ethylmorphine and 
p-chloro-N-methylaniline, O-demethylation of £-nitroanisole, reduction 
of p-nitrobenzoic acid, hydrolysis of phenolphthalein glucuronide and 
conjugation of 4-methylumbelliferone, was examined. This activity was 
either not detectable or present at a rate no greater than 301 of that 
maternal liver (excluding g-glucuronidase activity). Foetal liver and 
certain steroidogenic organs studied exhibited comparable drug-metabolizing 
activity to that of placenta. The routes of detoxication in the placenta 
were usually distinct from those of maternal liver, and were not mediated 
through cytochrome P-450. Pretreatment of pregnant animals with enzyme 
inducing agents resulted in a proliferation of endoplasmic reticulum 
and drug-metabolizing activity of the maternal liver, but in the placenta 
the response was comparatively very small. The detoxicating capacity 
of the maternal liver did I not appear markedly reduced during pregnancy.
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Unlike placentae of rats and rabbits, those of humans and pigs 
demonstrated a steroid ring-A aromatizing system involved in oestrogen 
biosynthesis. In the human placenta, the activity was largely associated 
■with the microsomes. Nicotinamide was required in the homogenizing media 
for optimal activity, and in certain cases there was a need for Mg .
The multienzyme complex proved resistant to solubilization by treatment 
with deoxycholate, Triton WR-1339, papain, lipase and sonication. No 
inhibition of activity was observed in the presence of up to 90i CO with 
O2 maintained at 5%. The studies strongly indicated that the steroid ring- 
A aromatizating system studied in the placenta was not mediated by a 
cytochrome P-450 mixed function oxidase system. Incubations in the 
presence of a variety of steroids, fatty acids and xenobiotics characterized 
the enzymes involved.
The placentae of rats, rabbits and humans were found not.to 
w-hydroxylate lauric acid, unlike the enzyme system of liver which is 
capable of oxygenating drugs and steroids also.
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A. INTRODUCTION
Among all the membrane systems of the body the placenta is unique.
It separates two distinct individuals with differing genetic compositions, 
physiological responses and sensitivities to drugs. Our understanding 
of certain aspects of the placenta including its morphology and mechanism 
of transfer is well documented, as is the increasing awareness of the 
endocrinologist to the important elaboration of steroid hormones which 
take place in this organ. However, until quite recently, the pharmacologist 
considered the placenta to be a relatively inert organ - important primarily 
as a somewhat inefficient distribution barrier for drugs with high molecular 
weight, or low partition coefficients or both.
Over the past five years, interest in the placenta as a drug-metabolizing 
organ has greatly increased. It has long been known that the placenta 
is an extremely important organ with respect to normal foetal development 
and which is also capable of catalyzing a large variety of reactions 
involving endogenous substrates. It was reasoned that the same, or similar 
biochemical systems might also catalyze drug biotransformations. Indeed, 
the cytochrome P-450 mediated monooxygenase system of the liver has been 
shown to catalyze the hydroxylation of drugs, steroids and fatty acids.
The presence of drug-metabolizing enzymes in the placenta could therefore 
have important pharmacological and toxicological implications for the 
foetus, neonate and pregnant female. _
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B. THE PLACENTA
i) Biochemical functions.
The basic role of the placenta is to bring the maternal and foetal 
circulations into close proximity to permit effective exchange of naturally 
occurring materials. In addition to its transport activity, the placenta 
shares many hepatic functions during the greater part of gestation. The 
existence of these metabolic functions was forshadowed by the discovery 
of glycogen in the placenta by Claude Bernard. He inferred from his 
discovery that the organ may be associated with carbohydrate metabolism 
in the foetus. Subsequent investigations have shown this to be the case; 
the human placenta behaves as a liver for the developing embryo until 
about the 10th to 12th week of gestation, secreting glucose and otherwise 
controlling its concentration in the embryonic blood stream (Villee, 1953).
It is suspected, though there is little available evidence, that the placenta 
may also serve as a metabolic organ in lipid (Biezenski, 1969, 1970;
Biezenski et al, 1971) and protein (Friesen, 1968) metabolism for the 
developing foetus. This led Claude Bernard to term the organ the auxiliary 
foetal liver. Later in pregnancy, as the true foetal liver becomes more 
competent, these metabolic functions are apparently largely relinquished.
The placenta is also of major importance in steroid transformation 
and is second only; to the adrenal glands in this capacity. It is involved 
in the biosynthesis, degradation and conjugation of hormones. It has long 
been established that the placenta is a source of chorionic gonadotrophins 
and also of progesterone and oestrogens (Williams, 1963). The foetus and 
placenta complement one another as a coordinated endocrine organ, elaborating 
most biologically hctive steroids (Diczfalusy, 1964). ,
When Hagerman (1964, 1969) reviewed the enzymology of the placenta, 
it was apparent that almost eveiy class of animal enzyme was present, 
including those found in most metabolic pathways, with the exception of 
the urea cycle. For historical and technical reasons, hydrolytic enzymes 
have been examined in greatest detail with oxidation-reduction systems second 
in order. Group-transferring enzymes, the carbon-carbon bond-forming and -breaking 
enzymes, have received much less attention. No enzymes which function specifically 
in substrate transport by the placenta are recognised. Of particular note is 
the large number of steroid-metabolizing enzymes, as predicted from the 
known functions of the placenta. The placenta appears, therefore, to be an
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organ of very generalized metabolic capabilities, sharing the functions 
of liver, kidney and lung.
ii) Types of placentation
Placentae may be classified according to general shape and intimacy 
of fusion between foetal and maternal tissues (Mossman, 1937).
Fig. 1.1 Placental Types (after Young, 1956)
Maternal uterine 
mucous membrane Foetal chorion
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Examples
Epithelio-chorial + + + + + + + + Horse, pig, donkey
Syndesmo- chorial + + + - + + + + Cow, sheep, goat
Endothelio-chorial + + - - + + + + Dog, cat
Haemo-chorial + - - - + + + + Primates, some rodents
Haemo-endothelial + + + Some rodents and 
rabbits
Human placentation is referred to as haemo-chorial, while that of higher 
rodents is termed haemo-endothelial. The latter is the nearest approach 
to actual intermingling of the blood of the two circulations in which 
chorionic villi reduce to bare blood vessels whose endothelial walls alone 
separate the foetal blood from the maternal sinuses (Fig. 1.2). As the 
physical barrier between the two systems is reduced so the efficiency of
5
the transmission increases but later in pregnancy this is somewhat offset 
by the degenerative changes (fibrinoid deposition, calcification, endothelial 
proliferation) which occur in some villi.
Fig. 1.2 Diagrams of the various types of placenta showing
relations between foetal and maternal tissues
Foetal
Maternal
foetaL blood
maternal
blood
A, Epithelio-chorial; B, syndesmo-chorial; C, endothelio-chorial;
D, haemo-chorial; E, haemo-endothelial. (Young, 1965)
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In addition to fundamental differences in placentation, morphological v 
changes may also occur in a single species as gestation progresses. It is not
always valid, therefore, to make inferences in one species based on 
quantitative data obtained in another. As a consequence it has been 
necessary to develop a "functional profile" for the placenta of each 
species, based on multiple physiological criteria (Page, 1957; Greene 
et al, 1965).
iii) Placental transfer of drugs
The concept of a simple semipermeable filter has been replaced by one
in which the placenta selectively controls the rates of transfer of a
wide variety of materials. It is held that any substances found in the 
maternal or foetal blood should be able to cross the placenta to some 
extent unless it is destroyed or altered during passage (Page, 1957).
A very low degree of permeability, however, may slow the entry to a rate 
which renders a drug physiologically inactive and pharmacologically 
undetectable (Moya and Kvisselgaard, 1961).
The current mechanisms accepted as significant in placental transfer 
include simple diffusion (Page, 1957), facilitated diffusion (carrier 
systems; Moya and Kvisselgaard, 1961), active transport (enzymatic; Page,
1960) and special processes (pinocytosis and membrane discontinuities;
Snoeck, 1958). The passage of most drugs is dependent on simple diffusion, 
the rate of transfer being governed by certain physicochemical factors in 
accordance with Fick’s Law of diffusion (Moya and Thorndike, 1962). In 
contrast, but few of the substances essential for foetal development cross 
the placenta by simple diffusion, since the transfer is usually against a 
concentration gradient.
As with the blood-brain barrier, the rate of entry is primarily 
governed by the lipid-solubility of the non-ionized drug molecule. Other 
factors, such as the concentration gradient and molecular weight, are 
normally of secondary importance. The gradient is a function of the 
quantity of drug administered, which in turn is affected by a) the 
distribution throughout the maternal and foetal extracellular space, 
b) binding to protein elements in plasma and tissues, c) excretion and 
metabolism by the mother, foetus and placenta, d) pathological changes
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within the placenta and e) the volume of perfusing blood. As for molecular 
weight, substances of small molecular size diffuse freely across the placenta, 
but as the size increases the factor of lipid solubility becomes more important. 
Most drugs with a molecular weight of less than 600 cross relatively 
easily, but to drugs with molecular weights over 1000 the placenta is 
virtually impermeable. Drugs having a molecular weight in the range 
of 600 to 1000 have not been studied extensively.
Present day evidence clearly demonstrates that most drugs having the 
appropriate lipid solubility and low molecular weight traverse the placenta 
and enter the foetal circulation (Moya and Smith, 1965; Ginsburg, 1971;
Asling and Way, 1971). Central nervous depressant drugs such as morphine, 
the barbiturates and general anaesthetics, when given to the mother during 
labour can enter the foetal circulation in amounts which can depress the 
breathing of the new bom child. Sulphonamides, penicillin and other 
antibiotics pass across in small amounts as also do alcohol and nicotine. 
Environmental pollutants such as pesticides (O'Leary et al, 1970; Eliason 
and Posner, 1971), rodenticides (Gibson and Becker, 1970) and food 
additives like cyclamate (Pitkin et al, 1970) are also known to traverse 
the placenta. In contrast, oestrogens conjugated as glucuronides are 
unable to penetrate the barrier (Dancis et al, 1958).
Of particular relevance to the present investigations is the trans­
placental passage of 3-methylcholanthrene (Guibert et al, 1971). When 
administered orally (1-10 mg) to mice approaching full-term, the 
carcinogen (100 ng) and ten times more of its metabolites was found in each 
foetus of the litter. The maximum concentration of 3-methylcholanthrene in 
the whole foetus was reached in 3 h. and seemed to accummulate preferentially 
in the thymus and lungs. Bresnick and Stevenson (1968) have demonstrated 
placental transfer of 3-methylcholanthrene in the rat. Long acting 
barbiturates, such as phenobarbital (also used in this study as an enzyme 
inducer), establish a plasma equilibrium within 30 min. of maternal 
administration. This is because they are weak acids existing mostly 
as fat-soluble, undissociated molecules in the physiological pH range.
C. DRUG METABOLISM
The biological fate of a drug depends on a host of factors, 
including those which determine its volume of distribution, its 
excretion into air, bile and urine, and its metabolism by various 
enzyme systems in the body. A number of foreign compounds (xenobiotics) 
closely resemble normal body substances and thus can interact with 
rather specific transport systems, carrier proteins, and enzymes. 
Analogues of purines, pyrimidines, fatty acids, steroids, amino acids, 
and biogenic amines belong to this group. In general, however, foreign 
compounds have no endogenous counterpart and are metabolized by non-­
specific enzymes and transported by either passive diffusion or 
non-specific transport systems.
Foreign compounds enter the body mostly by absorption from the 
gastrointestinal tract and are taken via the portal vein to the liver 
where they are detoxicated i.e. the pharmacological activity is 
neutralized. The detoxication products are then excreted in the bile 
to be voided in the faeces, or are taken to the kidneys and excreted 
in the urine. Secondary sites of detoxication are located in other 
tissues, such as the skin, lungs, kidneys and gastrointestinal tract 
(including the bacterial flora).
Xenobiotics are metabolized along a diversity of chemical pathways 
leading to a variety of urinary metabolites. Williams (1959) indicated 
that foreign compounds are usually converted into metabolites of ever 
increasing polarity until finally they can be readily excreted by the 
kidney. This process usually takes place in two consecutive phases 
(Fig. 1.3): (I) Polar groups are introduced into nonpolar compounds 
by oxidation, reduction and hydrolysis reactions, or alkyl groups are 
removed to uncover potential polar groups; (II) the polar group is 
conjugated with glucuronate, sulphate, glycine, acetate or methyl groups. 
Probably the majority of compounds undergo this two-phase metabolism, 
though clearly only one phase may be necessary for excretion of some 
compounds. The metabolites exhibit different volumes of distribution 
and are excreted by the kidney at different rates. Thus the relative 
amounts of metabolites in urine provide only indirect and frequently 
false estimates of their concentrations in body tissues and blood plasma.
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For this reason, many studies of drug metabolism include the isolation 
of metabolites from tissues. Even in these investigations, however, 
the relative importance and location of the enzymes operative in 
drug metabolism in different tissues are obscure because the metabolites 
may be located in tissues other than those in which they are formed.
Fig. 1.3 General pathways of drug metabolism by non-specific
enzymes m the liver
Reactions Substrate Examples Localization of Enzymes
Phase I
Oxidations
hydroxylations biphenyl
1
microsomes
dealkylations ethylmorphine microsomes
oxide formation chlorpromazine microsomes
desulphuration thiobarbital microsomes
dehalogenation halothane microsomes
alcohol oxidation alcohol soluble fraction,
microsomes (minor)
aldehyde oxidation benzaldehyde soluble fraction
Reductions
aldehyde reduction chloral hydrate soluble fraction
azoreduction p-d ime thy1aminoa zobenzene microsomes
nitroreduction p-nitrobenzoic acid microsomes, soluble 
fraction
Hydrolyses
de-esterification acetanilide microsomes, soluble 
fraction
deamination p-hydroxybenzamide microsomes, soluble 
fraction
Phase II
glucuronide
conjugation 4-methylumbe11i ferone microsomes
acetylation isoniazid mitochondria, soluble 
fraction
methylation thiouracil soluble fraction
mercapturic acid 
formation aniline soluble fraction
sulphate conjugation phenol soluble fraction
Essentially after Gillette (1971a)
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From a pharmacological point of view, phase I reactions may be 
subdivided into those which lead to biological activation, a change in 
biological activity or to inactivation. Similarly phase II reactions may 
result in either a detoxication, or by means of what is known as lethal 
synthesis, result in an intoxication. Since most drug metabolites are 
less biologically active than the parent compound, metabolism normally 
constitutes a process of detoxication.
i) Drug metabolism in the liver
The metabolism of foreign compounds may be classified according 
to whether they are catalyzed by enzymes located in the microsomes and 
those associated with other sites. The endoplasmic reticulum of the 
liver is the major site for the microsomal transformations of foreign 
compounds. In addition there are other transformations but insufficient 
is known of their mechanisms, and the location of the enzymes concerned, 
to allow for a fuller classification.
The endoplasmic reticulum of the cells of the liver and other 
tissues is a lipoprotein tubular network extending from the cell wall 
throughout the whole of the cytoplasm. The presence of localized 
areas of ribosomes divides the reticulum into two distinct types; 
namely the rough endoplasmic reticulum where ribosomes adhere to the 
tubular network, and the smooth endoplasmic reticulum which is 
devoid of ribosomes. Associated mainly with the smooth endoplasmic 
reticulum are certain enzymes called 'inixed function oxidases” which 
are concerned in the metabolism of foreign compounds, steroids and 
lipids. The enzymes are in close asssocation with the lipoprotein 
membrane of the endoplasmic reticulum. They appear to be synthesized 
in the rough reticulum, but when this becomes saturated with enzymes, 
the ribosomes appear to remove themselves leaving smooth reticulum 
(Emster and Orrenius, 1965).
The enormous versatility of the microsomal drug metabolizing 
system is less remarkable when the reactions are visualized simply as 
different kinds of hydroylation reactions (Gillette, 1966).
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Aromatic hydroxylation
[0]
CH-CO-NH-CJH,. ---- > CH--00-NH-C.H.-0H3 6 5 3 6 4
N-Dealkylation
[0]
R-NH-CH^ ---- •> [R-NH-CH20H] — > RNH2 + CH20
Deamination
[0]
R-CH(NH2)-CH3 — — > [R-C(OH)(NH2)-CH3] — > r-co-ch3 + nh3 
Sulplioxidat ion
[0]
R-S-R" ---- > R-SO-R''
18All these reactions require NADPII and oxygen, and experiments with 0?
18and H2 0 (in the hydroxylation of phenylalanine (Kaufman, 1957) and 
steroid hormones (Mason, 1957)) have shown that the oxygen introduced 
into the foreign compound is derived from molecular oxygen and not from 
water. It has been inferred that in liver microsomes, NADPH reduces 
a component which in turn reacts with molecular oxygen to form an 
’’active oxygen" intermediate. The "active oxygen" seems to be involved 
in the oxidation of a variety of substrates by a group of non-specific 
enzymes in microsomes. Gillette (1963) formulated the overall reaction 
as follows:-
i
1. NADPH + A + H+ •---> AH2 + NADP+
2. AH2 + C>2  >"active oxygen"
3. "Active oxygen" + drug  > oxidized drug + A + H20
NADPH + 02 + drug = NADP+ + H20 + oxidized drug.
where A represent the reducible component. Gillette assumed that A is 
a microsomal flavoprotein, NADPH-cytochrome c reductase, but gave no 
details on the nature of "active oxygen". Omura and Sato (1962) have 
since suggested that "A" is a haemoprotein,and as its reduced form 
combines with carbon monoxide to give a Soret peak at 450 nm, have
termed it cytochrome P-450 (Hill et al, 1970; Mannering, 1971).
Considerable evidence has now been presented for the participation of 
cytochrome P-450 in the oxygenative metabolism of fatty acids, cholesterol,
steroid hormones and haem, as well as in the metabolism of xenobiotics.
12
Since cytochrome P-450 was implicated in the oxygenation of 
xeniobiotics (Cooper et al, 1965), a wide variety of evidence ranging 
from the initial finding that cytochrome c inhibits the various 
reactions (Gillette et al, 1958) to the finding that an antibody of 
NADPH-cytochrome c reductase blocks aniline hydroxylation of liver 
microsomes (Omura, 1969) has af finned the belief that NADPH-cytochrome 
c reductase mediates the reduction of cytochrome P-450 by NADPH. The 
relative proportion of NADPH-cytochrome c reductase and cytochrome 
P-450 in liver microsomes is not 1:1, and the available information 
suggests that a molecule of reductase may serve to reduce as many as 
20 molecules of cytochrome P-450 (Estabrook and Cohen, 1969).
The current sequence of events proposed for cytochrome P-450 
mediated mixed-function oxidation reactions involves interaction of 
the drug with oxidized cytochrome P-450 to form a complex which is 
reduced either directly by NADPH-cytochrome c reductase or indirectly 
via an unidentified electron carrier. The reduced cytochrome P-450 
substrate coup lex then reacts with oxygen to form an ’’active oxygen” 
conplex, which decomposes with the formation of the oxidized drug and 
oxidized cytochrome P-450 (Gillette, 1971b). Estabrook et al (1971) 
have expanded this scheme to include cytochrome b^ as the electron 
donor to the oxygenated intermediate of the reduced cytochrome P-450 
substrate complex (Fig. 1.4). The result of this electron donation 
is to initiate a concerted reaction for the hydroxylation of substrate 
and regeneration of the ferric form of cytochrome P-450. Furthermore 
the mechanism proposed suggests that the concentration of reduced 
cytochrome bj. is limiting when there is a suboptimal supply of 
NADPH-reducing equivalents available, i.e. the partitioning of reducing 
equivalents does not saturate the second electron requiring reaction 
for cytochrome P-450 function. Under these conditions, NATH can then 
provide the necessary reducing equivalents for the obligatory second 
electron donation reaction.
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so +
3+
-NADPH
2 +
-450
CO
CO
3+ 2 +
P-450'
NADP
Fig. 1.4 Proposed scheme for drug hydroxylation by cytochrome P-450 
indicating sites of interaction of cytochrome b and various^flavoproteins 
(Estabrook £t al_, 1971) . Cytochrome P-450 is shown as P-450 (the valence 
state of the Fe of the haemoprotein is indicated), S is the drug substrate 
and SO the hydroxylated drug. The flavoprotein, NADPH-cytochrome c reductase 
is shown as fp^; the flavoprotein, NADH-cytochrome b^ _ reductase is shown as 
fp ; and X indicates an unknown carrier from cytochrome b^ _ or fp^ to 
cytochrome P-450.
The sequence of events in cholesterol side chain cleavage, and 
llg-hydroxylation of steroids in the adrenocortical mitochondria 
(Simpson and Boyd, 1967; Cooper et al, 1967) and C-21 hydroxylation 
of steroids in adrenocortical microsomes (Cooper et al, 1965;
Estabrook et al, 1963) requires NADPH reduction of cytochrome P-450 
via an electron transport chain which includes a flavoprotein as 
acceptor of electrons from NADPH (Omura et al, 1966). This flavoprotein 
has been generally assumed to be NADPH-cytochrome c reductase although 
an additional component, a non-haem iron protein, adrenodoxin, is 
required for the NADPH dependent reduction of both cytochrome c and 
cytochrome P-450 in adrenocortical mitochondria. Masters et al_ (1971) 
demonstrated, however, that NADPH-cytochrome c reductase antibody 
inhibited cytochrome P-450 reduction in bovine adrenocortical 
microsomes but not in mitochondria. Similarly, adrenodoxin antibody 
uncoupled NADPH dependent cytochrome P-450 reduction in adrenocortical 
mitochondria, but was without effect on the microsomal systems 
of liver and adrenal cortex.
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Much of the speculation regarding the components of the microsomal 
drug-metabolizing system exists because attempts to solubilize cyto­
chrome P-450 in an active form have failed. Recent studies (Lu and 
Coon, 1968; Lu et al, 1969; Strobel et al, 1970) have done much to 
solve this problem. Solubilization of hepatic microsomes with a 
mixture of dithiothreitol, glycerol and deoxycholate in potassium 
citrate buffer produced an extract which was resolved into a fraction 
containing cytochrome P-450, a fraction containing NADPH reductase and 
another containing phosphatidylcholine. All three fractions are 
necessary for the maximal oxidation of drugs (benzphetamine, aminopyrine, 
ethylmorphine, hexobarbital, norcodeine, p-nitroanisole) or for the 
u)-hydroxylation of laurate. Comparable preparations from microsomes of 
kidney cortex exhibit a low rate of drug oxidation and show differences 
in steroid substrate binding to cytochrome P-450 (Jakobsson et al, 1970).
Various substrates and inhibitors combine with the oxidized 
form of cytochrome P-450 and thereby cause small but significant 
changes in its absorbance spectrum (Schenkman et al, 1967). In 
general, two types of spectral changes are observed. Some substances, 
such as hexobarbital and ethylmorphine, cause a decrease in absorbancy 
at 420 nm and an increase at about 385 nm and are called type I 
substances. Other compounds, such as nicotinamide and aniline, 
cause an increase in absorbancy at about 430 nm and a decrease at about 
390 nm and are called type II substances. Still other substances, 
such as N-methyl-DPEA, appear to cause both type I and II spectral 
changes (Sasame and Gillette, 1969). The binding affinity (K ■ value) 
of substrate to cytochrome P-450, which is measured spectrophotometrically, 
is not comparable to the Km value (Mannering, 1971). The rate- 
controlling step in the oxidation of type I compounds is considered to 
be the rate of reduction of the cytochrome P-450-substrate complex.
Whether this is the case for type II compounds remains to be determined 
(Gillette, 1971a).
Spectral changes in the reduced cytochrome P-450 spectrum occur 
with metyrapone (Hildebrandt et al, 1969) as well as with CO (Estabrook 
et al, 1970). In the case of the former, the complex exhibits a distinct 
absorbance at 446 nm. Metyrapone may interfere with mixed function 
oxidase reactions by modifying or obstructing the site of O2 (and
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therefore CO) interaction with reduced cytochrome P-450 (Hildebrandt 
et £l, 1969). The inactive complex is not readily dissociable. Recently 
Imai and Sato (1966, 1968) suggested the existence of two forms of 
cytochrome P-450. Using ethyl isocyanide as the ligand for reduced 
cytochrome P-450, two Soret peaks at 430 nm and 455 nm were observed.
The relative size of the two peaks was pH- dependent.
The mechanism by which phenobarbital and many other drugs stimulate 
the synthesis of the microsomal drug-metabolizing system has long 
been considered to be different from the mechanism whereby polycyclic 
hydrocarbons produce their inductive effects (Mannering, 1968). Poly­
cyclic hydrocarbons are now thoughtto induce the synthesis of a 
variant of Cytochrome P-450, called P-448 (Kuntzman et_ al, 1969), P-446 
(Hildebrandt et al, 1968) or P^-450 (Mannering, 1971). Cytochrome 
P-450 and its variant exist in interconvertible forms which exhibit 
different substrate binding properties (Lu et al, 1972).
Evidence for the existence of different species of cytochrome 
P-450 is now accumulating. In addition to studies of kidney cortex 
cytochrome P-450 (Orrenius and Thor, 1969; Lu, Strobel and Coon, 1969) 
discussed previously, Jefcoate et al (1970) have separated two forms 
of adrenocortical mitochondrial cytochrome P-450. One form demonstrated 
high 113-hydroxylase activity for 11-deoxycorticosterone but low 
activity for side-chain cleavage of cholesterol, while the second 
exhibited the reverse activities. This was further supported by 
the work of Young et al (1970) and similarly two types of adrenal cytochrome 
P-450, as evidenced by metyrapone induced spectra, has been postulated 
(Sweat et al, 1970). Wada et al (1969) believe there may be a multiplicity 
of the hepatic haemoprotein, since there exists a specific form for 
7a-hydroxylation of cholesterol. Different forms of cytochrome P-450 
could be a consequence of the subcellular localization (Ichikawa et al,
1970).
The nature of hepatic nitroreduction has been the centre of much 
speculation (Fouts and Brodie, 1957; Kato, Oshima and Takanaka, 1969). 
Gillette, Kamm and Sasame (1968) have proposed an electron transport 
scheme which may explain the oxidative and reductive functions of the 
microsomal drug-metabolizing system:-
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Fig. 1.5 How the microsomal electron transfer system might
function in both the oxidation and reduction of drugs.
In a consideration of the phase II reactions, glucuronide formation 
is the major conjugating mechanism present in the liver, probably because 
of the general availability of glucose in biological systems. Condensation 
of the foreign compound with D-glucuronic acid is involved (Dutton, 1966; 
Parke, 1968), the latter reacting as uridine diphosphate glucuronic acid 
(UDPGA) which is formed from UDP-Glucose as shown below. The C-l atom 
of glucuronic acid is present in the a configuration but with drugs forms 
a glucuronide with a 3-configuration. All glucuronides have a free 
carboxyl group.
pyrophorylase
Glucose-1-phosphate + DTP ----  > UDP-glucose + pyrophosphate (PpOy )
UDPG-dehydrogenase
(soluble) +
UDP-glucose + 2NAD + H^O ------------- > UDP-glucuronic acid + 2NADII + 211
UDP-glucuronyl transferase 
(microsomal)
UDP-glucuronic acid + RZH -------:----- > RZ - glucuronic acid + UDP.
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where Z is 0, CO, NH or S.
COOH
CH COOH
CH.O-P-O-P'
OH
ethylumbelliferone UDPGA 4-methylumbelliferone
glucuronide
ii) Factors affecting drug metabolism
To innumerate in detail all the factors influencing drug metabolism 
(Parke, 1968, 1972; Gillette, 1971a) is beyond the scope of this survey.
Let it suffice that species (Williams, 1971), genetic factors and strain 
differences (Parke, 1968), age (Basu, Dickerson and Parke, 1971), nutrition 
(Adlard et al, 1969), sex (Kato and Gillette, 1965), hormones (Conney and 
Garren, 1961), pregnancy (Neale, 1970), foreign compounds (Conney, 1967;
Anders, 1971), and stress (Parke, 1968) may all either enhance or inhibit 
drug metabolism.
a) Endogenous steroids and oral contraceptives.
Since drugs and steroids appear to be alternative substrates 
for the same hepatic microsomal mixed-function oxygenase system, 
they may show competitive inhibition in vitro, and within a short 
period after administration in vivo. Endogenous steroids such as 
cortisol, progesterone, testosterone, androsterone and oestradiol-173 
have indeed been shown to competitively inhibit the in vitro 
hydroxylation of hexobarbital and N-demethylation of ethylmorphine
i  “
(Tephly and Mannering, 1968).
Inhibition of the in vitro para-hydroxylation of biphenyl and 
demethylation of 4-methoxybiphenyl occurred in the presence of contraceptive 
steroids (progesterone, norethynodrel, norethisterone, ethynodiol 
acetate) at 10 ^-10 %. Far lower concentrations of norethynodrel and 
progesterone inhibited side-chain hydroxylation of hexobarbital and
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aromatic-ring hydroxylation of zoxazolamine (Juchau and Fouts, 1966). 
Reduction of £-nitrobenzoate was largely unaffected by either agent. 
Subcutaneous administration for 10 days with either oestradiol-178, 
diethylstilbestrol, chlorotrianisene or clomiphene citrate was reported 
to reduce the in vitro N-demethylation of p-chloro-N-methylaniline 
by up to 40% in the liver of male rats (Fahim, Hall and Jones, 1971).
In contrast, whereas oestradiol-173 and stilbestrol reducedthe activity 
in female rat livers, chlorotrianisene and clomiphene citrate 
(derivatives of diethylstilbestrol ) increased dealkylation by about 
401. Similarly, the pretreatment with medroxyprogesterone alone or 
combined with ethynylestradiol increase! the in vitro 0-demethylation 
of £-nitroanisole (Jori et al, 1969). The prolonged treatment of 
rats (18 days) with mestranol plus ethynodiol diacetate produced a 
significant increase in the aromatic hydroxylation of biphenyl (30%), 
which was not shown by the same dosage of either steroid administered 
alone. No stimulation of cytochrome P-450 levels or glucuronyl 
transferase activity was found (Neale, 1970).
Contraceptive steroids appear therefore to be acceptable 
substrates for hepatic microsomal drug-metabolizing enzymes, and 
give rise to a modest inhibition in. vitro, and to variable extents 
of induction of such enzymic activities in vivo; on prolonged treatment 
this finally returns to approximately normal levels (Parke, 1972).
b) Pregnancy
During pregnancy there is a considerable increase in the formation 
of circulating hormones, particularly progestogens and oestrogens. Since 
these steroid hormones may be metabolized by the same hepatic microsomal 
enzymes which metabolize drugs it is possible that they may also 
competitively inhibit the metabolism of drugs. The diminished . 
conjugation with glucuronic acid observed during pregnancy (Cessi,
1952; Hsia et al, 1960) may be due to the elevated levels of progesterone 
and pregnanediol (Creaven and Parke, 1965) which are known inhibitors 
of UDP-glucuronyl transferase activity (Hsia, et al, 1963). Oral 
contraceptives may also behave as inhibitors (Hargreaves et al, 1971). 
Neale and Parke (1969) showed that full-term pregnant rats exhibited 
reductions of 30-50% in the concentration of liver microsomal protein 
and cytochrome P-450, and in the specific activities of biphenyl-4- 
hydroxylase and 4-methylumbelliferone UDP-glucuronyl trans.ferase.
However, due to liver enlargement these deficiencies were fully
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compensated for, and the total drug-metabolizing capacity may 
marginally have exceeded that of the non-pregnant animal. In the 
pregnant rabbit where little increase in liver size was observed, 
there was no change in microsomal protein or cytochrome P-450. 
Biphenyl-4-hydroxylase activity was unaffected but UDP-glucuronyl 
transferase activity was decreased by some 20% and coumarin-’7- 
hydroxylase activity was inhibited by up to 70%. Guarino et al
(1969) demonstrated that although the K for ethylmoxphine N^demethylation 
was unaltered at day 20 of pregnancy in the rat liver, the Vmax 
was significantly reduced, possibly due to a decrease in enzyme 
concentration.
c) Age
The increased sentivity of the foetus and new bom to the effects 
of drugs is well documented (Catz and Yaffe, 1967; Yeary et al, 1966).
The longer duration of action and the greater toxicity of drugs in 
the foetus and the newborn are mainly attributed to an apparent 
absence or low activity of the drug-metabolizing enzymes in the 
liver (Jondorf et al, 1959; Fouts and Hart, 1965; Parke, 1968).
Negligible hydroxylation or reduction of xenobiotics was reported to 
occur in the liver of newborn rabbits, but some activity appeared after 
14 days, and full adult activity at 28 days (Fouts. and Adamson, 1959).
In accord with the developmental pattern shown by Kato et al (1964),
Basu, Dickerson and Parke (1971) demonstrated rat liver biphenyl-2- 
hydroxylase activity reached a peak at 21 days, biphenyl-4-hydroxylase 
activity and 4-methylumbelliferone UDP-glucuronyl transferase at 
24 days, cytochrome P-450 levels at 31 days and p-nitrobenzoate 
reductase at 38 days of age. Activity then decreased with age, 
biphenyl-2-hydroxylase activity falling to a negligible level after 
52 days. The overall pattern suggests drug-metabolizing activity, 
comparable to that of adult levels, is attained after 4-6 weeks after 
birth (Flint et al, 1964; Krasner, 1968; Sims and Grover, 1967; Short 
and Davis, 1970; Henderson, 1971; Bhatnagar, 1971).
Gram et al (1969) showed that the activities and values of 
aniline hydroxylase and ethylmorphine N-demethylase of rat liver 
increased during the first few weeks after birth, but there was no 
correlation between the activities of the two enzymes, nor between 
either of these and the hepatic cytochrome P-450 content. Enzyme
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induction in immature animals has been reported following 3- 
methylcholanthrene (Conney. et al, 1960), benzo[a]pyrene (Inscoe 
and Axelrod, 1960), phenobarbital (Hart et al, 1962) and chlordane 
(Fouts.and Hart, 1965) treatment. Darby (1971) produced changes 
in drug-metabolizing activity of the livers of suckling rats as a 
result of treating lactating mothers with phenobarbital and 
chlorpromazine.
Foetal drug metabolism is correspondingly low or undetectable 
(Pelkonen et al, 1969, 1971a, b; Dixon and Willson, 1968; Hart et al, 
1962; Creaven and Parke,1965; Short and Davis, 1970; Dutton, 1966).
The foetus exhibited negligible benzo[a]pyrene hydroxylase activity 
(Yaffe et al, 1970; Mirkin, 1970), but oral administration (40 mg/kg) 
of the polycyclic hydrocarbon to rats 13-18 days pregnant stimulated 
enzymic activity within 24 h. Induction appeared to be under control 
of progressive foetal development (Schlede and Merker, 1972). Dixon 
and Willson (1968) demonstrated that hexobarbital and zoxazolamine 
metabolism by rabbit foetal liver was unaffected by phenobarbital 
pretreatment, though chlordane stimulated the latter activity. In 
contrast, Hart et al (1962) demonstrated that hexobarbital and 
aminopyrine metabolism in rabbit foetal liver could be stimulated 
by phenobarbital pretreatment, but only on the day prior to parturition.
The decrease in 3“glucuronidase activity in foetal mouse liver 
is reported to be accompanied by an increase in glucuronidation 
towards full-term (Lewy and Conchie, 1966). At birth glucuronide 
formation remained, however, very low mainly due to deficiencies in UDP- 
glucuronyl transferase, UDPG-dehydrogenase and UDPGA. No natural 
inhibitors of foetal liver glucuronide formation are known. Since 
the composition of the endoplasmic reticulum varies with growth, then 
so may the accessibility of the substrate to the microsomal transferase. 
As a consequence of certain factors causing inadequate conjugation of 
bilirubin and chloramphenicol, toxic levels of these substrates may 
accumulate leading to kemicterus and "Gray Baby" syndrome respectively.
Opinions differ as to the cause of low drug-metabolizing activity 
in the foetus and neonate. Fouts and Hart (1965) considered it due to 
a lack of stimulus to the enzyme-forming systems. It has been 
demonstrated, however, that newborn rabbits contain a material Which 
inhibits the metabolism of amphetamine, hexobarbital, aminopyrine and 
acetanilid (Fouts and Adamson, 1959). More recently Feuer and Liscio
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(1970) suggested that the depression of the hydroxyl ation of 4-methyl- 
coumarin in rat foetal and neonatal liver was caused through an 
interference by substances formed by the mother.
iii) Placental drug metabolism
The unique role of the placenta in the maintenance of normal foetal 
development poses many pharmacological and toxicological questions 
pertaining to the actions and interactions of exogenously administered 
drugs and chemicals upon the multiple functions of this organ. Only 
recently has interest developed with regard to the possible significance 
of the biotransformation of drugs and foreign compounds in placental 
tissues (Juchau and Yaffe, 1969; Mirkin, 1970; Juchau, 1972).
Electron microscopy of placental tissue has demonstrated significant 
quantities of smooth endoplasmic reticulum in trophoblastic cells (Strauss 
et al, 1965). The principal CO-binding pigment of placentae is present 
in both microsomes and mitochondria and has been identified as cytochrome 
P-450, resembling that associated with the hepatic microsomal drug-metabolizing 
enzymes (Meigs and Ryan, 1968). The mitochrondrial haemoprotein most 
probably participates in side-chain cleavage of cholesterol. Billiar 
and Little (1969) isolated a human placental mitochrondrial fraction which 
supported steroid 113-hydroxylation in the presence of bovine adrenal 
"mitochondrial’1 particles. No acid-labile sulphur or nonhaem iron was 
present in the placental extract, which chromatographically was similar to 
adrenodoxin.
The appearance of cytochrome P-450 in placental tissue may. follow 
an ontogenic pattern paralleling that of the developing liver, since it 
was not detectable in human placentae obtained between the ninth and 
twelfth weeks of gestation (Juchau, Niswander and Yaffe, 1968).
The presence of cytochrome P-450 is only indicative of a potential 
capacity for the biological oxygenation of foreign conpounds. Drugs are 
considered to be metabolized by oxidation, reduction, hydrolysis and 
conjugation processes, and the extents of these aspects of drug metabolism 
occurring in the placenta will now be considered, 
a) Oxidation
These reactions involve mixed function oxidase and dehydrogenase 
enzymes. Of the latter, only NAD-dependent alcohol dehydrogenase has 
been shown to accept a xenobiotic substrate. Conflicting results have 
been reported for placental catalysis of mixed function oxidation of
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foreign compounds. These discrepancies may possibly be explained 
in terns of species differences, or gestational age, or both.
Homogenates of human placental tissue from 9 to 12 weeks of gestation 
exhibited minimal oxidative deamination of 1-amphetamine, N-demethylation 
of aminopyrine, para-hydroxylation of aniline, O-demethylation of codeine, 
sulphoxidation of chlorpromazine, side-chain oxidation of hexobarbital, 
hydroxylation of benzo [a]pyrene and zoxazolamine (Juchau, Niswander 
and Yaffe, 1968). In rabbits at 2 weeks of gestation, Dixon and Willson 
(1968) observed significant levels of hexobarbital metabolism following 
pretreatment of animals with chlordane. Zoxazolamine was metabolized 
at several gestational periods, though activity declined towards 
full-teim; zoxazolamine oxidation by 9,000g.av. supernatants of 
placentae occurred at week 2 of gestation, and represented 20% of 
that observed in the maternal liver at the same period. Chlordane 
pretreatment enhanced zoxazolamine metabolism whereas phenobarbital 
was without effect.
Bertd' et al (1969) reported catalysis of aminopyrine N-demethylation 
in rabbit placental 9,000g.av. supernatant fractions at days 14 and 30 
of gestation. The activity increased following phenobarbital treatment 
and was higher at day i4 than at day 30. N-Demethylation of amino­
pyrine was not detectable with human placental homogenates at 9-12 
weeks and at full-term (Juchau, Niswander and Yaffe, 1968; Van Petten 
et al, 1968). Fahim et al (1970) reported placental N-demethylation 
of p^chloro-N-methylaniline which could be stimulated following prolonged 
phenobarbital administration. Pelkonen et al (1971b) demonstrated 
low N-demethylase activity for p-methylani 1 ine in human placentae 
from early pregnancy. Meperidine was slowly metabolized by full-term 
human placentae, but by an alternative route to N-demethylation (Van 
Petten et al, 1968). No measurable N-demethylation of 3-methyl-4- 
monomethylaminoazobenzene was observed in human placentae that were 
obtained after birth from non-cigarette smoking mothers, but was 
readily apparent in those of subjects with histories of regular 
cigarette smoking (Welch et al, 1969).
Strychnine was oxidized nt low levels in rat and rabbit placental 
homogenates following pretreatment of animals with phenobarbital 
(Pecile et al, 1969). Van Petten et al (1968) reported rapid oxidative 
metabolism of pentobarbital and amphetamine in 9,000g.av. supernatant
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fractions of human placentae at full-term. Other investigators 
(Pelkonen et al, 1971b; Dixon and Willson, 1968; Hagerman, 1969; Hebb 
and Ratkovic, 1962), however, have reported negative results with 
respect to drug oxygenation in the human placenta.
Juchau and Symms (1972) investigated the mechanism of aniline 
para-hydroxylation in the human placenta. Comparisons of a model 
tissue free-system with that of the soluble fraction of human 
placenta indicated that haemoglobin was a principal factor responsible 
for the observed catalysis. The complete model system necessary 
for oxidation included an electron donor, such as NADPH or NADH, a 
suitable haemoprotein, molecular 0^  and the substrate. The study 
suggested placental trophoblasts per se were either devoid of, or 
extremely low in, aniline para-hydroxylating activity.
Aromatic hydroxylase activity was studied by Creaven and Parke 
(1965) who reported no oxidative metabolism of coumarin and biphenyl by 
foetal or placental tissue preparations. The metabolism of benzo[a]pyrene 
in the liver to a variety of hydroxylated metabolites (Chapter 2) has 
been well documented (Gelboin and Wiebel, 1971; Nebert and Bausserman, 1971; 
Gelboin, 1971; Nebert et al, 1972). Benzo [a] pyrene hydroxylase (also 
known as aiyl hydrocarbon hydroxylase) activity has been expressed in 
terms of the major metabolite formed i.e. the 3-hydroxy derivative.
The presence of polycyclic hydrocarbons in cigarette smoke is reported 
to induce human placental benzo[a]pyrene hydroxylase activity (Welch 
et al, 1968, 1969; Nebert, Winkler and Gelboin, 1969; Conney et al,
1971). Little or no aromatic hydroxylation occurred in human placentae 
obtained after childbirth from non-smokers, but this enzymic activity 
was found in placentae obtained from women who smoked 10-40 cigarettes 
a day. In individuals all smoking the same number of cigarettes, 
placental benzo [a]pyrene hydroxylase activity varied 25 fold. The 
variability of the induction of benzo[a]pyrene hydroxylase in some 
people exposed to polycyclic hydrocarbons is of interest since it 
may reflect an increased carcinogenic risk in those individuals with 
poor response. Whereas cigarette smoking enhanced the in vivo metabolism 
of nicotine in man (Beckett and Triggs, 1967), it was without effect 
on the human placentai enzyme system which catalyses the aromatization 
of the ring-A of steroid hormones (Conney.et al, 1971).
Oral dosing (20 mg/kg) with a variety of polycyclic aromatic 
hydrocarbons induced rat placental benzo [a ]pyrene hydroxylase activity
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particularly when 1,2-benzanthracene was the inducing agent (Conney 
et al, 1971). Schlede and Merker (1972) studied benzo [a]pyrene 
induction from the 13th day to the 18th day of gestation. Maximal 
benzo[a]pyrene hydroxylase activity could not be achieved before 
day 15 of pregnancy; electron micrographs demonstrated a swelling and 
enlargement of the endoplasmic reticulum within the trophoblast cells.
Juchau, Niswander and Yaffe (1968) did not detect benzo [a] pyrene 
hydroxylation in the placenta at 9-12 weeks of gestation, whereas 
Pelkonen et al,(1971b) found minimal hydroxylase activity during 
early pregnancy when the foetal weight ranged from 7 to 600 g. At 
8-10 weeks of gestation, the levels of benzo[a]pyrene hydroxylase 
activity in homogenates (l,000g.av. x 10 min. pellet resuspended) of 
human placentae or foetal livers was undetectable regardless of 
maternal smoking habits (Juchau, 1971). At 11-13 weeks of gestation, 
very low levels of hydroxylase activity were observed in placentae of 
cigarette-smoking mothers, and slightly higher levels were apparent 
in placentae of smokers at 14-16 weeks of gestation. Steroids 
synthesized by human placenta i.e. oestradiol-173, oestrone and 
progesterone, markedly inhibited the placental hydroxylation of 
benzo[a]pyrene. Cholesterol, dehydroepiandrosterone, testosterone, and 
androstenedione, which serve as substrates for other placental mixed 
function oxidase systems, however, exhibited comparatively minor 
inhibitory effects.
High concentrations of NADPH are required to saturate the
placental benzo[a]pyrene hydroxylase system an observation which
correlated with the K values with respect to NADPH (Human = 8.2 x 10 M^,
Rat = 3.4 x 10 Tf) found with these tissues. The high V values - max
(Human = 132 units, Rat = 50.5 units of activity) observed in human
placental preparations, compared with rat placental preparations,
suggested that the human enzyme was capable of metabolizing larger
amounts of benzo [a ]pyrene in the presence of very high NADPH and/or
benzo [ajpyrene concentrations. Concentrations of NADPH in vivo,
however, might be expected to limit the actual turnover rate. The
K (1.3 x 10 M^) and V (2850 units of activity) of the maternal m v max v
liver enzyme was indicative of the greater substrate affinity and 
turnover rate. Although some differences between human and rat 
placental benzo[a] pyrene hydroxylases were observed, the similarities 
appeared to be more striking. The systems were alike in respect to
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their K^’s, the effect of inhibitors (CO and steroids), sub- 
cellular localization, pH optima and apparent inducibility.
In the consideration of placental drug metabolism, 
cigarette smoking is now thought to possibly produce teratogenic 
effects (Fedrick et al, 1971). It may also produce low weight 
placentae and foetuses, and increase the risk of spontaneous 
abortion (Kullander and Kallen, 1971; Yerushalmy, 1971, 1972;
! Mulcahy et al, 1970). The position is complicated by the 
presence of CO in cigarette smoke, which avidly binds to haemoglobin, 
and may therefore cause hypoxia of the foetus (Longo, 1970;
Lawther and Commis, 1970). CO is also produced by the placenta 
in the breakdown of haem (Drabkin, 1970).
b) Reduction
Reduction of a wide variety of substrates has been shown to 
occur in the presence of placental subcellular fractions 
(Van Petten et al, 1968; Juchau, 1969; Juchau, Krasner and 
Yaffe, 1968, 1970; Juchau, Niswander and Yaffe, 1968; Juchau 
and Yaffe, 1967; Pelkonen et al, 1971b). Transfer of reducing 
equivalents from NADH or NADPH to one-electron (potassium 
ferricyanide and cytochrome c), two-electron (2,6-dichloro- 
phenolindophenol), four electron (neoprontosil), and six-electron 
(p-nitrobenzoic acid) acceptor molecules were accelerated in 
the presence of human placental soluble fractions. Generation 
of the initial electron donor was important since each of the 
reactions described proceed spontaneously, albeit slowly.
Placental homogenates contain relatively high concentrations 
of substrates for enzymes of the hexose monophosphate shunt 
pathway such that, by virtue of a highly active placental path­
way, comparatively large quantities of NADPH can be generated 
or regenerated during the course of incubation. Van Petten 
et al (1968) found it necessary, however, to supplement 
placental preparations with rat liver 105,000 g.av. supernatant 
to compensate for a reported deficiency in glucose-6-phosphate 
dehydrogenase activity (Ginsberg and Jeacock, 1964).
Reduction of p-nitrobenzoic acid is reported to proceed 
via both enzymic and non-enzymic pathways, involving NADPH- 
and NADH-generating systems, non-enzymic reduction of flavins
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by either agent, and non-enzymic reduction of the aromatic nitro 
group by a reduced flavin (Juchau, 1969). Anaerobic conditions 
were required to prevent rapid reoxidation of reduced flavins 
and/or reduced intermediates, and the reaction was markedly 
inhibited by C>2 and CO. Whole homogenate was required for the 
non-enzymic reduction of the flavins and a protein bound, heat- 
stable intermediate appeared essential for the reaction. The 
unknown component was not extractable with organic solvents and 
possessed a molecular weight of 60,000-80,000 (Juchau, 1972).
It was not associated with any particular subcellular fraction. 
Placental nitroreduction was not affected by phenobarbital or
3-methylcholanthrene pretreatment.
The essential conponents of a model nitroreductase system 
(Juchau, Krasner and Yaffe, 1970) included NADPH or NADH as 
initial electron donors, a flavin (FAD, FMN or riboflavin), a 
sulphydryl donor (e.g. GSH or cysteine), and a salt to provide 
optimal ionic strength. Variations of the conponents of this 
system increased the reaction rate to only one tenth that 
observed in the presence of boiled, dialyzed human placental 
or rat hepatic 104,000 g.av. supernatant fractions. It was 
apparent that differing mechanisms of electron transport from 
NADPH or NADH to ]3-nitrobenzoic acid existed for liver and 
placenta as well as for homogenate subfractions of a given tissue.
In human placental soluble fraction, the carrier (or 
carrier system) appeared to be heat stable, non-dialyzable and
00-sensitive. The system in rat hepatic soluble fraction/however, 
appeared considerably more complex. Liver homogenates readily 
catalyzed the reaction in the absence of added flavins. Additions 
of added flavins markedly stimulated the reaction in non-dialyzed 
preparations but profoundly inhibited in dialyzed fractions 
(in concentrations which inhibited the model system and that of 
the placental soluble fraction) . This may have indicated the 
presence of a dialyzable factor in rat liver supernatant which 
was activated by flavins. The reaction in hepatic soluble 
fractions was inhibited (approx. 501) by boiling, indicating 
the presence of enzymic conponents. The electron transport 
mechanisms in rat placental soluble fraction also appeared
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complex, since the difference between the activity in human as 
compared with rat placental homogenates could not be explained 
solely on the basis of tissue flavin content. Adamson et al 
(1965) also concluded that species differences in hepatic 
nitroreductase activity was not due simply to variations in flavin 
content.
Oxygen bound by haemoglobin may have exerted an inhibitory 
influence on nitroreduction. The fact that boiled, homogenized 
whole blood catalyzed the reaction at a much more rapid rate 
than fresh whole blood supported this supposition. Juchau (1969) 
found that human placental homogenates from early gestations 
(8-16 weeks) catalyzed the reduction of p_-nitrobenzoic acid more 
efficiently than did full-term homogenates. The presence of a 
higher blood content in placental homogenates at full-term may 
account for this observation. Experiments with blood, however, 
indicated that the placenta possesses factors catalytic in 
nitroreduction which are independent of those found in blood.
The CD-sensitivity of human placental nitroreduction 
indicated that an interaction with an electron carrier, other 
than flavin,may occur (Juchau, Krasner and Yaffe, 1970).
c) Hydrolysis
Hydrolytic processes have been studied in some detail in 
the placenta (Hagerman, 1969). Hydrolysis of foreign compounds, 
however, have not systematically been investigated. Sulphatases 
and phosphatases appeared to catalyze hydrolysis of corresponding 
ester linkages for a variety of compounds and with high specific 
activities. For example, hydrolysis of several phenolic and 
naptholic phosphates appeared to proceed rapidly in placental 
tissues (Ahmed and King, 1960), as did hydrolysis of ^ -nitrophenol 
sulphate. Juchau (1972) reported vigorous hydrolysis of p-nitro- 
catechol sulphate by particulate fractions at several pHfs, and 
the extensive hydrolysis of procaine by placental soluble 
fractions has also been reported (Juchau and Yaffe, 1969), 
although later studies indicated that catalysis was almost entirely 
due to plasma esterases. Still other studies have shown that the 
amide link of procainamide was not hydrolyzed to any detectable 
degree by placental whole homogenates, 9,000 g. av. supernatant,
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or by microsomal fractions (Juchau, 1972). Acetylsalicylic acid 
was hydrolyzed at a slow rate in placental soluble fractions, 
but this activity was also probably due to the presence of 
plasma esterases (Juchau and Yaffe, 1969). Of pharmacological 
interest is the reported high level of placental acetylcholinesterase 
(Hagerman, 1969).
3-glucuronidase has been shown active in human placenta 
(Fishman and Anlyan, 1947; Conte, 1965) and from histochemical 
studies in the rat placenta, Bulmer (1962, 1965) concluded that 
activity declined towards full-term, there always being more 
in the foetal placenta than in the maternal placenta. Under 
physiological conditions, reversal of the hydrolytic reaction 
to form glucuronides is unlikely, though it may be achieved 
in vitro (Hagerman, 1969).
Parke (1968) suggested tissue 3-glucuronidase is probably 
not primarily concerned with the hydrolysis of xenobiotic 
glucuronides, but functions to regulate hormonal activity by 
liberating active hormones from their inactive glucuronides.
However, naphthol-3-D-glucuronide is reported to be hydrolyzed 
by a placental enzyme (Christie, 1968). Similarly, phenophthalein 
glucuronide is hydrolyzed by placental preparations of rat 
(Bernard and Odell, 1950), guinea pig (Panattori, 1956) and human 
(Starzowski and Waronski, 1959) in that order of activity.
Tissue 3-glucuronidase is considered to be localized in 
both the microsomal and lysomal subcellular fractions (Fishman 
et al, 1967). Contractor and Shane (1972) were unable, however, 
to resolve placental 3-glucuronidase activity this discreetly.
d) Conjugation
The placenta is largely deficient in its capacity for 
conjugating xenobiotics. Choline acetyltransferase has been 
reported in placentae of monkey and man (Hebb and Raikovic, 1962) 
and N-acetylation of foreign compounds has been shown to occur 
with placental preparations (Berte et al} 1969; Juchau, Niswander 
and Yaffe, 1968; Uher, 1969; Van Petten et al, 1968) . N-Acetylation 
is associated with the placental soluble fraction (Juchau and 
Yaffe, 1969). Using trophoblastic tissue culture, Uher (1969)
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showed that a higher ratio of acetylated to nonacetylated 
sulphamethoxypyrimidine appeared in the culture medium than 
occurred in the blood of adult humans; the N-acetylated 
derivative is more toxic than the parent compound. No 
placental acetylation of sulphanilamide, isoniazid and 
p-aminosalicylic acid has been demonstrated.
Glucuronide conjugation in the placenta has been reported 
twice, in face of many negative findings. UDPG-Dehydrogenase and 
UDP-glucuronyl transferase activity, associated with bilirubin 
conjugation, have been demonstrated in the placental fraction 
prepared by centrifugation at 80,000 g.av. (Brown et al, 1958), 
and Berte et al (1969) have demonstrated glucuronide formation 
with oxazepam in the presence of rabbit placental 9,000 g.av. 
supernatant fractions. Conjugating activity was higher at day 14 
of gestation than at day 30 and was increased by pretreatment 
with phenobarbital but not with the substrate. Dutton (1966) 
suggested that though the placenta does not seem a significant 
site of glucuronide formation, perhaps the correct substrates 
have yet to be presented to it. The organ functions protectively, 
allowing bilirubin (Shier et al, 1971) and oestrogens (Ginsburg, 
1971) to pass out but not to return (maternally conjugated) 
as their glucuronides (Dancis et al, 1958) . What conjugation 
there is in the placenta it seems is largely associated with 
sulphate (Troen et al, 1966). However, UDPG-dehydrogenase has 
been shown in placenta (Dutton, 1959) , as has endoplasmic 
reticulum (Strauss et al, 1965) and large stores of glycogen.
UDP-Glucuronyl transferase seems intimately associated with 
glycogen, sedimenting with glycogen particles at 23,000 g.av 
x 15 min. Glucuronide formation associated with fractions 
prepared by other centrifugation procedures parellels their 
glycogen contents; in this respect it is of interest that 
Gunn rats, deficient in the enzyme, are deficient also in liver 
glycogen (Halac and Franks, 1960). This association does not 
always hold, however (Dutton, 1966; Short and Davis, 1970).
Glycine- conjugation is catalyzed in the presence of 
human placental mitochondria (Juchau and Yaffe, 1969).
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D. OESTROGEN BIOSYNTHESIS IN THE PLACENTA
Following the decay of the corpus luteum and the diminished 
contribution of the ovary to the supply of oestrogens and progestogens, 
the substantial increase in steroidogenesis observed in the later 
stages of pregnancy is achieved by the placenta and foetus acting 
as a co-ordinated endocrine organ. At mid-pregnancy, the foeto- 
placental unit exists as a balanced system of physiological enzyme 
activities, some of the steroidogenic enzymes being present mainly, 
if not exclusively, in the placenta and others in the foetus (Diczfalusy, 
1964). Thus the foetus and placenta together are able to elaborate 
most biologically-active steroids, including oestrogens, accounting 
for the greatly increased amounts produced during human pregnancy.
Oestrogen formation in the placenta is largely dependent on the 
provision of steroidal precursors reaching it via the foetal and 
maternal blood streams. Though the enzyme complex responsible for the 
aromatization of ring-A of steroids is well-developed in the foetus 
(Mancuso et al, 1968; Wu et al, 1970), this does not appear to be 
significantly concerned in the synthesis of oestrogens since this is 
dependent on an adequate supply of C^g-4-ene-3-one steroids, which 
would be derived principally from the placenta.
i) Placental Steroid Ring-A aromatization in different species
Aromarization of ring A of C^g steroids to the corresponding 
phenolic oestrogens has been demonstrated in the placentae of sheep, 
cow, horse, pig (Ainsworth and Ryan, 1966), orangutan (Ainsworth and 
Ryan, 1969b), rhesus monkey, macaque cynomolgus, squirrel monkey, 
baboon (Ainsworth and Ryan, 1969a) and goat (Ainsworth and Ryan, 1970), 
as well as in the human. It was not detectable in guinea pig, rabbit 
(Ainsworth and Ryan, 1966) or rat (Ryan, 1969) but it has been inferred 
from the work of Vinson and Jones (1964) that the mouse placenta does 
contain a steroid aromatizing system.
ii) Substrate specificity
The substrate specificity of this , enzyme system indicates that 
the steroids must be unsaturated in ring A or B, with a A^-unsaturation
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as a customary requirement (dehydroepiendrosterone is aromatized in 
vitro but is almost certainly first oxidized to the A^-3-Ketone).
Hydroxy substitution at 017 (a or 3) does not prevent aromatization; 
axial substituents at Oil slow the reaction, and 19-nor compounds 
ate only slowly converted. The presence of rings C and D is required, 
although conpounds with a 5 membered ring B are acted upon. Substitutions 
at 11a- or 9a- do not interfere with the activity of the enzyme, but 
021 hydroxysteroids are inert. The oxidized compounds 19-hydroxy- 
androstenedione, 19-hydroxy dehydroepiandrosterone and 19-oxoandrostenedione 
as well as 19-carboxyandrostenedione, are all readily aromatized.
The rate of aromatization of various substances may be summarized 
(Hayano et al, 1960; Ryan, 1960) relative to A^-androstene-3,17-dione 
(androstenedione 100):
testosterone and dehydroepiandrosterone, 100; 19-hydroxy and 19-oxo- 
androstenedione, 110-120; 17-methyl testosterone, 44; A^^-androstadiene- 
3,17-dione, A'*' ,^ -androstadiene-173-ol-3-one,63-hydroxyandrostenedione, 
23-hydroxytestosterone and 19-nortestosterone, 20 to 25.
iii) Principal oestrogens synthesized by the human placenta
Oestrone, aestradiol-173 and oestriol are the main oestrogens 
produced by human placenta. It appears oestradiol-173 is formed largely 
from oestrone, which is in turn produced from dehydroepiandrosterone 
(via androstenedione), the 17-oxo group being present during aromatization 
(Lamb et al, 1967). Placental 173 -hydroxysteroid oxidoreductases 
maintain relatively more of the neutral and phenolic steroids in the 
17-oxo form (Karavolas et al, 1969)
Oestriol synthesis from 16a-hydroxydehydroepiandrosterone (probably 
via 16a-hydroxy-androstenedione and -oestrone) may quantitatively be 
the most important pathway. Oestrone and oestradiol-173 are not 
converted into oestriol since the placenta appears unable to hydroxylate 
oestrogen at the 16a position (Jackanicz and Diczfalusy, 1968). In 
the foetal compartment, more 16a-hydroxylation occurs before than 
after aromatization (Nakayama et al, 1968). The high level of oestriol 
excreted during pregnancy is peculiar to humans.
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iv) Supply of precursors for oestrogen biosynthesis
The ultimate precursor of both oestrogens and progestogens 
within the foeto-placental unit is cholesterol derived from the 
maternal circulation (Hellig et al, 1968J.
FoetalCholesterol —> Pregnenolone -> Dehydroepiandrosterone
Adrenal
Foetal Liver
vPlacentalOestriol <-------- —  16a-Hydroxydehydroepiandrosterone
Aromatization
The foetus lacks 38-hydroxysteroid dehydrogenase and depends on the
4
placenta to furnish A -3-oxo-steroids, while the placenta is deficient 
in the desmolase activity which converts steroids to C^g steroids 
and is dependent on foetal and maternal sources for important C^g 
compounds. The 16a-steroid hydroxylase is abundent in foetal liver 
and adrenals but absent from the placenta; thus the adrenal supplies 
dehydroepiandrosterone sulphate which is converted to the 16a-hydroxy 
derivative in the foetal liver and then to oestriol in theoplacenta.
v) Mechanism of placental aromatization
Various mechanisms have been proposed for oestrogen synthesis 
(Dorfman and Ungar, 1965; Ryan, 1963; Wilcox and Engel, 1965a,b).
In the normal course of events, 19-hydroxylation of a C^g steroid 
(Axelrod and Goldzieher, 1962), which may precede formation of a
4-en-3one grouping, is followed by conversion into the 19-oxo compound. 
This is hydroxylated in the 18-position, and the hydroxyl group is 
then eliminated together with the aldehyde group from C-19 (Akhtar 
and Skinner , 1968). Earlier workers (Morato et al, 1961) using 
19-hydroxyandrostenedione reported the elimination of C-19 as 
formaldehyde, but with 19-oxo-androstenedione as the precursor, formic 
acid was released.
Akhtar and Skinner (1968) studied the intermediary role of the 
19-oxoandrogen in the biosynthesis of oestrogens. [16a-19-Hydroxy (VI)
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and 19-oxodehydroepiandrostereone (VII) incubated separately under 
anaerobic conditions with human placental microsomal fraction, in the 
presence of NADP , were readily converted into the corresponding ketones, 
19-hydroxy (II) and 19-oxoandrostenedione (IV). Substitution of NAD+
•f
for NADP produced the same result. When the biological conversion of
19-oxodehydroepiandrostereone (VII) was carried out in the presence
of NADP+ but under aerobic conditions, oestrone was foimed in 15% yield.
However under identical conditions 19-hydroxydehydroepiandrostereone
(VI) produced no significant amount of oestrone (approx. 2%) , but a
compound with the properties of 19-oxoandrostenedione (IV) was formed
in 5% yield. In these incubations a limited amount of NADPH is
generated as a result of the enzymic oxidation of the 38-hydroxyl
group by reactions of the types 1 and 2 (Fig. 1.6) to the conjugated
ketone. Akhtar and Skinner (1968) suggest that the NADPH formed in
these reactions is used in both the conversions of (II)-— >(IV) and
(IV)— >(V). This conclusion on the involvement of NADPH and in
these transformations was further substantiated by the following experiments.
19-Oxodehydroepiandrosterone (VII) was incubated with placental 
microsomes in the presence of NADP and C ,^ but newly generated NADPH 
(reaction 2) was rapidly removed by the inclusion of GSSG and glutathione 
reductase in the incubation mixture. In this situation, no significant 
conversion of compound (VII) into oestrone occurred. However, a generous 
supply of NADPH in similar incubation conditions but without GSSG and 
glutathione reductase gave a high conversion of both (VI) and (VII) 
into oestrone.
To directly demonstrate the transformation of [16a-^ H] 19-hydroxy- 
androstenedione (II) to its 19-oxo derivative (IV) under conditions 
of oestrone biosynthesis, the former conpound (II) was incubated with 
NADP+ and placental microsomes under air and non-radioactive 19-oxodehydro- 
epiandresterone (VII) was added to the incubation mixture to supply 
a steady but limited amount of NADPH as in reaction 2. The non-radioactive 
aldehyde formed by the reaction (VII)— >(IV) also served to trap the 
radioactive intermediate. In this experiment about 3% of the radio­
activity of conpound (II) was incorporated into compound (IV).
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Akhtar and Skinner (1968) concluded that the conversion of 
19-hydroxyandrostenedione (II) into oestrone (V) occurs in at least 
two stages both requiring NADPH and C^ , the first stage being the 
formation of 19-oxoandrostenedione (IV). Accumulation of compound (IV) 
under conditions of oestrogen biosynthesis was best shown when the 
transformation was completed in the presence of limited NADPH. These 
findings, in conjunction with those of Townsley and Brodie (1968) are 
consistent with a mechanism involving 13-hydroxylation of a 19-oxo- 
androgen of the type (IV) followed by the concerted loss of the 19-oxo 
group as formic acid and the 13hydroxyl group as OH” resulting in the 
formation of a 1,10 double bond (Fig. 1.7). In this mechanism the 
hydroxylation at position 13 has the dual function of i) providing a 
leaving group to facilitate the loss of the 19-oxo group and ii) allowing 
the desaturation of ring A to produce a phenolic structure (Skinner, 1968).
Fig. 1.7 Removal of formic acid from 19-oxoandrogens facilitated by
1-3 hydroxylation (After Skinner, 1968)
Y X
o H
NADPH
O O
(iv) 1-8-hydroxy-19-oxo compound
(vi)
OH
HO
4
Enolization 0
Oestrone (v)
X and Y+ are components of the enzyme active site.
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Brodie et al (1969) reported separately that desaturation in 
ring A to produce the aromatic structure concerns cis 13, 23 elimination^ 
essentially this involves activation of the O l  position for anion
2(3')
loss by formation of a A  ^^-enol. The 23 (axial) hydrogen would be 
stereoelectronically favoured for elimination in this process. Thus 
it is possible that the substrate or intermediate could bind, enolize 
to some degree and be released before conversion to oestrone.
The oxidative step in desaturation involves the C-13 hydrogen
in the rate determining step, requiring NADPH and (Townsley and
Brodie, 1968). In evaluating likely mechanisms, dehydrogenation or
hydroxylation-dehydration, 23-hydroxy-19-norandrostenedione was found
inactive as an oestrogen precursor. Since the 2a-, 13-, and 103-hydroxy
isomers were also poor substrates compared to 19-norandrostenedione,
it did not appear that a free hydroxyl compound was an intermediate.
Cis-desaturation though not often demonstrated, has been shown to
occur in the introduction of the A^ bond in the transformation of 
7A -cholestenol to 7-dehydrocholesterol and cholesterol in rat liver 
preparations (Akhtar and Marsh, 1967). The enzyme also requires 
molecular but not NADPH (D&mpsey, 1965).
The release of formaldehyde following aromatization of 19-hydroxy- 
androstenedione (Morato et al, 1961) is contrary to the mechanism just 
described. If the existence of a C-19-diol is accepted, then aromatization 
must be accompanied by the liberation of formic acid, with oxidation 
occurring at the level of an aldehyde.
ch3oh
v/
H.CHO h .c o 2h
s/
co„
Recent investigations (Horn and Finkelstein, 1971) into human 
placental aromatization of testosterone and epitestosterone indicate 
different biochemical pathways may be involved, and suggests therefore 
a multiplicity of enzyme systems. Certainly the mechanism of oestrogen
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biosynthesis in micro-organisms is dissimilar from that of human 
placenta (Korn et al, 1969; Pan et al, 1969; Brodie et al, 1968).
vi) Nature of placental aromatizating enzyme system
Ryan (1959) estimated that human placental microsomes, when 
supplemented with NADPH and incubated at pH 7.0 in air, produce 
approximately 1 mg of oestrogen per h. for an average 500 g placenta. 
This activity is evenly distributed between smooth and rough surfaced 
microsomal subfractions (Isurugi et al, 1971). Aromatization has also 
been shown to occur to a lesser degree with the mitochondrial fraction 
(Shaw et al, 1969; Aleem et al, 1970).
Hollander and Hollander (1960) observed a pH optimum of 7.3
for the microsomal system, and found 0.03-0.3 M Na , 0.1 M K and 
++
0.01 M Mg enhanced aromatization. The enzyme system was stable 
when kept overnight at room temperature at pH 7.0, and at -20° for 
several months. It was also stable when stored for 24 h. at 0° at 
pH 9.0, but not at pH 3.0. Solubilization was effected by treatment 
in a 10 KC Raytheon sonic oscillator for 10-30 min, but not by 
treatment with deoxycholate, digitonin, RNAase, lipase, lyophilization, 
butanol or acetone. Soluble aromatization enzyme activity could be 
precipipated by (NH^SO^ at pH 7.0 when saturation was less than 
33%. The extent of conversion was proportional to the amount of 
protein, possibly indicating a bound unknown cofactor limiting the 
reaction. Either NADPH or NADH was essential to testosterone 
aromatization and could not be replaced by N-benzyl-dihydronicotinamide, 
GSH, cysteine, dehydroascorbic acid, or Catalase had no effect.
The system was totally inhibited by FMN or FAD at 10"  ^M.
Ryan (1959) reported a pH optimum of 7.0 for androstenedione 
aromatization, and NADPH was specifically required. A nitrogen 
atmosphere inhibited the conversion, though essentially no change was
4**f ■"
observed in the presence of EDTA, Cu , Hg , CN or iodoacetate. When 
air was replaced by a 51 02~95l ^  atmosphere, the rate of aromatization 
of androstenedione and its 19-hydroxy derivative was reduced 30-351 while 
no inhibition occurred if 19-oxoandrostenedione was the substrate 
(Meigs and Ryan, 1971). The aromatization of all three steroids in
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51 O2 was not inhibited when CO was added at a concentration 8.8 times 
that of C^ . However, this same COrC^ ratio decreased aromatization 
of 19-norandrostenedione from 51 to 95% and the aromatization of 
1,4-androstadienedione to 10-16%. Hydroxylation of the A ring of 
19-norandrostenedione was also inhibited by CO to the same extent as 
was its aromatization. These findings have been interpreted as 
evidence for the existence of three mixed function oxidases active in 
steroid aromatization (as also suggested with testosterone and 
epitestosterone as substrates), one of which may be a form of cytochrome 
P-450. The participation of NADPH-cytochrome c reductase in a 
cytochrome P-450-linked oxygenation reaction is unlikely since it is 
Cu++ sensitive.
Human placental aromatization is inhibited by metyrapone (SU 4885) 
which may reflect the uncoupling of 19-hydroxylation (Giles and Griffiths, 
1964). Despite considerable individual differences, a 50% decrease 
in oestrone formation was consistently obtained in the presence of 
4.42 ymol of metyrapone. In contrast, the enhanced activity caused by 
clomiphene citrate has been attributed to inhibition of the NADPH 
disposal systems (Hagerman et al, 1966).
Laumas et al (1968) investigated oestrogen biosynthesis in micro­
somal fractions obtained from placentae of normal and toxaemic subj ects. 
Aromatization of 19-hydroxyandrostenedione, androstenedione and 
testosterone was reduced in toxaemia. Kinetic studies with 19-hydroxy- 
androstenedione showed that in both normal and toxaemic placentae, 
the maximum conversion was attained within one hour, and this remained 
unchanged when continued for up to 4 h. Human chorionic gonadotrophin 
was without effect on either system as originally suggested by Ryan 
(1959). The low rate of oestrogen biosynthesis found with toxaemia 
was not due to insufficient precursors, but was possibly due to co­
factors or a defect or deficiency in the enzyme system responsible 
for the conversion.
Diminished aromatization observed in placentae from premature 
deliveries has been explained by a reduced protein content (Sybulski, 
1969), whereas in diabetes, the activity per unit weight of tissue 
is reduced as a consequence of hyperplasia. In contrast, intrauterine
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foetal malnutrition gives rise to an elevated placental oestrogen 
biosynthesis and may reflect a compensatory mechanisms for decreased 
placental size.
Mowszowicz et al (1970) demonstrated that the aromatization of 
testosterone by human placental microsomes was delayed by binding 
testosterone to an "active protein fraction" purified from pregnant 
woman serum (free of albumin and transcortin). Similar inhibitory 
effects were observed using albumin in high concentrations. The "active 
protein fraction", in spite of its weak affinity, m y  through its 
high capacity, influence the transfer of testosterone to target 
metabolic organs.
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E. PROGRAMME OF RESEARCH
The major consideration of the present programme of research was 
to ascertain whether or not the placenta is capable of metabolizing 
drugs. In view of the high levels of microsomal oxygenases responsible 
for steroid ring-A aromatization, which may at least in part be due 
cytochrome P-450, it is possible that the oxidative metabolism of drugs 
and possibly fatty acids may also be mediated via comparable enzymic 
pathways. It was therefore necessary to investigate these routes of 
metabolism in the placenta to ascertain whether any common mechanism(s) 
exists.
Accordingly the following areas were studied:
i) Drug metabolism
a) A determination of the qualitative and quantitative nature of 
the placental biotransformation of foreign compounds.
b) The effect of species, gestation and inducing agents of hepatic 
drug-metabolizing enzymes on placental detoxication.
c) Variations in foetal and maternal liver detoxication under 
comparable experimental conditions used for placental investigations.
d) Examine whether placental drug-metabolizing activity has any 
implications for the foetus, neonate and pregnant female.
ii) Oestrogen biosynthesis
a) Prepare an enzyme assay procedure to measure steroid ring-A 
aromatization.
b) Attempt enzyme solubilization.
c) Characterize the hydroxylation reaction and determine whether 
cytochrome P-450 participates as the terminal oxygenase.
d) Study briefly oestrogen biosynthesis in non-placental tissues.
e) Examine the possibility of inducing steroid ring-A aromatization.
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iii) a)-Hyroxylation of lauric acid
a) Determine whether w-hydroxy 1 ation of fatty acids occurs in 
the placenta.
b) Examine the possibility of stimulating activity with inducing 
agents.
c) Study whether cytochrome P-450 mediates w-hydroxylation in 
the placenta.
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CHAPTER 2
MATERIALS AND METHODS
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1. REAGENTS
Isotopically labelled compounds: [7a- H^] androst-4-ene-3,17-dione 
98% (3.1 Ci/imol) ,[4-^C] testosterone98% (58.2 mCi/mmol) and [l-^c] 
lauric acid 981 (21.0 mCi/mmol) were supplied by the Radiochemical 
Centre (Amersham) and stored at 4° in benzene/ethanol (9:1 v/v). Specific 
activity was determined as described in Methods .
Steroids: oestrone (m.p.258-62°), oestrone-3-methyl ether (m.p.169°), 
oestradiol-17(3 (m.p.222°), oestradiol-17p -3-methyl ether (m.p.1180) and 
oestriol (m.p.288°) were purchased from Sigma Chemical Co., testosterone 
(m.p.152°), testos terone acetate (m.p.140°), androstenedione (m.p.17 2°), 
and dehydroepiandrosterone (m.p. 150°) were supplied by Steraloids. Purity 
was examined by melting points and following t.l.c.
Drugs: biphenyl (m.p.70°), 2-hydroxybiphenyl (m.p.56.5°) and
4-hydroxybiphenyl (m.p.166.5°) from B.D.H. were purified as described 
by Bridges, Creaven and Williams (1965); £-chloro-N-methylaniline 
hydrochloride (m.p.105°: Calbiochem. Ltd.), benzo[a]pyrene (m.p.179°:
Eastman Organic Chemicals), ethylmorphine (May and Baker) and zoxazolamine 
(2-amino-5-chlorobenzoxazole or flexin; Ortho Pharmaceuticals Ltd.) were 
used as supplied; £-nitroanisole (m.p.38°: Ralph N. Emanuel Ltd.) was 
reciyst. from ethanol; 4-methylumbelliferone (Koch-Light Ltd.) was purified 
according to the method of Mead, Smith and Williams (1955), and the 
glucuronide prepared as described by Woolen and Walker (1965) from 
acetobromomethylglucuronate (prepared according to Bollenback et al, 1955) 
and 4-methylumbelliferone (m.p. 185°).
Incubation materials: 2-(£-iodophenyl)-3-(p-nitrophenyl)-5-phenyltetra- 
zolium chloride (INT: BEH), adenosine triphosphate (ATP), 2-amino-2-hydroxy- 
methylpropane-l , 3-diol(tris),glucose-6-phosphate (G-6-P), glucose-6-phosphate 
dehydrogenase (G-6-P-D), nicotine-adenine dinucleotide (NAD), nicotine- 
adenine dinucleotide phosphate (NADP), uridine diphosphate glucuronic acid 
(UDPGA:Sigma Chemical Co.), reduced nicotine-adenine dinucleotide phosphate 
(NADPH:P.L. Biochemicals Ltd.), Ketodase (3-glucuronidase: Nutritional 
Biochemicals Corp.), 3,3-dimethylglutarate (DMG), flavin mononucleotide 
(FMN), tween 80 (Koch-Light Ltd.), carbon monoxide (CO), nitrogen (N2),. 
oxygen ^ )  and air (British Oxygen) were used as supplied.
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Enzyme inhibitors: metyrapone [2-methyl-l,2-bis-(3-py r idyl) propan-1-one], 
aminoglutethimide [ a- (p-aminophenyl)-a-ethylglutarimide], glutethimide(a-phenyl- 
a-phenylglutarimide: CIBA), Lilly 18947 (2,4-dichloro-6-phenylphenoxyethyl- 
diethylamine), DPEA (2,4-dichloro-6-phenylphenoxyethylamine: Eli Lilly Inters. 
Corp.), SKF-525A (2-diethylaminoethyl-2,2-diphenyl valerate hydrochloride:
Smith, Kline and French Labs. Ltd.), p-hydroxymercuribenzoate, a,a''-bipyrridyl 
and 3-mercaptoethylamine (Sigma Chemical Co.) were used as supplied.
Reagents for assays: acetylacetone (redistilled), bromothymol blue, 
molybdophosphoric acid, naphthylethylene-diamine (N.E.D.), rhodamine B 
(BDH) and p_- dime thy 1 aminob en z al dehy de (Calbiochem. Ltd.) were used as 
purchased; succinic acid (m.p. 182°: BDH) was recryst. from water, 
p_-nitrophenol (m.p.97°: Hopkin and Williams Ltd.) from benzene and 
Pfchloroaniline hydrochloride (Calbiochem. Ltd.) from ethanol; 
w-hydroxylauric acid was kindly donated by Dr. M.J. Coon (Dept. Biol. Chem., 
Univ. Michigan, Ann Arbor, Michigan 48104).
Chromatography reagents: Kieselgel Hp 254 + 366 nac^ silica
gel G (Anderman & Co. Ltd.), sephadex G-25 (Pharmacia) and silicic acid (BDH) 
were prepared as described in methods.
General reagents: isosafrole (Eastman Organic Chemicals), phenobarbital 
(May and Baker), dimethyl POPOP [l,4-bis-2-(4-methyl-5-phenyloxazolyl)-benzene: 
Koch-Light Ltd], PPO (2,5-diphenyloxazole: Packard) and heparin (Evans Medical 
Ltd.) were used as supplied.
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2. SOURCE OF PLACENTAE
i) Animals
The majority of animal investigations involved using rats and 
rabbits. Six to eight Wistar/albino rats were housed in plastic 
cages on Steralit bedding, and kept in rooms reserved for rats only. 
Spillers autoclaved small animal diet and water was provided ad 
libitum. The gestational period was determined from the date of 
mating and foetal size, full-term animals weighing 300-350g. Rats 
were killed by cervical fracture at 9.30 a.m. to minimise effects due 
to diurnal variations (Radialowski and Bousquet, 1968; Jori et al, 
1971; Burke et al, 1972).
New Zealand white rabbits, supplied by Westwood Hybrid Table 
Rabbits Ltd., Plymouth, and weighing between 3.5-6,0kg, were housed 
separately in metal cages. Dixons rabbit pellets and water were 
provided ad libitum. The gestational period was readily determined 
by the day of mating.
ii) Humans
Human placentae were kindly provided by the following:- 
The South London Hospital for Women and Children, Clapham South,
London, S.W.4.
St. Thomas' Hospital, London, S.E.l.
St. Luke’s Hospital, Guildford, Surrey.
An arrangement with these hospitals gave prior warning of pending 
deliveries. Placentae would be temporarily stored in polythene bags 
in a refrigerator ice-box. Under no circumstances were placentae 
washed under the tap as is the usual procedure for examining the 
integrity of the organ. Foetal and placental tissue from early 
gestation was obtained from therapeutic abortions. Under favourable 
circumstances, placentae would be processed at 4° within 30 min. of 
delivery.
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Background information regarding the source of placentae was 
obtained with a questionnaire, normally completed by the nurse.
Full-term organs weighed between 500- 700g.
3. PREPARATION OF PARTICULATE FRACTIONS
i) For Drug Metabolism Studies
Pooled placentae of experimental animals, or a portion of 
human or pig placentae were transferred to ice-cold 1.151 (W/v)
KC1, cut into small pieces and weighed. Three volumes (v/w) of 
1.15% KC1 were added and the tissue homogenised with a Potter- 
Elvehjem (1936) homogenizer fitted with a teflon pestle. The 
homogenates were centrifuged at 10,000g.av. for 20 min. at 3° and 
the supernatant was taken as the enzyme source. The microsomal 
fraction was obtained by centrifuging the supernatant at 105,000g.av. 
for 60 min. Maternal and foetal liver were processed in this manner. 
The methodology was modified for some assays.
a) Metabolism of zoxazolamine
The assay procedure of Conney, Trousof and Bums (1960), 
whole homogenates ( 101 w/v) were prepared in 0.25 M sucrose.
For the method of Juchau et al (1965), the 9,000g.av. (for 30 
min.) was used as the enzyme source, tissue having been 
homogenized in two volumes of 1.15% KC1.
b) N-Demethylation of ethylmorphine ,
Human placentae were homogenized as for the aromatization 
assay using an equal volume (W/v) of 1.15% KC1. After 
centrifugation for 10 min. at 800g.av. the supernatant was 
normally taken as the enzyme source.
c) Q-Demethylation of p-nitroanisole
Microsomal fractions were prepared and washed in five 
volumes (V/w) of 0.25 M sucrose (containing 2g. of EDTA and 
2.42g. oftris, buffer/litre, adjusted to pH 7.4 with HC1).
d) NrDemethylation of p-chloro-N-methylaniline
Rat placentae were homogenized in 2 volumes (v/w) of 1.15% 
KC1, and livers in 3 volumes. Washed testicular microsomes 
were resuspended to a protein concentration of 15 mg/ml, and 
hepatic microsomes to 10 mg/ml.
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e) Metabolism of benzo (a)pyrene
Particulate fractions were prepared according to Welch et al 
(1969) and Juchau (1971). Where whole homogenates were employed, 
details of preparations are given in Chapter 4.
f) Hydrolysis of phenolphthalein glucuronide
Subcellular fractions were isolated in 0.25 M sucrose in 
the same manner as for the aromatization assay.
g) Cytochrome P-450 studies
The 10,000g.av. (free of nuclear and cell debris) and 
105,000g.av. sediments were washed twice in 1.151 KC1 or 0.1 M 
phosphate buffer, pH 7.4, and resuspended to a protein concentration 
of up to 15 mg/ml. Different isolation procedures are discussed 
in Chapter 3.
ii) For the Steroid Aromatization Assay
Fresh human and pig placentae were dissected free of foetal 
membranes and processed at 4° essentially after the method of Ryan 
(1959). Placental tissue, teased free of large blood vessels, was 
put through a meat grinder, washed in saline over muslin cloth and 
weighed. One volume of 0.25 M sucrose (containing 0.05 M phosphate 
buffer, pH 7.0 and 0.04 M nicotinamide) to two parts by weight of 
placenta was homogenized in a Kenwood liquidizer for 5 min. at half 
speed and 7 min. at full speed. Homogenates were occasionally 
filtered through cheese cloth.
Nuclear and cell debris sedimented at 600g.av. for 10 min. and 
mitochondria at 4,000g.av. for 10 min. and further centrifugation at 
10,000g.av. for 20 min. deposited lysosomes. Microsomes, collected 
at 105,000g.av. for 60 min. were washed once in 0.05 M phosphate 
buffer, pH 7.1 and resedimented. The microsomal content of 30g. wet 
weight placenta was resuspended in phosphate buffer (2.5 ml) with a 
Potter-Elvehjem homogenizer, and taken as the enzyme source. If not 
used immediately, washed microsomal pellets could be stored at -15° 
under 501 (v/v) glycerol in phosphate buffer for several weeks.
Placentae of rats, rabbits and guinea pigs were processed in the 
same manner, except that tissue disruption was effected with a 
Potter-Elvehj em homogenizer.
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iii) For o)-Hydroxylation Studies
Placental and hepatic tissues were homogenized in 4 volumes 
(v/w) of 0.25 M sucrose, and particulate fractions collected as for drug 
metabolism studies.
iv) For Marker Enzymes
Human placentae, in 3 volumes (v/w) of 0.25 M sucrose ( 5 mM 
tris-HCl, pH 7.4), were homogenized according to the aromatization 
assay. Nuclear and cell debris were collected at 600g.av. for 10 min. 
mitochondria at 4,OOOg.av. for 10 min, lysosomes at 10,OOOg.av. for 
15 min. and microsomes at 105,OOOg.av. for 60 min. leaving only the 
soluble fraction. Particulate fractions were washed and then 
resuspended in a quarter of the original volume of homogenate in 
0.25 M sucrose (5 mM tris-HCl, pH 7.4). Aliquots (0.25 and 0.5 ml) 
were removed for enzyme assay.
v) For Electron Microscopy
Mitochondrial and microsomal fractions were isolated as for 
cytochrome P-450 studies.
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4. ASSAYS OF DRUG-METABOLIZING ENZYMES
i) Hydroxylation of Biphenyl
Biphenyl is hydroxylated either to the ortho- or para-derivative.
ho
minor path
major pa'
Biphenyl
ortho-Hydroxybiphenyl
para-Hydroxybipheny1
Ortho- and para-hydroxylated biphenyl are highly fluorescent and 
may be determined in the presence of each other because ortho-hydroxy- 
biphenyl shows excited-state ionization, whereas the para isomer does 
not. The in vitro hydroxylation of biphenyl was measured according to 
the method of Creaven et al (1965).
ii) Reduction of p-Nitrobenzoic Acid
p-Nitrobenzoic acid is converted enzymically to p-aminobenzoi c 
acid; the reaction is believed to involve nitroso and hydroxylamine 
intermediates as follows :-
CO_H
Liver Enzyme
NADPH_
—   2 ►
p-nitrobenzoic acid
c o 2h
NHOH
CO_H C02H
unstable intermediates p- aminobenzoic 
acid
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Method
The assay of nitro-reductase is based on that of Fouts and Brodie 
(1957) as modified by Gingell (unpublished). The incubation medium was 
as follows
Enzyme preparation* ..
Substrate solution in tris buffer** 
Mg++ (as MgCl2)
Glucose-6-phosphate 
FMN ..
NADP ..
1.0 ml
2.0 ml
25.0 ymol
25.0 ymol 
0.125 ymol 
0.25 ymol
Total volume = 5.0 ml.
* In those cases where rat liver 104,OOOg.av. supernatant (1 ml) 
was added to the incubation media, the total volume was increased 
to 6 ml.
** The substrate solution was prepared by dissolving £-nitrobenzoic 
acid (0.835g) in tris buffer solution then adjusting the pH to 
7.-62 at 23° with dilute HC1, and the volume to 500 ml, such that 
the concentration of the tris in the final solution was 0.05 M.
The homogenate was obtained as described previously. The incubation 
was carried out under nitrogen in wide side-arm glass tubes stoppered 
with rubber bungs. Nitrogen was fed into the tube by a needle inserted 
through the rubber stopper and flowed out to the next tube via the side- 
arm. The incubation tubes were evacuated and then preflushed with N2 
for ten min. while standing in ice-cold water. The incubation was for 
30 min. at 37° in a Mickel shaking water bath.
The reaction was terminated by flushing the system of tubes for 
one min. with 02, immersing in ice-cold water, and adding 25% (w/v) 
trichloroacetic acid (1 ml) to precipitate protein. The incubation 
mixtures were then centrifuged at 2,000 r.p.m. for ten min. in an MSE 
Super Magnum centrifuge at room temp. Then an aliquot of the supernatant 
(4 ml) was taken and used in the Bratton and Marshall (1939) test as 
follows:- 0.5 ml of 0.1% NaN02 was added and allowed to stand for
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three min. then repeatedly shaken with 0.5 ml at 0.51 ammonium sulphamate: 
after a further three minutes, shaking was repeated with 0.5 ml of 0.1 
N.E.D. The volume was made up to 10 ml with water and allowed to stand 
for 30 min. before reading at 545 nm in a Unicam SP 500. Standards of 
p-aminobenzoic acid (0-250 nmol) had been used to prepare a standard 
curve (Fig. 2.1).
Fig. 2.1 Standard Curve for p-Aminobenzoic Acid
(Bratton and Marshall Reaction)
1 . 0 - j
0.8
0.6
0.2
125
-9Concentration of p-ammobenzoic acid (x 10 M)
250
53
O
N
®
(iii) Metabolism of Zoxazolamine
The major pathway for the metabolism in man of zoxazolamine is 
via hydroxylation in the benzene ring to form 6-hydroxy zoxazolamine 
(Conney, Trousof and Bums, 1960). Small amounts of chlorzoxazone 
are formed by the substitution of the amino group for a hydroxyl 
group.
cr
Chlorzoxazone
Cl
Zoxazolamine
HO
Cl
6-Hydroxyzoxazolamine
Method
Dixon and Willson (1968) have reported the in vitro metabolism 
of zoxazolamine by placental tissues, but information concerning the 
assay conditions which they employed do not appear to be available. It 
has, therefore, become necessary to modify one of the zoxazolamine 
assays used for studying the hepatic system. These are based on 
determining the loss of substrate following a one hour incubation.
The zoxazolamine is extracted from biological material at pH >
8.0 into either n-heptane or 1,2-dichloroethane. The drug is then 
re-extracted into HC1 and measured spectrophotometrically at 278 nm 
where it exhibits a pronounced absorption maximum (refer to accompanying 
graph, Fig. 2.2). Chlorzoxazone and 6-hydroxy zoxazolamine do not 
interfere with this assay, but nicotinamide does and has to be selectively 
removed. An acidic solution of zoxazolamine is quite stable at room tenp. 
(Fig. 2.3).
In this chapter two standard methods for determining the metabolism 
of zoxazolamine in vitro are reported. Chapter 4 contains a comparison 
of these two systems and the development of an assay for placental 
studies.
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(a) Metabolism of zoxazolamine as measured by the method of 
Conney, Trousof and Bums (I960)
Tissue homogenates (101 w/v) in ice-cold 0.25 M sucrose solution 
were prepared and assayed in duplicate. The homogenate from 100 mg of 
tissue was pipetted into the ice-cold test tubes (15 ml) which contained
the following:-
G-6-P (0.03 M) ... ... ... ... 0.2 ml
NADP (200yg) ... ... ... ... 0.1ml
NAD (lOOyg) ... ... ... ... 0.1ml
ATP (0.01 M) ... ... ... ... 0.2ml
Nicotinamide (0.6 M) ... ... ... ... 0.1 ml
KC1 (2.0 M) ... ... ... ... 0.1 ml
MgCl2 (0.1 M) ... ... ... ... 0.1 ml
Potassium phosphate buffer, pH 7.4 (0.1 W) ... 0.5 ml
Total volume 1.4 ml
Zoxazolamine was dissolved by adding 1 M HC1 (0.24 ml) to the drug (20 mg) 
and then diluting with water to a final concentration of 200 yg per ml.
An aliquot (0.5 ml) of this solution was taken as the substrate. The 
final volume of the reaction mixture was adjusted to 3.0 ml with water.
The samples were incubated aerobically at 37° in a shaking bath. The 
reaction was stopped by the addition of 0.5 M NaOH (1 ml).
Each incubate was then extracted with 1,2-dichloroethane (20 ml) 
for 30 min. on a rotaiy mixer. The organic phase was then shaken with 
a saturated solution of sodium tetraborate (10 ml) for 10 min. An 
aliquot (10 ml) of the organic phase was extracted with 0.1 | HC1 (5 ml) 
for a further 10 min. The optical density of the acid solution at 278 nm 
was recorded. Centrifugation was employed where necessary. The amount 
of zoxazolamine metabolized was calculated as the difference in the 
amounts extracted from the zero time samples (unincubated) and incubated 
samples.
(b) Metabolism of zoxazolamine as measured by the method of Juchau q£ al (1965)
An aliquot (1 ml) of the enzyme preparation was incubated for 60 min. 
in a shaking water bath at 37° under an oxygen atmosphere with 2.3 ml of
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of phosphate buffer (0.1 M, pH 7.34); 1.0 ml of phosphate buffer 
containing G-6-P (10 mg/ml), nicotinamide (30.5 mg/ml) and MgSO^
(6.2 mg/ml); 0.2 ml of NADP (2.0 mg/ml of phosphate buffer), and 
0.05 ml of zoxazolamine (1.0 mg/ml in phosphate buffer - the drug 
was initially dissolved in a small volume of 0.1 M HC1 and then made 
up to the final concentration with the buffer.
After the incubation, a sample (2.0 ml) of the media was shaken 
for 30 min. with n-heptane (25 ml) containing 1.51 isoamyl alcohol 
and 1.0 M NaOH (0.5 ml), and then centrifuged (1,000 r.p.m.) for 
5 min. Following aspiration of the aqueous layer, the organic phase 
was shaken with 0.1 M acetate buffer, pH 5.6 (7.0 ml) for 5 min. 
and then centrifuged. Part of the n-heptane layer (15 ml) was then 
shaken with 0.1 M HC1 (7.0 ml) and again centrifuged. The extinction 
of the acid extract was determined as described previously.
(iv) H-Demethylation of Ethylmorphine
The in vitro N-demethylation is followed by measuring the release 
of formaldehyde.
CH_
OH
Ethylmorphine
Microsomal Enzyme
CH_OH
OH
Unstable intermediate
+ HCHO
OH
The formaldehyde is trapped by semicarbazide in the incubation medium.
h2c=o + nh2nhconh2 h2c=nnhoonh2
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Method
The enzyme preparation was incorporated into the reaction mixture 
essentially after that of Holtzman et al, 1968.
MgCl2 (15 pnol) .. .. .. .. .. 0.3 ml
G-6-P (30 ymol) .. . . .. .. .. 0.4 ml
NADP (1.5 ymol) .. . . . .  .. .. 0.3 ml
G-6-P dehydrogenase (2 Units) .. ... .. 0.5 ml
Enzyme preparation ..   .. 0.2 ml
Ethylmorphine (4 ymol) .. .. .. .. 0.2 ml
Semicarbazide (4 mg), .......  .. .. 0.3 ml
Total volume 2.5 ml
The pH of the semicarbazide solution was acid and needed adjusting from
4.0 to 7.4. All cofactors were prepared in tris buffer (150 mM/L) pH 7.4.
A stock standard formaldehyde solution (19.25 yg/ml) was used to prepare a 
standard curve (Fig. 2.4), taking aliquots of 0.1-1.5 ml to which was added 
the 800 g.av. supernatant (0.5 ml) and semicarbazide (0.5 ml) solution.
The final volume was made up to 2.5 ml with tris buffer, pH 7.4.
Fig. 2.4 Formaldehyde Standard Curve 
(Nash Reaction)
0.5
0.4-
0.2-
0.1-
Concentration of formaldehyde (yg/2.5 ml)
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The enzyme preparation was incubated under at 37° using stoppered
test tubes to prevent the release of formaldehyde. The incubation time
was varied between 1060 min. All the reactions were carried out in
duplicate. The reaction was stopped by the addition of 15V (W/v) ZnSO^
solution (1 ml) followed by a saturated solution of Ba(0H)7 (2 ml).
I ^
After centrifugation formaldehyde was determined in the clear supernatant
(2.0 ml) by a modified Nash (Nash, 1953) reagent (2 ml) consisting of
4 ml of acetylacetone per litre of 4 M ammonium acetate in 0.1 M acetic acid.
The yellow colour, due to the formation of 3:5-diacetyl-l:4-dihydrolutidine,
develops fully after 40 min of incubation at 37°. Under optimum conditions
the molecular extinction in terms of formaldehyde has a smooth maximum
of 8,000 at 412 nm, independent of dilution.
HCHO + CH3COCH2COCH3 
(for semicarbazones) ammonium
^acetate H
CH
3;4 diacetyl-l;4-dihydrolutidine
Extinction values were determined with the aid of a Unicam SP 500 
spectrophotometer. The colour fades on extended exposure to daylight, 
therefore absorption readings were always recorded immediately, and the 
Nash reagent prepared on the day of the experiment.
(v) O-Demethylation of p-Nitroanisole
p-Nitroanisole is O-demethylated to release formaldehyde and 
p-nitrophenol, both of which are easy to detect in vitro.
■ft
NO„
Microsomal
Enzyme
NADPKL
<?h 2oh
NO.
+ HCHO
]D-nitroanisole Unstable intermediate js-nitrophenol
60
The Netter procedure (Netter and Seidel, 1964) for following the 
reaction depends on determining the amount of p-nitrophenol released 
into an alkaline media, as the compound is yellow under these 
conditions and absorbs strongly at 420 nm. It requires a dual beam 
spectrophotometer in order to refer the experiment incubate to a blank. 
The procedure is ideally suited for kinetic studies. The alternative 
method is to determine the amount of formaldehyde released using the 
Nash procedure. Both methods were examined for suitable use with 
placental preparations. As with the metabolism of zoxazolamine, the 
experimental comparisons of the two procedures about to be described 
are given in Chapter 4.
Method
For this assay, microsomal fractions were prepared and washed 
in 0.25 M sucrose (containing 2 g. of EDTA and 2.42 g. of tris buffer/ 
litre, adjusted to pH 7.4 with HC1), and finally resuspended in the 
buffered sucrose at a concentration of 5 mg. of protein per ml. The 
reaction mixture consisted of:-
NADP (297 yg/ml H20)    0.2 ml
Microsomal preparation (2 mg of protein) ... 0.4 ml
G-6-P (5 mg/ml) ... ... ... 0.3 ml
G-6-P-dehydrogenase (0.3 Unit) ... ... 0.3 ml
p-Nitroanisole (61,2,142.8,224.2 or 306 yg)... 0.3 ml
Semicarbazide (20 mg/ml. ^0) ... ... 0.2 ml
Nicotinamide (16.3 mg/ml) ... ... ... 0.3 ml
Total volume = 2.0 ml
The £-nitroanisole was dissolved in 0.066 M phosphate buffer, pH 7.85 
with heating immediately prior to use. The nicotinamide, G-6-P and 
G-6-P-D were also taken up in this buffer, whereas the NADP and semi­
carbazide (pH adjusted to 7.85) were used in water.
When employing the Netter procedure, the incubation mixture was 
placed in a cuvette within the heated (37°) carriage of a Pye Unicam 
SP 800. On attaining the temperature of 37° the raction was initiated 
by the addition of G-6-P-dehydrogenase to the experimental cuvette 
alone, and addition of buffer to the control incubate. After rapid 
mixing the O-demethylation was monitored by measuring the increase in
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absorption at 420 nm, due to the production of p-nitrophenol, at one 
min. intervals. This change in optical density was recorded automatically 
on a moving chart, and four experimental incubations could be followed 
simultaneously. A ten-fold increase in sensitivity could be achieved 
by using the Pye Unicam SP.1800 with a scale expansion of 0 — — > 0.2 
absorbance. It was only possible to monitor one set of cuvettes by 
this means.
If the release of formaldehyde was to be followed, the same 
reaction mixture was incubated for 60 min. at 37° and then stopped 
with 201 (W/v) trichloroacetic acid (0.5 ml). An aliquot (1.5 ml) of 
the supernatant following protein precipitation was removed to an 
equal volume of Nash reagent. The p-nitrophenol does not ionize at 
this pH and therefore does not interfere with this colour reaction.
The release of formaldehyde was determined in the same manner as it 
was for the N-demethylation of ethylmorphine. Standard curves for 
p-nitrophenol (Fig. 2.5) and formaldehyde were prepared.
Fig. 2.5
Standard Curve for p-Nitrophenol
1.4
1.2-
1.0-
0.8-
0.6-
0.4-
0.2
Concentration of p-nitrophenol (yg/2 ml incubate)
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(vi) N-Demethylation of p-Chloro-Nrmethylaniline
The N-demethylation o£ £-chloro-N^methylaniline produces £-chloroaniline, 
though small amounts of £-aminophenol and £rhydroxy-N-me thy lani 1 ine are
also formed.
-CH
NADPH+ O
£-Chloro-N-me thy1ani1in^
+ HCHO
£-Chloroaniline + Formaldehyde
£~Aminophenol ) Minor
£-Hydroxy-N-methyl-) metab- 
aniline ) olites
The £-chloroaniline formed is treated with Ehrlich ’ s Reagent 
(£-dimethylaminobenzaldehyde in ^ SO^) to produce a characteristic yellow 
colour. The optical density of this Schiffs base is measured at 445. nm.
Method
The Kupfer and Bruggeman (1966) reaction mixture consisted of
NADP (1.6 pmol)
Nicotinamide (20 Unol) .. 
MgCl2 (30 vmol) ..
G-6-P (16 Wnol)
G-6-P-dehydrogenase (0.3 Unit) 
£-Chloro-N-methylaniline (3 ymol) 
10,OOOg.av. supernatant *.
Total volume
0.3 ml 
0.3 ml 
0.4 ml 
0.4 ml 
0.3 ml 
0.1 ml 
0.2 ml
2.0 ml
Gofactors were prepared in 0.05 M phosphate buffer, pH 7.4. The 
substrate was dissolved in water as the hydrochloride. The incubation 
time was varied between 20-60 min. and carried out under an atmosphere 
of air. Following this, the incubation tubes were placed in an iced-water 
bath and the Ehrlich reagent (3 ml of a solution of 20 mg of £-dimethylamino-
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benzaldehyde per ml of 1 M H^SO^) was added to develop the colour and 
precipitate the protein. The samples were then centrifuged at 2,500 r.p.m. 
for 60 min. at 4°. The extinction of the yellow supernatant was then 
recorded in a Pye Unicam SP. 500 at 445 nm.
In the case of control incubates, the substrate was added after 
the Ehrlich's reagent. A range of £-chloroaniline standards (5-20 nmol.) 
were also added to the reaction mixture (being prepared in water as the 
hydrochloride), the substrate again being added after the Ehrlich's 
reagent (standard graph: Fig. 2.6, and absorption spectrum of the colour 
complex, Fig. 2.7).
Various attempts at improving this assay procedure are described 
in Chapter 4, where it is concluded that microsomal preparations were 
better suited for placental and testicular studies.
Fig. 2.6
p-Cloroaniline Standard Curve 
(Ehrlich's Reagent)
0.6
0.5
0.4-
0.3
0.2
Concentration of £-chloroaniline (nmol/2 ml)
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(vii) Metabolism of Benzo [a]pyrene
The carcinogenic polycyclic hydrocarbon, benzo [a]pyrene undergoes 
mainly hydroxylation in the liver of various species, including man 
(Conney, Miller and Miller, 1957; Kuntzman et al, 1966; Alvares et gl, 
*1968). In vitro, 3-hydroxy-benzo[a]pyrene is reported to be the major 
end product.
Benzo(ttjpyrene
hydroxylation hydroxylation epoxidation
ydroxybenzopyrene 6-Hydroxybenzopyrene 4,5-Dihydro-4,5- 
dihydroxybenzopyrene
hydroxylation
OH
3,6-Dihydroxybenzopyrene 1,6-Dihydroxybenzopyrene
66
The advantage of using benzo[a]pyrene as a model substrate is that 
small amounts of tissue can be used in the assay since the products of 
the hydroxylation reaction are very fluorescent and thereby small amounts 
of product and reaction rates can be determined. The activation and 
fluorescence spextra of other metabolites and those of 3-hydroxybenzo[ a] pyrene 
are identical in NaOH. Therefore the hydroxylation is normally expressed 
as ng. equivalents of 3-hydroxybenzo [ajpyrene formed, even though the 
fluorescence measured represents a mixture of hydroxylated metabolites.
The Kuntzman et al (1966) modification of Wattenberg et al' s (1962) 
procedure is based on the fact that a solution of 3-hydroxybenzo [a]pyrene 
(10 mg/ml) in 0.1 M. NaOH results in 260 fluorescence units (exc X 
= 382; fluor X - 510 nm.) when the spectrophotofluorimeter is adjusted 
to read 880 fluorescence units (exc X = 340; fluor X = 445 nm) with 
quinine sulphate solution (3 yg ml) in 0.1 M H^SO^. At the wavelengths 
used for measurements of the hydroxylated metabolites of benzo [a]pyrene, 
the shoulder of the quinine sulphate peak gives a reading of about 34 
units. Kuntzman et al (1966) corrected his results for a 61% recovery 
that was obtained when 3-hydroxybenzo [a]pyrene was added to liver homo­
genates and extracted according to his method. The fluorescence of a 
Solution of 3-hydroxybenzo [a]pyrene is linear to at least 100 ng/ml in
1.0 M NaOH, and the quinine sulphate is also linear but to much higher 
concentrations (Fig. 2.8).
Methods
Benzo [a] pyrene hydroxylase activity was measured according to the 
methods of Welch et al (1969) and Juchau (1971). The formation of 3-hydroxy- 
benzo[a]pyrene was expressed as ng. equivalents or unit of fluorescence, 
where one unit of extracted hydroxylated benzo [a] pyrene in 1.0 M NaOH 
equalled 100 ng/ml of quinine sulphate in 0.1 M ^ SO^.
(viii) Hydrolysis of Phenolphtalein Glucuronide
A modification of the Talalay et al (1946) technique was devised 
for measuring placental 3-glucuronidase activity.
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Fig 2.8
Quinine Sulphate Standard Curve
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500-
400
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100-
016 0.9 1.2 1
Concentration of quinine sulphate (yg/ml. 0.05 M I^SO^)
0.3
Fig 2.9
Phenolphthalein Standard Curve
0.251
0.20
0.15
0.10-
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) 40 60 80
Concentration of phenolphthalein (yg/2.5 ml.)
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Methods
Human placental and rat liver particulate fractions were prepared 
in 0.25 M sucrose according to the procedure described previously for 
the aromatization assay. The reaction mixture consisted of the 
following:-
0.1 M Acetate buffer, pH 4.4 .. .. .. 2.00 ml
Phenolphthalein glucuronide (2.5 ymol) .. 0.25 ml
Enzyme Preparation .. .. .. .. 0.25 ml
Total volume 2.50 ml.
The 60 min. incubation at 37° was stopped with 51 (W/V) perchloric acid 
(1 ml) and centrifuged. An aliquot (2 ml) of the supernatant was 
then removed to 0.4 M glycine buffer, pH 10.45 (7.5 ml). This buffer 
was prepared by dissolving glycine (16.3 g) and NaCl(12.65 g) in water 
to which was added 10.9 ml of NaOH (100 g per 100 ml) and then made 
up to one litre with further additions of water. The phenolphthalein 
colour which develops at this alkaline pH is measured at 540 nm.
In the case of control incubates, the substrate was added after 
the 5% (w/v) perchloric acid. Standards of phenolphthalein (10-100 yg 
from a stock solution of 100 mg/100 ml of 80S ethanol) were incubated 
in place of the substrate (Fig. 2.9) when it was shown that the 
glucuronide did not absorb at 540 nm. A detailed account of the develop­
ment of this assay is reported in Chapter 4.
(ix) Conjugation of 4-Methylumbelliferone
The formation of 4-methylumbelliferone glucuronide was measured 
according to the method of Arias (1962) as modified by Neale (1970).
Method
The formation of the glucuronide was determined fluorimetrically 
after reincubating with 8-glucuronidase to release the conjugated 
4-methyl-umbelliferone. In the primary incubation, the media contained
0.1 M tris buffer, pH 7.6 .. .. .. 0.3 ml
4-Methylumbelliferone (0.6 ymol) .. .. 0.3 ml
UDPGA (5 ymol) .. .. .. .. 0.2 ml
Enzyme preparation .. . . .. 0.2 ml
Total volume 1.0 ml
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For hepatic tissues, the homogenate was diluted 1 in 20 before
use. The incubation was carried out in 20 ml glass-stoppered test-
tubes (unstopp&red for incubation) in a Mickel shaking incubator.
Immediately after a 30 min. incubation at 37°, the tubes were placed
in iced-water, and 2.0 ml of distilled water was added. The
incubation mixture was then shaken twice with CHCl^ (10 ml) in 20 ml
test tubes to denature protein and extract unconjugated 4-methyl -
umbelliferone. After each extraction the tubes were centrifuged at
2,000 r.p.m. for 10 min. Aliquots (0.5 ml) of the aqueous layer were
then incubated for 30 min. at 37° with 0.1 M acetate buffer, pH 4.6
(1.0 ml) and 500 units of ketodase (3-glucuronidase) in a total
volume of 2.0 ml. Following this, 0.5 M glycine buffer, pH 10.4
(5 ml) was added and the fluorescence determined in a Baird-Atomic
spectrophotofluorimeter, and compared to the fluorescence of similar
aliquots carried through the same procedure without the ketodase.
The exc was 368 nm and the fluor A _  was 442 nm. The increase max max
in fluorescence following incubation with 3-glucuronidase was considered 
to indicate the amount of 4-methylunibelliferone which was conjugated 
with glucuronic acid in the initial incubation. It was necessary 
to prepare a standard solution of 4-methylumbelliferone and estimate 
its fluorescence (Fig. 2.10).
Fig 2.10 4-Methylumbelliferone Standard Curve
6
5
4
3
Concentration of 4-methylumbelliferone (yg/7 ml)
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(x) Placental Cytochrome P-450
Cytochrome P-450 is present in extra-hepatic tissues in low 
concentrations. Its detection is fraught with technical difficulties, 
and therefore the methodology has been considered in detail in 
Chapter 3.
Carbon monoxide difference spectrum: Aliquots (3 ml) of either the
mitochondrial or microsomal preparations were transferred to two 
quartz cuvettes. GO was passed through one of these cuvettes for 30 sec. 
by means of a Pasteur pipette. Both cells were then placed in an 
SP 1800 dual beam spectrophotometer, and using the scale expansion the 
difference spectrum between 390-500 nm was recorded. From this it is 
possible to determine the carbonmonoxy-haemoglobin absorption at 420 nm. 
To each cuvette was then added several mg. of ^ 820 ,^ and the reduced 
CO spectra was recorded over the same wavelength range. The two spectra 
were superinposed one on top of the other. The absorption at 450 nm 
is due to the presence of placental cytochrome P-450, and the increase 
in absorption at 420 nm is due to the inactive, degraded form of P-450, 
cytochrome P-42Q. Omura and Sato (1964bjhave determined the molar 
extinction coefficients of P-450 and P-420 as being 91 mM”1 cm"'*' and 
llOmM”* cm 1 respectively. These extinction values, based on the 
protoheme content of the haemoproteins from rabbit liver microsomes, 
are measured by the absorption difference between 450 nm and 490 nm, 
and 420 nm and 490 ran. Placental P-450 and P-420 levels were normally 
expressed as nmoles/mg of protein.
Alternative method for 00 difference spectrum: In order to remove the
carbonmonoxy-haemoglobin interference of the P-450 spectrum, CO was passed 
into both cuvettes. This balances out the 420 nm absorption. The 
experimental preparation was then reduced with ^ 282©^ (2 mg) and the 
absorption spectrum from 390-500 nm was recorded.
Ethyl isocyanide difference spectrum: Ethyl isocyanide was also employed
as a ligand for reduced cytochrome P-450. The procedure was the same 
as the first method described, except that instead of CO an ethanolic 
solution of ethyl isocyanide (0.1 ml containing 3.43 ymol) was added to 
the experimental sample. The reduced spectrum was recorded in the 
same manner.
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Binding studies: Substrates for the hepatic mixed function oxygenase
system can bind to oxidized cytochrome P-450 in the form of an enzyme- 
substrate complex. This phenomena can be observed spectrally. One 
class of spectral change (termed type I) is characterized by the 
appearance of a trough at 420 nm and an absorption peak at 385-390 nm.
The second class of spectral change (termed type II), often elicited 
by compounds containing nitrogen, sulphur or oxygen, is characterized 
by the appearance of an absorption peak at about 430 nm and a trough at 
about 390 nm. These binding spectra were achieved by adding microlitre 
quantities (with the use of a Hamiliton micro-syringe) of various 
solutions containing drugs, steroids and fatty acids to the experimental 
cuvette, and by adding an equal volume of solvent to the reference cell.
The protein concentrations of the microsomal and mitochondrial preparations 
used were maintained at about 2 mg of protein/ml and the spectrum
recorded on a 0 -- > 0.2 absorbance scale. Increasing the quantity of
binding substrate increased the magnitude of the spectral change until 
cytochrome P-450 was saturated. A plot of the reciprocal of the 
concentration of the compound, which has been added to the microsomal 
or mitochondrial preparation (2.5 ml), against the reciprocal of the 
change in optical density (from the bottom of the trough to the top of 
the peak), where the line passes through the horizontal axis, gives 
the Kg or binding constant. This is equivalent to the concentration of 
substrate required for half maximal spectral change.
Base line
1-3 = Different protein 
levels
Optical Density Change 
= A + B
ve substrates
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Cytochrome estimations: Cytochrome was determined from the
difference spectrum between NADP (0.2 m^)-reduced and air-saturated 
microsomes (2 mg of protein/ml). The concentration of cytochrome 
bg was measured from the increment of molar extinction between 424 nm 
(peak) and 409 nm in the difference spectrum assuming a molar extinction 
coefficient of 185 mM ^cm~^ (Omura and Sato, 1964a). The haemoprotein 
was measured in terms of nmoles/mg of protein.
(xi) Protein Measurement
Protein was measured by the method of Lowry et al (1951). Bovine 
serum albumin was used for protein standards (Fig. 2.11).
Fig. 2.11 Protein Standard Curve
(Lowry Reaction)
1.0
100 200 300 400 500
Concentration of bovine serum albumin (pg/ml)
(xii) Enzyme Induction
The effect of a number of inducing agents on placental steroid and 
drug metabolizing enzymes was studied. The animals were pretreated 
daily with an intraperitoneal injection of either 50 mg/kg of sodium 
phenobarbital (in saline) or 20 mg/kg of 3-methylcholanthrene ( in ethyl
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oleate) for three days and the last dose was given 24 hours before the 
experiment. Animals used in isosafrole experiments were fed on a 
commercial diet (Spillers Small Animal) containing 0.251 isosafrole 
in ground nut oil. The control animals were given saline, ethyl oleate 
and ground nut oil respectively.
H HC=CH-CH
3
3-Methylcholanthrene Phenobarbital Isosafrole
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5. DEVELOPMENT OF THE AROMATIZATION ASSAY
i) Introduction
In the proposed study on the aromatization of androgens to 
oestrogens, an in vitro assay was developed to monitor placental 
microsomal steroid hydroxylations. The nature of the investigation 
required an effective and convenient procedure. Employing crude enzyme 
preparations the steroid substrate and primary metabolites may be 
exposed to many enzymes simultaneously, and hence further transformations 
may occur. Thus comprehensive chemical purifications of the metabolites 
may be necessary, and hence the time involved may become extensive. An 
appraisal of the available assay procedures, the incubations, extractions, 
purification of the metabolites and determination of oestrogen, were 
therefore undertaken.
ii) Incubation Details
Most reaction mixtures used for placental aromatization of 
androgens are based on the original procedure of Ryan (1959). In this 
study, the highest oestrogen yield was obtained using the incubation 
mixture of Skinner and Akhtar (1969), and was therefore used in preference 
to that of Laumas et al (1968). A typical reaction mixture consisted of:-
Microsomal preparation (= 30g in 0.05M phosphate buffer,
pH 7.1) 2.5 ml
Steroid substrate (0.66 ymol of androstenedione) 0.1ml
NADP (5.2 ymol) ... ... ... ... ... 0.9 ml
G-6-P-dehydrogenase (0.5 Unit) ... ... ... 0.5 ml
G-6-P (26.0 ymol) ... ... ... ... ... 1.0 ml
Total volume 5 ml.
Cofactors were dissolved in 0.05 M phosphate buffer, pH 7.1 and the
steroid substrate in propylene glycol or methanol. The incubation lasted 
1-2 h under air at 37°, and was initiated by the addition of substrate.
The 50 ml conical fl&sks, containing the reaction mixtures, were incubated 
in a Baird and Tatlock shaking water bath.
iii) Extraction and Measurement of Oestrogens
To assess the suitability of different extraction techniques, 
it was necessary to quantitatively measure oestrogens.
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a) Ittrich*s modification of the Kober reaction
The Kober reaction (Kober, 1938) consists of treating 
oestrogens with both quinol and H^SO^ and heating to produce 
a colour complex. Ethereal extracts were routinely dried under 
N2 in the presence of 21 (w/v) quihol in ethanol (0.5 ml) , and 
the residue dissolved in glass-distilled water (0.4 ml) with 
warming. Samples were then placed in a boiling water bath for 
40 min. in the presence of conc. H^SO^ (0.7 ml), after which 
further glass-distilled water (1.5 ml) was added. According to 
the Ittrich procedure (Ittrich 1960a,b.), the ice-cobled Kober 
colour complex may be extracted with 21 (w/v) p-nitrophenol in 
II (v/v) ethanolic tetrabromoethane by mechanical shaking for 
2 min. and subsequent centrifugation (2,500 r.p.m. for 10 min.). 
Following aspiration of the aqueous phase, the tetrabromoethane 
extracts were stored in the dark at 4° in readiness for fluorimetry. 
Tetrabromoethane resulted in a more sensitive fluorescent reaction 
than did trichloroethane or chloroform, and extracted less non­
specific background material. This measurement required reagents 
of the highest purity and acid-washed glassware.
b) Excitation and fluorescence maxima of the oestrone Kober chromogen
The primary metabolite of androstenedione in the placenta is
oestrone, In agreement with Scholler (1968), the excitation and
fluorescence maxima of the oestrone Kober chromagen was found to
be exc \ = 542 nm and fluor \ = 561 nm (Fig. 2.12; 2.13). ThelucLX max.
optimal maxima for total oestrogen was exc 535 nm and
fluor X „ = 560 nm. max
c) Deterioration of the Kober chromogen with time
The stability of a range of oestrone standards (2-20 yg), 
subjected to Ittrich*s modified Kober reaction, was measured at 15 min. 
intervals up to a period of 105 min. (Fig. 2.14). At zero time the 
fluorescence increased linearly up to an oestrone concentration of 
10 yg/3 ml which was reduced to 6 yg/3 ml after the mixture was 
kept in the dark for 105 min. at 4°C. The greater the initial 
fluorescence, the more marked was the loss with time.
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Fig. 2.13 Fluorescence scan of oestrone Kober chromogen
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d) Effect of androstenedione on the oestrone Kober chromogen
The effect of androstenedione on the formation and stability 
with time of the oestrone Kober chromogen was determined (Fig. 2.15).
In the presence of a nine-fold concentration of androstenedione, 
the fluorescence of the oestrone chromogen no longer increased 
linearly within the concentration range 0-10 yg/8 ml., and demonstrated 
a rapid diminution of its fluorescence within 75 min.
iv) Oestrogen Extraction Procedures
A variety of methods for isolating oestrogens, mostly from urine, 
were considered for use with the aromatization assay (Conaill and Muir,
1968; Brombacher et al, 1968; Nordstrom, 1968; Oakey et al, 1967;
Cohen, 1969; Corns and James, 1968; Eechaute and Demeester, 1965;
Roy, 1962; Hobkirk and Metcalf e-Gibson, 1963).
a) Gel filtration
Eechaute and Demeester (1965) described a procedure for gel 
filtration of enzymically hydrolyzed urine in which considerable 
purification of the oestrogen content was achieved. Free oestrogens, 
oestrone, oestradiol-173 and oestriol could be eluted quantitatively 
(about 951) with water from a sephadex G-25 column. The diethyl 
ether extracts of the eluates were washed with Na2Co2 buffer to 
remove further impurities without any loss of oestrogen, since 
although the pH is 10.3, the ionic strength of the solution is 
sufficient to prevent this. A subsequent wash with a bicarbonate 
solution removed acid impurities.
b) Rapid ether extraction (Nordstrom, 1968)
Crude oestrogen extracts are obtainable by several extractions 
with diethyl ether, and subsequently washing these with Na2C03 
buffer, pH 9.5. Oestrogens may be measured quantitatively, if 
the specific reaction is not affected by background material.
c) Comparison of the extractive efficiencies of the two procedures
Gel filtration produced inconsistent oestrone recoveries that 
were not related to different filtration rates of individual 
columns. In contrast, extraction with ether resulted in high oestrone 
recoveries that were relatively constant. A 63% oestrone recovery
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from placental incubates was achieved in the absence of androstenedione. 
An equimolar concentration of the latter steroid reduced oestrone 
chromogen fluorescence by 101, presumably by interfering with the 
Kober reaction and not by influencing oestrogen recovery. When 
placental incubates were extracted four times with ether, the 
oestrone was recovered mainly in the first two extracts (Fig. 2.16), 
though there was some variation in. the total recovery.
d) Partition with sodium hydroxide
Oestrogens being phenolic in character are readily taken up 
in alkali whereas neutral androgens are not. Oestrone was there­
fore partitioned between ether and 0.1 M NaOH to remove androstenedione. 
The alkaline extracts were then treated with 2 M HC1 to attain a 
pH of between 7.5-8.5, and oestrone re-extracted back into ether.
This modification affected considerable purification, but as a 
procedure was too time consuming to be of value.
e) Thin-layer chromatography
Ethereal extracts, previously washed with ^ C O ^  buffer,
pH 9.5, were applied to thin-layer chromatographic (t.l.c.) plates
as. bands. Fine capillary tubes were used for this application.
The 20 x 20 cm t.l.c. plates were coated with a layer (0.035 in.)
of double fluorescent silica gel (exc A = 254 nm and 366 nm).° V  max J
The solvent systems originally examined were:
Cyclohexane/Ethyl Acetate (1:1 by volume) 
Chloroform/Acetone (185:15)
Benzene/Ethyl Acetate (6:1) (2:1)
Cyclohexane/Ethyl Acetate/Ethanol (45:45:10) 
Benzene/Acetone (5V ^ 0) (3:1)
The solvent system which resolved most effectively the androgens 
and oestrogens under study was benzene/ethyl acetate (2:1). The 
following Rp values were determined with this solvent system.
Oestrone = 0.75
Oestradiol-173 = 0.50
Oestriol = 0.05
Androstenedione = 0.45
Testosterone = 0.29
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During the course of these investigations, a number of Rp values 
were determined for different steroids (Fig. 2.17). The 
3-oxo steroids such as androstenedione were visible under 
ultra-violet light as purple spots in concentrations as low as 
a few micrograms. Oestrogens could be located under u.v. light, 
particularly at 254 nm, as faint yellow regions, but detection 
of low levels could not be depended upon by this method alone.
The alternate method was to spray t.l.c. plates with 0.1 NJ KMnO.
4in alkali which readily shows A -3-oxo containing compounds as 
yellow spots against a purple background, and was effective 
down to 5 yg. For the aromatization assay, oestrone standards 
were spotted either side of the incubate band and were exposed to 
the KMnO^ reagent alone. Location of the experimental oestrone 
band was checked under u.v, at 254 nm.
f) Choice oestrogen pufication procedure
Placental incubates were extracted with ether (2 x 10 ml), 
which in turn was washed with ^ 2^3 buffer, pH 9.5. The organic 
extract was dried with anhydrous Na2S0  ^and evaporated under 
N2 at 37°. The residue was taken up in methanol (2 x 0.1 ml) 
and spotted on to a t.l.c. plate. Ether was the solvent of 
choice since chloroform and ether/ethanol extracted large amounts 
of microsomal lipid which served to reduce the R£ of oestrone. 
Ether was also the most readily evaporated.
The oestrogen recovery from a t.l.c. plate was virtually 
100%, but from a placental incubate it varied considerably. To 
determine the overall oestrogen recovery in the aromatization 
assay, reverse isotope dilution was introduced. 7a-[ H]Androst- 
4-ene-3,17-dione was incorporated into the incubate at 5 yCi 
per 0.66 ymol substrate. Following incubation, unlabelled 
oestrone (500 yg) in methanol (0.5 ml) was added to each reaction 
mixture prior to ether extraction.
After t.l.c. , oestrone was eluted with methanol (2 x 4.5 ml) 
which was made up to a final volume of 10 ml. Aliquots (0.1 ml) 
were taken for the Ittrich's modification of the Kober reaction 
and liquid scintillation counting. Oestrone standards were also 
taken through the Kober reaction (Fig. 2.18).
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Fig. 2.18
Oestrone Standard Curve 
(Kober Reaction)
Concentration of oestrone (yg/3 ml)
g) Liquid scintillation counting
Aliquots (0.1 ml) of oestrone in methanol were transferred 
to scintillation vials and dried under ^  before scintillator 
was added. The drying practice was eventually abandoned because 
it made very little difference in the counting efficiency. 
Naphthalene scintillator (10 ml) was replaced by one based on 
toluene (4 g. of PPO and 10 mg. of dimethyl POPOP per litre of 
toluene) giving a counting efficiency of approximately 50%. The 
liquid scintillation counters used were
Type of instrument
Tracerlab Spectromatic 
(ambient temperature)
Packard Model 3320 Tri-Carb 
Spectrometer
Packard Model 2425 Tri-Carb 
Spectrometer
Settings
Course Gain 32, Fine Gain 1.4 
Window 530, Threshold 25
Gain 45, Window 40-1000 
Gain 45, Window 40-1000
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Instrument settings were occasionally modified, though a Gain
3of 45 was normally optimal for H counting in the Packard 3320 
Tri-Carb (Fig. 2.19). The purity of the radioactive steroids 
used were routinely checked by t.l.c. and the melting point of 
unlabelled steroids were also determined at regular intervals.
The purity of isolated oestrone from placental incubates was 
determined by measuring the specific activity following several 
t.l.c. purifications, and also after methylation and acetylation, 
details of which are given in Chapter 5.
Fig. 2.19
Optimal Gain Setting for Tritium Counting
52-
51-
50-
iT
Gain settings
Packard Model 3320 Tri-Carb Spectrometer.
Window = 40-1000
h) Determination of oestrone yield
Knowing the specific activity of the isolated oestrone or 
oestradiol, it is possible to calculate the amount of product formed
using the simple equation:-
a = b ■ a = Oestrone produced enzymically (yg)
Z-l b = Oestrone added for reverse isotope
dilution (yg)
 ^_ sp. activity of androstenedione (yCi/ymol) 
sp. activity of oestrone (yCi/ymol)
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Aromatization was expressed in terms of pmol. of product; 
ymol/g. wet wt./h. and nmol/mg of protein/h. For control 
experiments, microsomal protein was boiled since ether was a 
poor denaturing agent.
i) Programme for measuring placental aromatization
3
Incubated microsomal preparation with [ H] androstenedione 
+ NADPH generating system for 60 min.
Add unlabelled oestrone (500 pg), ether extraction 
dry with Na2S0  ^and evaporate in ^
V
t.l.c. in benzene/ethyl acetate (2:1) 
Elute with methanol.
Liquid scintillation counting Ittrich*s modification of the
Kober reaction
Calculate sp. activity of oestrone 
Determine rate of aromatization.
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6. (d-HYDROXYLATION OF LAURIC ACID
COOH
CD—1
COOH
CH.
Laurie Acid
COOH
1 CH2) 9
CHOH
CH.
o)-l Hydroxy 
Laurie Acid
(CH9)2'10
ch2oh
w-Hydroxy Laurie Acid
COOH
ai2)io
oooh
1,12-dodecanedioic Acid
Methods
The procedure of Lu, Junk and Coon (1969) is based on incubating
r 14 ,
11- C J lauric acid with a microsomal preparation, and then purifying the 
to-hydroxy lauric acid so formed by silicic acid chromatography. The 
reaction mixture consists of:-
NADP (1 ymol) ... ... ... ... 0.3 ml.
G-6-P (5 ymol) ... ... ... ... 0.3 ml.
G-6-P-dehydrogenase (0.3 Unit) ... ... 0.3ml.
Lauric acid (125,000 d.p.m./0.4ymol)
Microsomal preparation (1 mg of protein)
Total Volume
Benzene solution dried 
under N2
0.1 ml.
1.0 ml.
Cofactors for the NADPH generating system were dissolved in 0.1 M phosphate 
buffer, pH 7.7. The 30 min. incubation carried out under air at 37°, was 
terminated with 101 (v/v) H2S04 (0.4 ml). Lauric acid and its metabolites
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were extracted with benzene/ether (9:1 by volume) (5ml).
Separation of metabolites was attempted with reverse phase partition 
chromatography using silica gel G. t.l.c. plates (0.030 inch thick) 
impregnated with 5% (V/v) liquid paraffin in light petroleum ether 
(60-80°). These were developed in acetic acid/acetonitrile (1:1 by 
volume), the solvent front being allowed to travel 15 cm. By counting 
1 cm bands of silica gel in a toluene/ethanol based scintillator (toluene 
1500 ml, ethanol 600 ml, PPO 4.5 g, dimethyl POPOP 150 mg) the Rp of 
lauric acid was determined as 0.79. Detection of fatty acids on t.l.c. 
was attempted with u.v. light (exc m^ax = 254 and 366 nm), ethanolic 
Rhodamine B (0.05V W/v), ethanolic molybdophosphoric acid (5% . w/v), and 
bromothymol blue (40 mg/100 ml. 0.1 M NaOH). The Rp values of the 
metabolites were indistinguishable from that of lauric acid. .
Lauric acid was separated from its polar metabolites by chromatography 
of a benzene/ether (9:1) extract on a silica acid column packed in benzene, 
and eluting with further benzene/ether (9:1) to remove the lauric acid 
(Lu, Junk and Coon, 1969). The metabolites, eluted with benzene/ether 
(1:1 by volume), could be separated by chromatography on a citrate- 
buffered silicic acid column. A uniform grade of silicic acid, obtained 
by wet floatation according to the method of Bulen et al (1952), was 
packed in columns as reported by Kusunose, Kusunose and Coon (1964).
Since the experiments undertaken were of a qualitative nature, 
purification of metabolites was not necessary. The elution patterns 
from the first silicic acid column were identical with those of Kusunose, 
Kusunose and Coon (1964).
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7. CHARACTERIZATION OF PLACENTAL SUBCELLULAR FRACTIONS
i) Marker Enzymes
The homogeneity of various subcellular fractions were examined 
by means of marker enzymes. Three systems were chosen; succinate 
dehydrogenase as a marker for mitochondria; acid phosphatase as a 
marker for lysosomes and glucose-6-phosphatase for microsomes.
a) Succinate dehydrogenase
Methods
The incubation mixture consisted of:-
0.3 ml of 0.2 M phosphate buffer, pH 7.4, containing 1.25 mg
of 2-(p-iodophenyl)-5-phenyltetrazolium chloride (INT) per ml.
0.25 ml or 0.5 ml of subcellular fraction.
0.2 ml of 0.3 M succinate adjusted to pH 7.4.
Following a 30 min. incubation at 37°, the reaction was terminated 
with ice-cold 6% (W/v) trichloroacetic acid (1.5 ml). The reduced 
INT was extracted with ethyl acetate (4 ml) and the mixture 
centrifuged to produce two immiscible layers. An aliquot (1 ml) 
of the organic layer was further diluted with ethyl acetate (6 ml) , 
and the extinction measured at 490 nm. Standards of reduced INT 
were carried through the procedure (Fig. 2.20).
Fig. 2.20
Reduced INT Standard Curve
0.05
0.10
0.15-
0.20.
0 3.*06 6 .'13 9.19 12^25 15.32 18.38
Concentration of reduced INT (yg/ml)
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b) Glucose-6-phosphatase 
Methods
The incubation mixtures consisted of:-
0.3 ml of 0.2 M 3,3-dimethylglutarate (EMG), pH 6.4
0.1 ml of 0.01 M EDTA di Na
0.25 ml or 0.50 ml of subcellular fraction
0.1 ml of 0.05 M glucose-6-phosphate.
Following a 30 min. incubation at 37°, the reaction was stopped with 6% 
(w/v) trichloroacetic acid (1.5 ml) and centrifuged. The supernatant 
was collected to which was added 51 (W/v) perchloric acid (1.5 ml) 
containing 0.6$ (W/v) ammonium molybdate, followed by freshly 
prepared 0.2V (W/v) ascorbic acid solution (0.5 ml). After 30 min. 
the absorbance of the developed colours was measured at 720 nm. 
Phosphate standards were carried through the reaction (Fig. 2.21).
Fig. 2.21
Phosphate Standard Curve
0.5
0.1-
Concentration of phosphate (yg/ml)
c) Acid phosphatase 
Method
The incubation mixture consisted of:--
0.3 ml of 0.2 M PMG, pH 5.0
0.25 ml or 0.50 ml of subcellular fraction
0.2 ml of 0.5 M Na-3-glycerophosphate preadjusted to pH 5.0.
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The tissue suspensions were frozen and thawed (cellosolve/solid CO^ ) 
at least five times. The procedure was as for glucose-6-phosphatase. 
All cofactors other than where stated were prepared in 5m^ tris, 
pH 7.4/0.25 y sucrose solution, and the pH adjusted where necessary. 
Enzyme activity was expressed in activity/mg of protein/hour.
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ii) Electron Microscopy
Electron microscopy was employed to verify the homogeneity of the 
mitochondrial and microsomal fractions of the full-term human placenta 
and the rat liver.
Method
The subcellular fractions were prepared as described for the 
cytochrome P-450 studies. The liver and placental pellets were 
extracted with 31 (W/v) glutaraldehyde, buffered with 0.1 M 
dimethylglutarate, pH 7.4. The hardened fractions were chopped into
3
very small blocks (1 cm ) with a scalpel blade. These were then 
fixed for 1 to 2 hours at 4° and then washed in double glass distilled 
water buffered at pH 7.4 for several hours, and post-fixed in II (w/v) 
osmic acid for one hour. The blocks were dehydrated by immersion 
in 301, 501 and 701 alcohol respectively for 5 min.. They were then 
rinsed in absolute alcohol twice for 5 min. and immersed in propylene 
oxide for 15 min. Finally they were embedded in araldite in capsules 
and left to harden. The four capsules were kindly cut, and examined 
under the electron microscope, in the Anatomy Department of the 
Royal College of Surgeons by kind permission of Professor G. Causey.
The preparation of rat liver mitochondria for electron microscopy 
was unsuccessful. However, for comparative purposes, a photograph of 
human liver mitochondria is included.
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INTRODUCTION
Cytochrome P-450, earlier referred to as the CO-binding pigment,
was first described by Klingenberg (1958), Garfinkel (1958) and
Omura and Sato (1962, 1964a, 1964b). It is found in abundance not 
only in hepatic microsomes, but also in the microsomes and mitochondria 
from the adrenal cortex, where it functions in the hydroxylation of 
steroids (Estabrook et al, 1963; Omura et al, 1965) although not in 
the oxidation of most drugs. Lesser amounts are found in the kidney 
and intestinal mucosa. The presence of cytochrome P-450 has also been 
reported in mitochondria from the corpus luteum (Yohro and Horie, 1967) 
and the placenta (Meigs and Ryan, 1968).
Cytochrome P-450 cannot be assumed to be identical in every tissue
or species; the substrate specificities of the enzyme systems involving
adrenal and hepatic cytochrome P-450 differ greatly, and differences 
are also seen in the substrate specificities of the drug-metabolizing 
systems of hepatic microsomes from various species. These differences 
are veiy likely due to the way in which cytochrome P-450 is associated 
with the microsomal membrane or in qualitative and quantitative differences 
in other components of the enzyme system, but it is also possible that 
cytochrome P-450 may exist in a variety of forms.
Cytochrome P-450 is measured by the difference spectrum seen when 
it is reduced, usually with dithionite, and combined with CO. NADH and 
NADPH reduce cytochrome P-450 only in the absence of molecular 0^ , the 
pigment being susceptible to autoxidation. About 501 inhibition of 
hydroxylation reactions is obtained when the CO/O^ ratio is about 1 
(Omura et al, 1965). Deteimination of the absolute spectrum of cytochrome 
P-450 is complicated by the presence of its derivative cytochrome P-420, 
and by cytochrome b^ . The problem has been solved to a large degree by 
removing cytochrome b^ from the microsomes with steapsin treatment, and 
by stabilizing cytochrome P-450 with glycerol. Cytochrome b^ has been 
selectively removed also by treatment with a proteolytic enzyme (Sato 
et al, 1969) and with a nonionic detergent, Lubrol WX (Miyake et al, 1968).
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Kinoshita and Horie (1967) proposed a method for obtaining the absolute
spectrum in microsomes, based on the knowledge that cytochrome b^ is the
only microsomal cytochrome other than cytochrome P-450 and that the
administration of inducing agents such as phenobarbital cause a large
increase in the concentration of cytochrome P-450 without affecting
appreciably the cytochrome b^ level. Suspensions of microsomes from
untreated rabbits, and rabbits treated with phenobarbital, were diluted
so that each contained an equal amount of cytochrome b,-. With respect
to the haemoprotein content, the only apparent difference between these
two preparations was their cytochrome P-450 content.
\
Solubilization of cytochrome P-450 from microsomes has been effected 
through a number of techniques including treatment of hepatic microsomes 
with the non-ionic detergent Triton N-101, and fractionating the supernatant 
on a DEAE cellulose column. Similarly, sodium deoxycholate and detergents 
such as Tween 80 have also brought cytochrome P-450 into solution. However, 
attempts at solubilization has often produced considerable degradation 
of cytochrome P-450 to its inactive form, cytochrome P-420.
Cytochrome P-450 may be converted to cytochrome P-420 by a wide 
variety of agents: snake venom containing phospholipase A (Omura and 
Sato, 1964a, 1964b), detergents such as sodium deoxycholate and 
lysolecithin; the metal-binding reagents, bathocuproine sulphonate, and 
bathophenanthroline sulphate; trypsin; urea; guanidine; neutral salts; 
the mercurial-sulphydryl binding agents: p-chloromercuribenzoate, 
p_-chloromercuriphenyl sulphate and HgCl^; iodine; aniline; alcohols; 
and a variety of amides and phenols. Cytochrome P-420 is frequently 
solubilized as it is formed, but this need not be the case; for example 
cytochrome P-420 that forms when microsomes are incubated with purified 
phospholipase C remains bound to the microsomes (Chaplin and Mannering,
1969).
Cytochrome b^ , a component of the endoplasmic reticulum, is largely 
responsible for the intense red colour of hepatic microsomal pellets. 
Interest in this haemoprotein stems largely from the effect it may have 
on the absolute spectrum of cytochrome P-450, and recent implications 
that it may participate as an electron donor in the oxygenation of drugs 
and steroids through the terminal oxygenase, cytochrome P-450 (Hildebrandt 
and Es tab rook, 1970). Cytochrome b^ is reduced by NADH through NADH-
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-cytochrome reductase, a specific flavoprotein. Reduced cytochrome 
b(- can reduce cytochrome c by a direct cytochrome to cytochrome transfer.
However, NADH cytochrome b^ reductase is not able to reduce cytochrome c 
in the absence of cytochrome b^ . The cytochrome b^ NADH difference 
spectrum is measured by the increment between the 424 nm absorbance peak 
and the 409 nm baseline.
Measurements of cytochrome P-450 and b^ in extrahepatic tissues 
is fraught with technical difficulties. The veiy nature of the organs, 
such as the quantity of connective tissue, makes tissue homogenization 
very difficult. The vigorous mechanical homogenization necessaiy to 
effect full tissue disruption is often sufficient to degrade cytochrome 
P-450 to cytochrome P-420. This is disadvantageous, since extrahepatic 
tissues are low in cytochrome P-450 to begin with. An additional hazard 
is the interference of the difference spectrum by the presence of 
carboxyhaemoglobin. In hepatic microsomes, the haemoglobin can normally 
be completely removed by several washings with 1.15% KC1. In the case of placenta, 
the veiy large quantities of blood present cannot effectively be removed by such 
a procedure.. It is indicated further on that the haemoglobin-binds to 
placental microsomes, and thereby readily masks the cytochrome P-450 
difference spectrum. In conjunction with low concentrations of cytochrome 
P-450 in extrahepatic tissues, there is often a correspondingly low 
microsomal content. Considered together, these factors make cytochrome 
P-450 determination difficult and probably accounts for the many negative 
findings.
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RESULTS
A. Cytochrome P-450 in the Wistar/albino rat
(i)Determination of cytochrome P-450 levels
The content of cytochrome P-450 and of placenta, foetal and 
maternal liver of the pregnant rat was measured. The presence of this 
haemoprotein was also investigated in mature male testes. Attempts 
were made to follow any variations in the levels of cytochrome P-450 
with the period of gestation. In rats up to fifteen days pregnant, 
the placentae were very small and ill-defined. Since it was difficult 
to free the placentae without the risk of simultaneously dissecting 
out foetal and uterine tissue, only animals at least fifteen days 
pregnant were studied. These were then divided into three groups 
depending on whether they had been pregnant for 15-17, 18-20 or 21 days 
(full-term).
Because of the low levels of cytochrome P-450 in the placenta, it 
was necessary to concentrate washed mitochondrial and microsomal 
suspensions to a protein concentration approaching 15 mg/ml. This was 
also the case for foetal liver microsomes. In contrast, maternal liver 
cytochrome P-450 could be determined in microsomal suspensions of protein 
concentrations lower than 1 mg/ml.
Measurements of placental cytochrome P-450 content are tabulated 
in Fig. 3.1. The changes in the reduced spectrum induced by ethyl 
isocyanide is expressed as changes in absorbance at 455 nm and 430 nm 
relative to 500 nm, per milligram of protein. The CO-binding haemoprotein 
could not be detected with rat placental mitochondrial fractions at a 
level equivalent to 0.01 nmol/mg of protein. The administration of 
3-methylcholanthrene, phenobarbital and hexobarbital did not induce 
measurable levels of cytochrome P-450. This negative finding was apparent 
although haemoglobin was more effectively removed from mitochondrial 
preparations than it was from those of microsomes. Cytochrome P-450 
appeared to be present in placental microsomes at 18-20 days of gestation, 
but not at 15-17 or 21 days. The level of 0.01 nmol/mg of protein was 
at the limit of sensitivity of the method. The absorption at 450 nm 
(Fig. 3.2) appeared as an extended peak. Using ethyl isocyanide as the 
ligand, the characteristic absorption at 430 nm was apparent but no
99
Fi
g,
 
3.
1 
Th
e 
Cy
to
ch
ro
me
 
P-
45
0 
Co
nt
en
t 
of 
Ra
t 
Pl
ac
en
ta
l 
Mi
cr
os
om
al
 
Pr
ep
ar
at
io
n
j=f
rdK>
§ o
rH
S  x
.3w
t/)m 0
I
P
•3o
p
0
Ps
p. 0 .'d
£  *H O K 
rO O
■S|u s
LOLOH*
otoH"
O
LOH'
op
•so
0 m  0
s ° 2
•H ££ 0 0 U 
p  cd /— \ fl rl H
S'S
rH O  0  '
Cd LO r— |
OO I o H Ph P.
,S
rH 0  
0  Q  P
1 1 8
o o m o LO o 
p  h- 
X  I bp U(^ 6
csj
to Oto Oto
cn
O
is-
to*
csj
•
O 
+ 1 
00 
O
00 
o 
+ 1
oo
O
V
O
o
csj
O
o 
+ 1
h-
o
o
v
o
V
o
V
o
V
o
V
o
V
o
V
'S £  v
cd cd cd rH rH rH
p rH rH rH rH cd cd cd
£ cd O O o P P P
0 t— \ P rX
•5
X •H •H •H
B C/> • H o u X X X
£  X J2 rH rH rH P P P
cd c? X X X cd cd cd
0  03 cd ,£ XJ r£ X X X
P X P p P Q o Q
P  to o 0 0 & £ £ £0  S_/ x S' S s 0 0 0
P 0 1 i 1 r£ X X
Pr X to to to P Pi Or
<P £
O  O  /-s
•H to
03 P  X
O  cd cd 
•H P  03
r- O s- t"- o t-- o
iH CS] rH rH CSJ rH CSJ
P  V) ' 1 l rH 1 1 l rH 1 I rH
0  0 LO oo CS] LO LO oo <N] LO oo CS]
P. CD rH rH rH rH rH rH rH
pH
cd
P
£
0
o
cd
rH /— s CT> H" LO H- vO cn \D vO rH
P  bO « • . • . • . . • • ' •
03
0  P
o o rH O o o O o o rH
+ 1 + 1 + 1 + | + 1 + 1 + 1 + 1 + 1 + l
rH ^
O CS] r^ - cn oo rH LO to to rH
o • • • • • • • ' • • •
Pi LO h- cn H" H- LO to to t>-
/— \ t— \ t— \ /— \ /— \ /— \ t— \ /— \ t— \
H" to H" H H" H* H"'_> V_> '■—' v_/ '_/ '—' v—' V_/ v_/ '— '
S CS] CN] O O rH O
**vO rH rH 00 rH rH rH cnrH
+ 1 + 1Cd /— x + | + 1 + | +1 + | + | + | + |B bfl.JH v_' to H- 00 00 b- rH o cn rH
£ cn LO r--. cn cn o CSJ tN. IS- o
< <SJ to to CSJ CN] to to to to to
Q
CO
100
Fi
gu
re
s 
in 
pa
re
nt
he
si
s 
re
pr
es
en
ts
 
th
e 
nu
mb
er
 
of 
an
im
al
s
absorption was seen at 455 nm. Pretreatment with phenobarbital and 
hexobarbital throughout the period of pregnancy studied was without 
effect on placental microsomal cytochrome P-450 (< 0.01 nmol/mg of 
protein). In contrast, 3-methylcholanthrene stimulated placental 
microsomal cytochrome P-450 to a level of 0.04 nmol/mg of protein.
This effect was, however, observed only at term and not at 15-20 days.
In Fig. 3.2 there is a strong absorbance at 420 nm, thought to be 
due to the presence of carboxyhaemoglobin (Omura and Sato, 1964a,1964b). 
Similarly, in the ethyl isocyanide reduced spectrum (Fig. 3.3), there 
is a peak absorbance at 430 nm, also possibly due to haemoglobin. Since 
washed placental microsomal pellets were devoid of red pigment, it was 
questioned whether the observations described above were due to the 
presence of haemoglobin. This was investigated by bubbling CO into the 
experimental cuvette, containing placental microsomes, without prior 
addition of ^ 2820 .^ The absorbance peak appeared at 415 nm instead 
of 420 nm. When this was repeated using the 105,000 g.av. supernatant 
of maternal liver, the characteristic carboxyhaemoglobin spectrum was 
obtained. Clearly the presence of microsomal material effected the 
oxidized absorbance spectrum of carboxyhaemoglobin. Following these 
observations, the absorption spectrum of reduced carboxyhaemoglobin was 
measured. Blood was procured from a rat by heart puncture. The red blood 
cells were washed, and then lysed in water. Using CO as the ligand, a 
reduced carboxyhaemoglobin spectrum was obtained with absorbance peaks 
at 470, 411 and 371 nm, and with ethyl isocyanide the maximum absorption 
was at 480, 425 and 375 nm. It was assumed from this experimental data 
that microsomes alter the absorption peak of reduced carboxyhaemoglobin 
from 411 nm to 420 nm, and that of the reduced ethyl isocyanide complex 
from 425 nm to 430 nm. It has been demonstrated further on in this chapter, 
that haemoglobin binds to placental microsomes, which would explain the 
phenomena described here.
Cytochrome P-450 in the rat maternal liver was associated with 
the microsomes only (Fig. 3.4). The level of the haemoprotein per 
milligram of protein was diminished throughout the period of pregnancy 
studied. As pregnancy progressed there was no marked change in liver 
weight, although the total cytochrome P-450 content of the liver was 
slightly reduced at full-term. Hexobarbital pretreatment did not
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Fig 3.2 CO Difference Spectrum of RAt Placental
Microsomal Cytochrome P-450
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Fig 3.3 Ethyl Isocyanide Different Spectrum of Rat Placental
Microsomal Cytochrome P-450
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significantly change maternal liver cytochrome P-450 levels at 15-17 
days of gestation, but 3-methylcholanthrene increased the concentration 
by 124% at the same period and by over 500% at full-term. Similarly, 
phenobarbital administration elevated the concentration of haemoprotein 
by 160% at 15-17 days, but by 283% at 18-20 days (total cytochrome 
P-450 in liver). In Fig. 3.4, it is apparent that carboxyhaemoglobin 
is less of a problem with hepatic microsomal preparations. The markedly 
higher cytochrome P-450 content of liver allows demonstration of the 
reduced ethyl isocyanide complex with absorption peaks occurring at 455 nm 
and 430 nm (Fig. 3.6).
In accord with many previous reports (Dallner et al, 1966), rat 
foetal liver was virtually devoid of cytochrome P-450 from day 15 to 21 
of gestation (Fig. 3.7). However, treatment with enzyme inducers 
stimulated haemoprotein synthesis, and hereby provided evidence of such 
agents having traversed the placental barrier. Hexobarbital induced 
foetal liver cytochrome P-450 at days 15-17, while 3-methylcholanthrene 
and phenobarbital were found to be effective by day 21. All inducers 
stimulated cytochrome P-450 levels to 0.08 nmol/mg of protein. Since 
hexobarbital, phenobarbital and 3-methylcholanthrene all induced to the 
same extent, there may be a limited capacity in the endoplasmic reticulum 
for this particular enzyme synthesis, or a feedback control determining 
the level of the cytochrome. The addition of ethyl isocyanide to reduced 
microsomes from a hexobarbital treated rat produced an absorbance at 430 nm 
but not 455 nm (Fig. 3.9). Since as with placental microsomes, the 
carboxyhaemoglobin contribution to the spectrum was greater than that 
by cytochrome P-450, the absorbance at 430 nm by foetal liver microsomes 
in the presence of ethyl isocyanide was probably also due to haemoglobin.
Placental microsomal preparations of Wistar/albino rat clearly 
contain very low concentrations of cytochrome P-450. The level in 
placental tissue at 18-20 days, represents only 1.36% and 0.69% of 
that found in the whole livers of pregnant and non-pregnant animals 
respectively. The haemoportein was found also in the placentae of full- 
term animals pretreated with 3-methylcholanthrene, and here the total 
content was only 0.79% of that observed in maternal liver. Barbiturates 
did not increase placental cytochrome P-450.
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Fig 3.8 CO Difference Spectrum of Rat Foetal Liver
Cytochrome P-450
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Fig 3.9 Ethyl Isocyanide Difference Spectrum of Foetal Rat Liver
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Fig, 3.10 The microsomal cytochrome P-450 content of rat placenta and
foetal liver expressed as a percentage of that of maternal liver
Tissue Gestation
(days)
Pretreatment % of Maternal Liver 
Cytochrome P-450 Content
Placenta 18-20 1.4
Placenta 21 3-Methylcholanthrene 0.8
Foetal Liver 15-17 Hexobarbital 0.3
Foetal Liver 21 3-Me thy lchol anthrene 0.1
Foetal Liver 21 Phenobarbital 0.1
Throughout the period of gestation studied, placental cytochrome 
bj. was not present in measurable amounts. The administration of 
hexobarbital, phenobarbital and 3-methylcholanthrene was without 
effect. In the maternal liver, the cytochrome b,- concentration was 
maintained at 0.25 nmol/mg of protein from day 15-21 of gestation. 
Induction experiments did not alter this level, though the overall 
content may have been marginally increased due to liver enlargement.
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(ii) Substrate binding to cytochrome P-450 in the rat
In characterizing placental oxygenases, the ability of drugs and 
steroids to produce type I and II spectral changes with cytochrome P-450 
was investigated. The occurence of binding is not indicative of 
metabolism, and metabolism may not require in vitro binding. For 
comparative purposes, the type of spectral change observed with hepatic 
microsomal preparations using the same compounds was also studied. The 
spectral dissociation constant (Kg)> which is the concentration of 
substrate required for half maximal spectral change, was determined 
where possible.
a) Rat placenta
The binding of various drugs and steroids to placental micro­
somal cytochrome P-450, obtained from control and 3-methycholanthrene- 
treated rats (full-term), did not prove possible. The minimal 
level of CO-binding haemoprotein prevented the detection of any 
spectral changes with the oxidized fractions. Metyrapone could 
not be used as an alternative ligand for reduced cytochrome P-450.
The same negative findings were obtained with placental mitochondrial 
fractions.
b) Rat maternal liver
It was also intended to investigate the nature of binding to 
cytochrome P-450 of compounds under study in the placenta. Female 
Wistar/albino rats (approx. 350 g) were killed by cervical fracture 
and the livers homogenized in 3 vol. of 1.15% KC1. The microsomal 
pellets were washed once in this media, and stored overnight under 
glycerol/0.05 M phosphate buffer, pH 7.4 (1:1 v/v) at -15°. The 
following day the pellets were resuspended in 0.1, M phosphate 
buffer, pH 7.4 to a protein concentration of 2.54 mg/ml. The 
cytochrome P-450 content was 0.76 nmol/mg of protein. The type of 
binding and Kg values found are shown in Fig. 3.11. The routine 
determination of Kg values is normally completed immediately 
microsomes have been isolated. Storage degrades cytochrome P-450 
to P-420, and hence diminishes the amount of binding and may also 
produce qualitative changes in the haemoprotein. Hence the Kg values 
shown here can only strictly be compared to those of similarly
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Fig. 3.11 The binding of various compounds to rat liver
microsomal cytochrome P-450
Compound Solvent Type of 
Binding
Ks
(iriM)
Text
Figures
Aminoglutethimide methanol II 0.50 3.12
Andros tenedione methanol I
Aniline ethanol II 0.29 3.18
Biphenyl ethanol I 3.17
Carbon tetrachloride ethanol I 3.33 3.15
DDT DMF I
Dimethyl formamide (DMF] - II?
Ethanol - II 50.00 3.14
Glutethimide methanol I 3.13
Iproniazid DMF II 3.19
Laurie acid methanol I
3-Methasone DMF H?
Metyrapone methanol II 9.0 x 10'2 3.20
Nicotinamide water II 0.83 3.16
Oestrone methanol I
Progesterone methanol I
SKF-525A DMF I 7.11 x 10-3
Spironolactone DMF II?
Testosterone methanol I
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Binding Spectra with Rat Liver Cytochrome P-450
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Metyrapone Binding to Rat Liver Cytochrome P-450
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stored microsomal preparations though in practice the K does not 
significantly change under these conditions of storage.
Nearly all the compounds tested showed a type I or II binding 
spectra, with the exception of dimethylformamide, 3-methasone and 
spironolactone. Determination of Kg values indicated that metyrapone 
and SKF-525A have a high affinity for hepatic cytochrome P-450. 
Nicotinamide, aniline, aminoglutethimide and glutethimide (Kg not 
measured) also readily bind to the haemoprotein, as did ethanol and 
iproniazid. The steroids, oestrone, progesterone, testosterone and 
3-methosone were generally poor binding substrates. Laurie acid 
produced a weak type I spectral change.
The addition of dithionite to both cuvettes abolished the type II 
spectrum of metyrapone and produced the characteristic absorbance at 
448 nm (Fig. 3.21).
(iii) Testicular cytochrome P-450
Rat testes (average pair weighing 3 g) were found to be low in 
microsomal protein (3 mg/g tissue) compared to liver (25 mg/g of tissue), 
but the cytochrome P-450 content, however, was found to be associated 
only with this fraction (Fig. 3.22). In Fig. 3.23, the testicular 
concentration of cytochrome P-450 per unit weight of microsomal protein 
was found to represent only 3.31 of that of liver.
Fig. 3 .23 Effect of phenobarbital pretreatment on testicular and 
hepatic microsomal cytochrome P-450 in the rat
Tissue Organ Wt (g) Pretreatment Cytochrome P-450 
(nmol/mg of protein)
Liver 21.0 - 0.67
Liver 27.7 Phenobarbital 1.42
Testes 5.3 - 0.02
Testes 5.8 Phenobarbital 0.02
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Pretreatment with phenobarbital increased the liver weight and cytochrome 
P-450 content (over 100%) but did not significantly effect either 
parameter of the testes. A brief study of ferret testes indicated 
that cytochrome P-450 (Fig 3.24) was present in the microsomal fraction 
(0.024 nmol/mg of protein) at a comparable level to that observed in 
rats. On two occasions, the CO-binding haemoprotein was also found in 
association with the crude mitochondrial preparation. This may be an 
artifact caused by inadequate homogenization, since the testes of 
ferrets are more fibrous in nature than those of the rat. Attempts at 
producing Type I and Type II binding spectra with testicular cytochrome 
P-450 was not possible. The reduced metyrapone spectrum was, however, 
demonstrated.
B. Cytochrome P-450 in the New Zealand White rabbit
(i) Determination of cytochrome P-450 levels
The presence of cytochrome P-450 in the placenta, maternal and 
foetal livers of full-term New Zealand White rabbits was determined.
From the accompanying table (Fig. 3.25) it can be seen that the micro­
somal and mitochondrial fractions of term placenta contain cytochrome 
P-450. On a mg of protein basis, each fraction exhibited 0.06 nmol of 
CO-binding haemoprotein. However, since the placenta was relatively 
richer in mitochondria than endoplasmic reticulum, then the total 
mitochondrial cytochrome P-450 was almost ten fold that observed in 
microsomes (Fig. 3.26). The administration of phenobarbital to a 
pregnant rabbit did not induce placental cytochrome P-450, which was, 
in fact, undetectable. In contrast, the foetal liver of a phenobarbital- 
treated animal readily exhibited microsomal cytochrome P-450 (0.5 nmol/mg 
of protein). Studies with the maternal liver indicated that the level 
of cytochrome P-450 in microsomes (Fig. 3.27) at day 30 of pregnancy was 
not markedly different from that found in the non-pregnant animal. 
Phenobarbital increased the total liver cytochrome P-450 content by 
approximately 21%. The combined microsomal and mitochondrial placental
i ' 1 ' ' '
cytochrome P-450 at full-term represented less than one-tenth that found 
in the maternal liver. Simarly, following phenobarbital pretreatment, 
the cytochrome P-450 content of the pooled foetal livers at day 30 of 
gestation was equivalent to only 1.51 of that present in the maternal
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Fig. 3.26. CO-Difference Spectrum of M icrosomal Cytochrome P-450
of Full-term Rabbit Placenta.
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Fig. 3.27 CO-Difference Spectra of Microsomal Cytochrome P-450
of Rabbit Liver
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liver. The use of ethyl isocyanide as the ligand for reduced cytochrome 
P-450. was carried out only with placental preparations. The familiar 
absorption at 430 nm was found only, and this probably reflected an 
interaction with haemoglobin rather than with cytochrome P-450.
Cytochrome b^ was not present in measurable levels in the placenta, 
but was readily detectable in maternal liver (0.5 nmol/mg of protein) 
throughout the period of gestation studied.
(ii) The binding of substrates to cytochrome P-450 in the rabbit
The possibility of producing Type I and II spectral changes with 
' placental cytochrome P-450 was reinvestigated with the rabbit. Comparable 
studies were completed with hepatic tissues, and the effect of 3-methyl- 
cholanthrene pretreatment was studied.
a) Rabbit placenta
As with rat placental preparations, microsomal and mitochondrial 
cytochrome P-450 isolated both from untreated and 3-methylcholanthrene 
treated rabbits did not produce binding spectra in the presence 
of various steroids and drugs. Metyrapone did not act as a ligand 
for the reduced haemoprotein in either subcellular fraction.
b) Rabbit maternal liver
Hepatic microsomes from a control (4.5 kg) and 3-methylchol- 
anthrene-treated rabbit (4.6 kg) were isolated as described 
previously for the rat. The washed pellets were stored for two 
nights at -15° as before. They were then resuspended in 0.1 | 
phosphate buffer, pH 7.4 to a protein concentration of 2 mg/ml.
Since not all binding studies were completed on one day, the 
resuspensions were stored overnight at 4°. The cytochrome P-450 
content (nmol/mg of protein) of these preparations was:
Control 3-MC Treated 
Original Microsomal Preparation 0.937 1.053
Microsomal Preparation stored at 4° 0.763 0.687
The control cytochrome P-450 level fell by 18.6%, whereas that of 
the 3-methyTcholanthrene-treated animal decreased by 34.8%. This 
may reflect a higher susceptibility of cytochrome P^-450 (the 
haemoprotein induced by polycyclic hydrocarbons), conpared to that
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of the control haemoprotein, to storage at 4°.
The type of spectral changes and Kg values determined are shown 
in Fig. 3.28 and Fig. 3.29. Metyrapone bound to oxidized microsomes, 
producing a type II spectral change, with greater affinity in the 
rabbit than the rat. The Kg value for the former was not influenced 
by 3-methylcholanthrene treatment. The reduced metyrapone spectra of 
treated and untreated hepatic microsomes both, however, exhibited a 
marked absorbance at 448 nm (Fig. 3.32). The binding affinities of 
both species for aniline was comparable, but the Kg value for 
nicotinamide was lower in the rat. 3-Methylcholanthrene administration 
appeared to increase the binding affinities of ethanol and nicotinamide 
for rabbit hepatic microsomes. The type of binding for the different 
compounds was the same in both species , with the exception of glutethimide.
In the male and female rat, glutethimide elicited a type I spectral 
change, but with female rabbit hepatic microsomes, a mixed type of 
binding was apparent (Fig. 3.30). On pretreatment with 3-methylcholanthrene, 
a distinct type II spectral change occurred with glutethimide (Fig. 3.31).
121
Fig. 3.2 8 The binding of various compounds to rabbit liver
microsomal cytochrome P-450
Compound Solvent Type of Binding K-(mM) Text
FiguresControl 3-MC* Control 3-MC*
Aminoglutethimide Methanol II 5.56
Andros tenedione Methanol ?
Aniline Ethanol II 0.10
Arachidonic Acid DMF ?
Glutethimide Methanol 1/11 II 100.00 3.30; 3.31
Imipramine DMF I
Iproniazid DMF II
Laurie Acid Methanol I 1.47
Metyrapone Methanol II II 0.15 0.15
Oestrone Methanol ?
Oestradiol Methanol . ?
Progesterone Methanol ?
_ _____ .... ,
* Pretreated with 3-methylcholanthrene
Fig. 3.29 The binding of various compounds to rabbit liver 
microsomal cytochrome P-450 stored at 4°
Compound Solvent Type of Binding K.(mM)
Control 3-MC* Control 3-MC*
Biphenyl I Ethanol I I
Ethanol - II II 2.86 2.00
Ethylmorphine 1.15% (w/v) KC1 I
Nicotinamide Water II II 3.64 2.50
p-Nitroanisole
'
0.1M P04 buffer, pH 8.0 ?
* Pretreated with 3-methylcholanthrene
122
Fig.3.30 Control Rabbit Fig.3.31 3-Methyldiolanthrene Treated
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Fig. 3.32 Metyrapone Binding Spectra with Rabbit Liver Cytochrome P-450
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(iii) Nature of glutethimide binding to rabbit liver cytochrome P-450
The nature of substrate binding to cytochrome P-450 is a subject of 
considerable controversy (Mannering, 1971) . The type I spectrum represents 
a spectral property of a substrate-monooxygenase interaction, the intensity 
of which tends to parallel enzyme activity. The type XI spectrum is 
caused possibly by a direct amine-ferroprotoporphyrin interaction via 
the sixth ligand of iron. Mitani and Horie (1969) postulated that type 
I and II spectral changes represent binding to the lipid and haem moieties 
of cytochrome P-450 respectively, and account for the high and low spin 
species seen in electron spin resonance. Pretreatment with polycyclic 
hydrocarbons has the effect of depressing type I binding and elevating 
type II. Schenkman (1970) believes that type II binding really is a 
manifestation of type I and II binding, because of the asymmetry of the 
spectrum. Induction with polycyclic hydrocarbons produces a symmetrical 
type II, thought to be due to the presence of inducer or a metabolite 
binding the type I site. Jefcoate et al (1969) have interpreted this 
phenomena as the existence of two forms of cytochrome P-450. In control 
and phenobarbital-treated animals, hepatic microsomal cytochrome P-450 
exhibits an anisotropic 3-line ESR spectrum typical of ferric iron with 
one unpaired electron (low spin). Following induction with 3-methyl- 
cholanthrene, however, a high spin (5 unpaired electrons) form of hepatic 
cytochrome P-450 exists. j
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Schenkman (1970) considered type I and II binding may occur 
simultaneously. Having demonstrated the aniline and hexobarbital 
binding spectra, hexobarbital was added to both cuvettes and the base­
line recorded, thus removing the type I spectral contribution. The 
addition of aniline to the experimental cuvette elicited an enhanced, 
symmetrical type II spectrum. If the hexobarbital contribution was 
determined by subtracting the aniline absorbance, a type I spectrum 
was shown. When a high level of aniline was added, a spectral change 
similar to that obtained by adding hexobarbital to both cuvettes, 
was observed when hexobarbital was added to the reference cuvette only.
These findings may help explain the binding of glutethimide to 
cytochrome P-450. In the male and female rat, it produces a type I 
spectral change. In the 3-methylcholanthrene pretreated pregnant 
rabbit, glutethimide binds type II, but in the untreated animal the 
binding appears to be a compromise between type I and II.
To investigate further the glutethimide binding, hepatic micro­
somes (stored 3 days at -15°) from an untreated pregnant rabbit 
(4.5 kg) were resuspended in 0.1 y phosphate buffer, pH 7.4 to a 
protein concentration of 2 mg/ml. Spectral changes in the presence 
of glutethimide (Fig. 3.33), aminoglutethimide (Fig. 3.35) and lauric 
acid (Fig. 3.34) were recorded. Aminoglutethimide was then injected 
into the experimental and reference microsomal preparations to a 
final concentration of 0.5 mM. A baseline was recorded which contained
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type II binding in both cells. Additions of glutethimide to the 
experimental cuvette, and methanol (the solvent) to the reference 
cuvette were then made, and the increasing spectral change measured 
(Fig. 3.37). The positions of the absorbance peaks and troughs did 
not alter, nor did the asymmetry, but the intensity spectral shift 
was less.
Concentration of Glutethimide % of Original Glutethimide
Spectral Change
2 mM 81
1 mM 94.5
0.5 m  113
When aminoglutethimide was added to the reference cuvette only, the 
spectra became symmetrical and there was a small shift in the absorption 
peak and trough wavelengths (Fig. 3.37).
Corresponding studies were carried out in the presence of 0.5 nM 
lauric acid (type I). The effect on the glutethimide spectrum is shown 
in Fig. 3.36.
Concentration of Glutethimide % of Original Glutethimide
Spectral Change
2 m  48.5
1 nM 47.4
0.5 m  59.6
The peak and trough wavelengths remained the same, though in samples 
Where lauric acid was added to the reference cuvette only, the spectrum 
became symmetrical. As with lauric acid, the spectral shift with 
glutethimide in the presence of 0.5 mM metyrapone was significantly 
reduced. The addition of metyrapone to the reference cuvette merely
produced an inverted type II spectrum (Fig. 3.38).
Aminoglutethimide, in low concentrations, appeared to enhance 
glutethimide binding at similarly low levels. By increasing the 
glutethimide concentration, the spectral change eventually diminished. 
Aminoglutethimide probably binds slightly type I, but essentially type II. 
The net result may be to block glutethimide binding type II, but not
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significantly limiting its type I binding, there being anple available 
glutethimide for such an interaction. The spectral change appeared 
more symmetrical here than before. When the glutethimide concentration 
was increased, the presence of any aminoglutethimide type I binding 
became apparent and reduced the maximal spectral change possible. The 
presence of aminoglutethimide in the reference cuvette was to super­
impose the inverted type II spectral change on the essentially type I 
glutethimide spectrum, thus producing the observed symmetry.
The presence of lauric acid was more marked than expected for a 
type I binding compound. This gives support to the idea that glutethimide 
is essentially a type I binding compound. Increasing the glutethimide 
concentration over 1 mM.had no significant effect on the already reduced 
spectral change. This is clearly related to differences in affinity 
of lauric acid and glutethimide for cytochrome P-450. The presence of 
lauric acid in the reference cuvette only was to invert the type I 
spectral change, with an absorption at 415 nm. This resembles a type 
II binding spectrum.
Metyrapone binds avidly to cytochrome P-450 and also exhibits more 
than one site of interaction. Because of this, metyrapone prevented 
the formation of a glutethimide induced spectral change. If metyrapone 
were to bind in the type II position only, it may be that such an 
interaction could prevent the simultaneous formation of a type I complex.
Glutethimide is a type I binding compound with rat liver microsomes. 
The introduction of an amino group changes the binding to type II.
In female rabbit, glutethimide appeared to bind both type I and II.
The administration of 3-methylcholanthrene produced an easily 
identifiable type II spectral change with glutethimide. This implied 
that the inducer (or a metabolite) was bound in the type I position, 
allowing glutethimide to interact at the type II site only, or that 
a new species of cytochrome P-450 had been synthesized with different 
substrate affinities. In the untreated rabbit, the markedly reduced 
spectral change of glutethimide in the presence of lauric acid, a 
type I compound, suggested that the former was basically a type I 
binding compound also. Its type II binding characteristics can 
presumably be attributed to the presence of an hefencyclic nitrogen 
molecule.
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Glutethimide Binding Spectra with Rabbit Liver Cytochrome P-450
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C. Cytochrome P-450 in the guinea pig
The haemo-chorial type of placentation in the guinea pig is the 
same as in humans (Kaye, 1971). Preliminary studies on full-term 
tissue (65-72 days), however, indicated cytochrome P-450 was not 
detectable. Therefore an experiment was designed that would minimise 
the breakdown of placental cytochrome P-450 in the homogenization and 
fractionation procedures. Guinea pig placentae (20 g) were homogenized 
in 2 vol. of 1.15% KC1 containing 0.2% (v/V)mercaptoethanol. The 
mitochondria, free of 600 g. av. (for 10 min) debris, were washed in 
20% (w/v) glycerol in 0.1 M phosphate buffer, pH 7.4 (0.2% (W/v) 
mercoptoethanol and 0.1% (w/v) dithiothreitol) and eventually resuspended 
in this media. The microsomal pellets were washed once in 0.1 | 
phosphate buffer, pH 7.4 (0.2% (W/v) mercaptoethanol) and then 
resuspended in this buffer.
Despite the use of these sulphydryl reagents and glycerol, no 
cytochrome P-450 could be detected in full-term guinea pig placental 
mitochondria and microsomes. Cytochromes P-420 and b^ were also 
unmeasurable.
D. Cytochrome P-450 in the pig
The mitochondrial and microsomal fractions were prepared from a 
full-term pig placenta (2.9 kg) and stored for a week at -15°. The 
tissue was processed as for human placentae. The microsomal content 
was found to be lower than that of placentae of other species 
(0.72 mg/g wet wt) . Cytochrome P-450 was not measurable in either 
fraction, though there were strong indications of mitochondrial 
cytochrome P-420. This suggested that pig placentae may contain the 
CO-binding haemoprotein, but that storage degraded it into the 
inactive derivate.
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E. Cytochrome P-450 in man
Meigs and Ryan (1968) have demonstrated the presence of cytochrome 
P-450 in human placental mitochondrial and microsomal subcellular 
fractions. The CO-difference spectrum was found to be readily masked by 
that of carboxyhaemoglobin. Many attempts at producing a clarified human 
placental cytochrome P-450 preparation have therefore been undertaken.
(i) Electron micrographs
The homogeneity of placental subcellular fractions, prepared for 
this study, were examined by electron microscopy. Mitochondrial and 
microsomal pellets from rat liver and human placenta were isolated as described 
in Materials and Methods. Photomicrographs of microsomal preparations 
demonstrated that the human placenta (Fig. 3.39) contains less ribosomes 
than that of rat liver (Fig. 3.40). Indeed, the placenta was generally 
deficient in fragments of endoplasmic reticulum. The photomicrographs 
of human liver shows elongated mitochondria (Fig. 3.42) with the cristae 
apparent as individual septa. By contrast, mitochondria isolated from 
full-term human placenta (Fig. 3.4l) are oval in shape and are devoid of 
cristae( possibly due to inperfect fixation). There appears to be little 
cross contamination between the mitochondrial and microsomal fraction.
(ii) Determination of cytochrome P-450 levels in placenta
Cytochrome P-450 was found in association with the mitochondrial 
and microsomal fractions of human placenta and all periods of gestation 
studied (Fig. 3.43). On a unit protein basis, the mitochondria contained 
a higher level of the haemoprotein (Fig.3.44) than was apparent in 
microsomes (Fig.3.45). Since the CO-difference spectrum of cytochrome 
P-450 was readily masked by that of haemoglobin, various attempts at clarifying 
human placental preparations were carried out.
a) Perfusion with 1.15% KC1
In this procedure, a fresh human placenta was perfused with 
1.151 KC1 via the umbilical veins. The apparatus consisted of a 
metabowl, two 10 litre aspirators and a vessel to collect the 
perfusate. The placenta would be catheterized and placed on the 
wire mesh floor of the metabowl (see diagram). The reservoirs of 
1.15% KC1 (7 litres) would be placed several feet above the placenta,
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Electron Micrograph
Full-term human placental microsomal preparation (x 41,000)
Electron Micrograph
Fig. 3.40 Rat liver microsomal preparation (x 41,000)
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«*■
Electron Micrograph
Fig. 5.41 Full-term human placental mitochondria (x 35,000)
135
Electron Micrograph
Fig. 5.42 Human liver mitochondria (x 35,000) 
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Fig.3.44 CO-Difference Spectrum o£ Human Placental Mitochondrial
Cytochrome P-450
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Perfusion of Human Placenta
Resevoirs of 1.15 
KC1
Metabowl
Catheters
Placenta
Mesh support
Stand
Receptacle 
for perfusate
Perfusion maintained at 4°
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but connected via two perfusing lines which fed the catheters.
A large vessel was then placed beneath the metabowl to collect the 
perfusate. Occasionally it was found necessaiy to use a peristaltic 
pump for perfusion. The latter was carried out at 4°. This 
technique enabled one to remove large quantities of blood, 
particularly if the organ was bathed in the media after perfusion.
The subsequent measurements of cytochrome P-450, however, demonstrated . 
that haemoglobin had not been fully removed. The explanation is that 
human placenta contains considerable amounts of clotted blood which 
cannot be removed completely by such a perfusion technique.
b) Perfusion with a Ca++chelating solution
Since clotted blood is difficult to remove under any circumstances, 
the prevention of coagulation appeared more appropriate. To achieve 
this, a large vessel containing sodium citrate (0.027 M) in Locke’s . 
solution, pH 7.4 (2.5 L) was stored at 4° at the maternity unit.
Locke’s solution: NaCI 9.80g/l
KC1 0.42g/l
NaHC03 1.23g/l
Glucose 1.75g/l
On delivery of a fresh placenta, 1000 I.U. of heparin was added to
this media and the organ then placed into the solution. The
container would then normally be transported in a bucket of ice.
Perfusion was carried out as before but using this Ca chelating solution. 
The umbilical cord was cut as close to the placenta as possible thus 
minimizing the resistance to perfusion. Eventually the organ was 
minced and further bathed in the solution over cheesecloth. Before 
homogenization, the minced tissue was washed in the media used for the 
subcellular fractionation. This procedure was found the most satisfactory 
and was therefore used in most determinations of cytochrome P-450 levels.
c) Clarification according to the method of Meigs and Ryan (1968)
For qualitative observations, Meigs and Ryan (1968) suspended 
particulate fractions (which had been previously washed in 0.154 M 
KC1 or 0.05 M potassium phosphate, pH 7.05) in 0.1 M glycylglycine 
(pH 7.05) to a concentration of 5-10 mg of protein/ml. CO was 
introduced into samples prior to reduction with ^ 282©^ (1 mg).
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This method was adequate for determining the presence of cytochrome 
P-450 but inadequate for removing haemoglobin. For quantitative 
measurements, Meigs and Ryan (1968) clarified particulate fractions 
with Triton N-101 following the procedure of Narasimhulu, Cooper 
and Rosenthal (1965), modified by the addition of glycerol to a 
final concentration of 25% and the substitution of 0.1 M glycylglycine 
(pH 7.05) as buffering agent. It has not proved possible to 
successfully repeat this work. The addition of Triton N-101 to both 
mitochondrial and microsomal^preparations resulted in precipitation 
of most proteins, including cytochrome P-450. Several attempts at 
such a clarification have all failed. The use of Triton WR-1339 in 
solubilizing the aromatization system was extended to clarifying 
cytochrome P-450. This is discussed in Chapter 5, where it was 
shown that the CO-binding haemoprotein was not solubilized.
d) Solubilization according to Voight et al (1968)
The hepatic system which 63_hydroxylates chenodeoxycholic acid 
and taurochenodeoxycholic acid has been solubilized from microsomes 
with 1.0 M phosphate buffer, pH 7.4. When the technique was applied 
to human placental microsomal and mitochondiral fractions, difficulty 
was experienced in keeping the buffer salts in solution at the 
temperatures (about 4°) used for processing. It was therefore 
necessary to work at a higher temperature (10°). However, it was 
found that the osmotic shock of 1.0 M phosphate buffer only solubilized 
haemoglobin and did not bring cytochrome P-450 into solution.
e) Sonication
The microsomal aromatization complex in placenta could not be 
solubilized through sonication. Details are given in Chapter 5 
regarding the technique employed, but it was shown that though 
cytochrome P-450 was not solubilized, haemoglobin appeared to be 
released from microsomes by such vigorous treatment.
(iii) Storage of placental cytochrome P-450
Cytochrome P-450 can readily be converted to cytochrome P-420 in the 
presence of detergents and by the change of pH. There are at least two 
types of cytochrome P-420; one having an ESR signal, whereas the other 
is without the typical ESR signal of microsomal Fe (Hashimoto et al, 1962).X — -
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The absorption maximum of the former can be reversed from 420 nm 
to 450 nm by the addition of glycerol or related compounds. Storage 
of placental microsomal and mitochondrial fractions as pellets at -15° 
prevented any significant loss of cytochrome P-450 over a two-week period. 
However, to thaw out such preparations required careful attention. By 
employing 501 (V/v) glycerol solution (in 0.05 M phosphate buffer, pH 7.0) to 
cover stored pellets at -15°, the preparations did not freeze and could be 
kept like this for longer periods than previously (up to 3 weeks). This 
was therefore the choice storage technique.
Particulate fractions could less effectively be stored as suspensions.
In Fig.3.46, there is a comparison between the storage features of hepatic 
and placental cytochrome P-450 at 4° and -10°. These preparations were 
resuspended in 1.15% KC1 at a protein concentration of 5-10 mg/ml.
Fig.3.46 Effect of storage on hepatic and placental cytochrome P-450
Time
(days)
Rat Liver Human Placenta
Microsomes Microsomes Mitochondria
-10° 4° -10° 4°
°orH1 4°
0 0.53 0.53 0.047 0.047 0.123 0.123
2 0.53 0.48 0.047 0.022 0.121 0.046
4 0.53 0.37 0.040 < 0.001 0.118 0.008
6 0.53 0.16 0.038 < 0.001 0.104 < 0.001
8 0.26 0.11 0.028 < 0.001 0.080 < 0.001
15 0.11 < 0.01 0.006 < 0.001 0.024 <c 0.001
Cytochrome P-450 concentration is expressed as nmol/mg of protein.
The rate of degradation of placental and hepatic cytochrome P-450 was 
comparable. However, storage at 4° resulted in the most rapid loss of the 
CO-binding haemoprotein.
Although it was advantageous to store placental preparations as 
pellets under a 50% glycerol solution, the resuspension of the former in 
20% (V/v) glycerol in 0.1 M phosphate buffer, pH 7.1 for quantitative
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measurements of cytochrome P-450 did not prove beneficial. Similarly, the 
inclusion of sulphydryl reagents, such as mercaptoethanol, dithiothreitol 
and reduced gluthathione, in the homogenizing media appeared to exert 
only a marginal effect on the stability of cytochrome P-450, and hence its 
quantitative measurement.
(iv) Effect of deoxycholate on placental cytochrome P-450
Surfacing-acting agents readily degrade cytochrome P-450 into the 
inactive derivative; ,P-420. This was readily demonstrated in Fig. 3.47 
with the hepatic haemoprotein where the decrease in absoiption at 450 nm 
was concomitant with an increase at 420 nm. The same phenomena was 
observed with the human placental mitochondrial and microsomal cytochromes 
(Fig. 3.48), after the addition of 2% (W/v) sodium deoxycholate (0.2 ml) 
to the experimental cuvette and an equal volume of water to the reference 
cuvette.
(v) Determination of cytochrome P-420 levels
The procedure of bubbling CO into the experimental cuvette and
recording the difference spectrum was to determine the contribution of
carboxyhaemoglobin to the absorbance at 420 nm. Reduction with dithionite
of both preparations produces an increase in 420 nm absorption in the
difference spectrum due to the presence of cytochrome P-420. Qmura and
Sato (1964a, 1964b) have determined the molar extinction coefficient of
- 1 - 1the rabbit liver cytochrome P-420 as 110 cm mM . Thus it is possible 
to determine the concentrations of the haemoprotein.
It has been shown, however, that reduction of the CO difference 
spectrum of the 105,000 g.av. supernatant of guinea pig, sow, rabbit 
and human placenta also resulted in an increase in 420 nm absorbance.
Since these fractions are devoid of cytochrome P-450 but abundant in 
haemoglobin, it appeared the latter was probably responsible for the 
enhanced absorption at 420 nm. Under normal circumstances it #as 
difficult to fully preclude haemoglobin from placental particulate 
fractions, and therefore measurement of cytochrome P-420 levels may be 
erroneous. For example, values for mitochondrial cytochrome P-420 of 
0.278 nmol/mg of protein and microsomal haemoprotein of 0.270 nmol/mg 
of protein have been determined. These concentrations exceed the maximal
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Fig.3.47 The Effect of Deoxycholate on the CO-Difference Spectrum of
Hepatic Cytochrome P-450
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levels of cytochrome P-450 measured and may therefore indicate a possible 
interference by haemoglobin of the accurate determination of cytochrome P-420 
levels.
The possibility that the masking effect of haemoglobin on the 
cytochrome P-450 difference spectrum may be overcome by gassing both 
cuvettes with CO before reduction with dithionite was investigated. The 
basis of this procedure was to balance out the absorption of carboxy- 
haemoglobin at 420 nm, and thai superimpose the reduced spectrum on this 
baseline which will then show the absorption due to the cytochrome P-450 
and P-420 content. Low levels of cytochrome P-450 were not detectable 
by this method, whereas they were using the standard procedure. This is 
because it is difficult to obtain a steady baseline when CO was introduced 
into both cuvettes. Measurement of higher concentrations of the haemo­
protein were; however, readily detectable (Fig.3.49)
(vi) Substrate binding to human placental cytochrome P-450
Comparable binding studies to those carried out with rat and
rabbit placentae were also investigated with full-term human tissue.
Biphenyl, lauric acid, androstenedione, progesterone, oestrone, glutethimide 
and aminoglutethimide failed to induce spectral changes in the presence of 
placental mitochondrial and microsomal particulate fractions. Metyrapone 
(2 mM) produced a spectral change, characterized by an absorption at 
418-20 nm and a trough at 390 nm, with oxidized particulate fractions.
This is similar to a type II binding spectrum except that here the 
absorption peak occurs at around 430 nm. Dithionite reduction resulted 
in the appearance of a 448 nm absorption (Fig. 3.50) with the mitochondrial 
preparation only. This gave support to the existence of human placental 
cytochrome P-450 and demonstrated a similarity to the hepatic CO-binding 
haemoprotein.
(vii) Human placental cytochrome b^
It was not possible to demonstrate cytochrome b^ in human placental 
tissue under any experimental situation. Since in most organs where it 
is found, the concentration is lower than that of cytochrome P-450, and 
it does not respond significantly to enzyme induction, the detection of 
cytochrome b^ is difficult.
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Measurement of Human Placental Mitochondrial Cytochrome P-450.
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(viii) Human foetal liver cytochrome P-450
Human foetuses were supplied with their placentae from therapeutic 
abortions. Little information regarding the background history of 
these foeto-placental units was provided, and therefore details of 
medication etc. cannot be considered here. The levels of foetal liver 
cytochrome P-450 are shown below (Fig.3.51) and for comparative purposes, 
those of the corresponding placentae are also included.
Fig.5.51 Variations in human placental and foetal liver
cytochrome P-450 content with period of gestation
Gestation
(weeks)
Foetal Liver PIarpnta
Microsomal Fraction Microsomal Fraction Mitochondrial
Fraction
15 0.65 0.07 0.13
16 0.66 0.13 0.23
19 1.98 0.41 0.36
22 1.65 0.31 0.30
Cytochrome P-450 expressed as nmol/g of tissue.
The human foetal liver exhibited a relatively high concentration of 
microsomal cytochrome P-450 which appeared to increase with gestation.
On a unit protein basis, the foetal liver CO-binding haemoprotein 
concentration exceeded the total level present in placenta at the 
corresponding period of pregnancy.
(ix) Human placental redox spectra
The presence of unknown cytochrome pigments in human mitochondrial 
and microsomal particular fractions was assessed by redox spectra. The 
relative absorption of oxidized and dithionite reduced fractions against 
that of buffer from 350-650 nm demonstrated no marked absorbance peaks. 
Insufficient time was available to repeat these experiments at liquid 
^  temperatures.
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Summary
In accordance with the findings of Meigs and Ryan (1968), cytochrome 
P-450 was found in association with the mitochondrial and microsomal 
fractions of human placenta. The level of CO-binding haemoprotein was 
greatest in the mitochondrial preparations through out the period of 
gestation studied. As with the hepatic cytochrome P-450, metyrapone could 
be used as an alternative ligand to CO, and deoxycholate was found to 
readily degrade the haemoprotein to its inactive derivative, cytochrome 
P-420. Storage at -10° and 4° resulted in a comparable loss of cytochrome 
P-450 in both hepatic and placental preparations. No apparent relationship 
existed between human placental cytochrome P-450 levels and any drug 
therapy or cigarette smoking which may have taken place during pregnancy.
Since a suitably clarified or solubilized placental cytochrome P-450 
preparation was not obtained, it has been impossible to elicit spectral 
changes in the presence of drug and steroid substrates. Similarly, 
haemoglobin contamination has hindered the accurate measurement of 
cytochrome P-420 levels. The redox spectra of human placental particulate 
fractions did not provide evidence of unknown cytochromes. Certainly 
cytochrome b^ was not present in measurable concentrations. The C0- 
difference spectra of particular fractions of pig placenta suggest that 
cytochrome P-420 may be present, but there was no evidence of cytochrome 
P-450.
The mitochondrial fraction of rat placenta appeared deficient in the 
CO-binding haemoprotein, whereas the microsomal preparations contain 
only very low concentrations. The absorption at 450 nm in the CO- 
difference spectrum was ill-defined and not readily measurable. Since 
this absorbance was apparent only in placentae from rats 18-20 days 
pregnant, and from full-term animals pretreated with 3-methylcholanthrene 
the nature of the cytochrome P-450 here was uncertain. Utilizing 
concentrated particular fractions for the CO-difference spectrum may 
produce an artefactual result. It has been indicated that the absorbance 
at 430 nm in the ethyl isocyanide difference spectrum was probably due 
to the presence of haemoglobin and not cytochrome P-450.
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In contrast, enzyme induction produced readily measurable levels 
of foetal liver cytochrome P-450 in the rat. It was also present in 
relatively high concentrations in human foetal liver, but how much this 
was a consequence of environmental factors is not known. The cytochrome 
P-450 content of maternal liver appeared to decline with progressive 
gestation, though this could be markedly stimulated with 3-methyl cholanthrene 
and phenobarbital. The CO-binding haemoprotein was also apparent in rat 
and ferret testicular microsomes, but as with rat placenta, phenobarbital 
did not elevate these concentrations. Metyrapone could be utilized as 
a ligand for reduced testicular cytochrome P-450.
The nature of rabbit placental cytochrome P-450 was also poorly 
defined since the absorbance was minimal at 450 nm. The reduction in 
microsomal and mitochondrial CO-binding haemoprotein following phenobarbital 
administration is perhaps analogous to the diminished drug-metabolizing 
activity observed occasionally under these conditions. These responses 
may reflect changes in placental function as a result of a toxicological 
effect. In the ethyl isocyanide difference spectrum, rabbit placental 
microsomal preparations produced only the absorption at 430 nm, but not 
at 455 nm as in the rat. Phenobarbital pretreatment resulted in an elevated 
foetal liver cytochrome P-450 content at full-term, approaching that of 
rat maternal liver on a unit protein basis. As in the rat, the total 
cytochrome P-450 content of the maternal liver was marginally reduced 
at full-term, though it could be induced with phenobarbital.
The binding of drugs and steroids to hepatic microsomes of rat and 
rabbit followed a comparable pattern, exhibiting similar K values. 
Glutethimide was the only exception, which elicited a type I spectral 
change with male and female rat liver microsomes, but a type II binding 
spectrum with hepatic microsomes from a 3-methyl cholanthrene-treated 
female rabbit. In the untreated rabbit, a mixed type I/I I spectral 
change was apparent. It was concluded that glutethimide was essentially 
a type I compound, but in the rabbit, it was able to slightly bind type II. 
This was perhaps evidence for more than one species of cytochrome P-450.
The administration of 3-methylcholanthrene to rabbits marginally reduced 
the Kg values for ethanol and nicotinamide but not for metyrapone. These 
findings may represent changes in the conformation of the binding sites or 
synthesis of new cytochrome P-450. Hie increased affinity may result in 
increased metabolism, though analogies between Kg and Km are no longer 
held valid.
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A. INTRODUCTION
Pregnant women in the United States take an average of four 
prescription drugs, plus proprietary compounds, and have an 
undetermined exposure to potentially toxic substances in food, cosmetics 
and household chemicals as well as in the general environment (Barnes, 
1968). The effects of these substances are not known, though it is 
recognized that pregnant women respond differently to drug therapy 
than do non-pregnant women.
Since most drugs and foreign compounds pass readily from maternal 
to foetal blood via the placenta, it is important to understand the 
enzymic capabilities of the organ with respect to xenobiotic metabolism 
because of the following possibilities suggested by Juchau (1972):
i) competition of xenobiotics with important endogenous substrates 
for placental enzyme systems; 
ii) placental catalysis of the conversion of foreign compounds to 
metabolites toxic to the foetus or pregnant female, or both; 
iii) interrelationships of drug biotransformation systems with
active transport systems known to be present in the placenta; 
iv) effects of such biotransformation reactions on the kinetics of 
distribution of certain drugs between maternal and foetal 
organisms (as has been shown for steroids); and
v) contribution of placental drug metabolic processes toward 
decreased foetal or maternal toxicity.
This last possibility has been given impetus by the notion that, 
particularly during early gestation, the placenta may serve as an 
auxiliary liver for the foetus. However, since the human placenta 
near full-term is only approximately one-half of the weight of the 
human liver, and in view of the lower microsomal content per unit 
weight of placenta compared with liver, it has been argued that the 
presence of the placenta would only result in a small increase in the 
total drug-metabolizing capacity of the body.
The investigations described here were undertaken to determine 
the significance of placental drug-metabolizing activity with respect
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to the maternal capacity to detoxicate foreign compounds and in the 
prevention of foetal toxicity. Using model substrates, the ability 
of the placenta to perform a variety of biotransformations including 
aromatic hydroxylation, 0- and N-demethylation, hydrolysis and glucuronide • 
formation was investigated. Comparisons were drawn between the routes 
of biotransformation in the placenta and maternal liver, and also in 
the subcellular distribution of this activity. The possibility of 
supplementing a placental deficiency of components necessary for drug 
metabolism with those from maternal liver was investigated. The 
effect of dialysis on enzyme activity present in placental particulate 
fractions was also studied. Changes in the detoxicating capacity were 
monitored during late pregnancy and following the administration of 
known hepatic enzyme inducing agents. A number of animal species, 
including rat, rabbit, pig and human, were investigated for differences 
in catalytic activity, bearing in mind the various forms of placentation.
In conjunction with the characterization of the drug-metabolizing 
activity of the placenta, comparable studies were carried out on foetal 
liver. It was thus possible to consider detoxication in the foeto- 
placental unit as a whole. Parallel studies regarding the changes in 
maternal liver drug-metabolizing activity during gestation provided 
an insight into the state of detoxication in the pregnant animal. For 
comparative purposes, the biotransformation of xenobiotics in steroid­
ogenic tissues such as testes, ovaries, adrenals and uterii were also 
briefly studied.
B. ASSAYS OF DRUG METABOLISM
(i) Hydroxylation of Biphenyl
a) Biphenyl-4-hydroxylase activity in the Wistar/albino rat 
The para-hydroxylation of biphenyl was minimal in particulate 
fractions of placenta and foetal liver at full-term (Fig. 4.1). 
Phenobarbital and 3-methylcholanthrene treatment reduced pooled 
placental weight and the rate of hydroxylation, whereas it caused 
maternal liver enlargement and stimulated the high biphenyl-4- 
hydroxylase activity, particularly when the barbiturate was given.
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The total placental capacity for para-hydroxylation was.4.1% of 
that of maternal liver. Pooled foetal liver activity represented 
only 1.4%.
Fortification of placental preparations with those of maternal 
liver indicated that in the former tissue bipheny 1 -4-hydroxylase 
activity was associated with the 105,000 g. av. supernatant 
(Fig. 4.2).
Fig. 4.2 Subcellular distribution of biphenyl-hydroxylase activity
Subcellular Fraction Incubated Biphenyl-4-hydroxylase Biphenyl^ 2-hydroxylase
with the Biphenyl Substrate ymol/g/h ymol/g/h
Maternal Liver Soluble Fraction
(105,000 g.av.) 0.22 < 0.01
Placental Soluble Fraction
(105,000 g.av.) 0.07 < 0.01
Placental Supernatant Fraction 
plus (10,000 g.av.)
Maternal Liver Soluble Fraction
(105,000 g.av.) 0.33 < 0.01
Foetal Liver Supernatant
(10,000 g.av.) 0.07 < 0.01
Foetal Liver Supernatant
plus (10,000 g.av.)
Maternal Liver Soluble Fraction
(105,000 g.av.) 0.33 < 0.01
Maternal Liver Supernatant
(10,000 g.av.) 1.85 < 0.01
The enzyme preparation was increased to 1.0 ml.
Some maternal liver para-hydroxylation of biphenyl (23.5%) was 
observed with the soluble fraction, possible due to "light1’ 
microsomes or inadequate homogenization. When maternal liver
105,000 g.av. supernatant was used to supplement the reported
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placental deficiency in glucose-6-phosphate dehydrogenase activity 
(Van Petten et al, 1968), the enhanced para-hydroxylation was 
only that due to the activity present in the liver soluble fraction. 
The same result was obtained when foetal liver preparations were 
supplemented with those of maternal liver.
b) Biphenyl-2-hydroxylase activity in the Wistar/albino rat
Phenobarbital and 3-methylcholanthrene were without effect
on the placental and foetal liver deficiency of ortho-hydroxylation 
of biphenyl at full-term. Biphenyl-2-hydroxylase activity in 
maternal liver was increased thirty-five fold with 3-methyl­
cholanthrene and twelve fold with phenobarbital (Fig. 4.3) .
Fig. 4.3 Effect of 3-methylcholanthrene and phenobarbital administration 
at full-term on the hydroxylation of biphenyl by maternal liver
Animal Wt. 
(g)
Maternal Liver Wt. 
(g)
Pretreatment Biphenyl-2-hydroxylase 
activity
pmol/g/h ymol/Liver/h
344 ±6 (10) 
344 ± 7 (5) 
376 ± 13 (5)
9.7 ± 0.4 
12.9 ± 0.4 
11.2 ±0.4
3-methylcholanthrene
Phenobarbital
0.01
0.35 ± 0.09 
0.12 ±0.04
0.10 ± 0.01 
4.52 ± 1.15 
1.34 ± 0.45
Figures in parenthesis represent the number of animals;
Mean ± S.D.
It is clear from these results that in vitro 2-hydroxylation is 
a minor route of biphenyl metabolism in the adult rat.
c) Hydroxylation of biphenyl by rat testes
Preliminary studies indicate rat testicular tissue hydroxylates 
biphenyl to a level comparable to that observed with full-term 
placentae.
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d) Hydroxylation of biphenyl in New Zealand white rabbit 
No para- and ortho-hydroxyl at ion of biphenyl occurred with full- 
term rabbit placentae, though it was apparent in foetal liver after 
phenobarbital treatment (Fig.4.4). The overall capacity for 
hydroxylation in the para- and ortho-positions of the latter represented 
11.7% and 6.9% of that of the maternal liver respectively. Biphenyl-4- 
hydroxylase activity of the maternal liver was reduced by 75% at full- 
term, whereas ortho-hydroxylation was no longer detectable. The rate 
of para-hydroxylation in full-term rabbit liver was comparable to that 
of rat, and could be stimulated eight-fold with phenobarbital. Ortho- 
hydroxylation was increased to non-pregnant maternal liver levels. 
Administration of phenobarbital to rats enhanced biphenyl-2-hydroxylase 
activity to the same level found in rabbit maternal liver, though 
3-methylcholanthrene increased this activity still higher.
e) Human placental and foetal liver hydroxylation of biphenyl
Human placentae,unlike those 0f rat and rabbit, can both ortho- and 
para-hydroxylate biphenyl (Fig.4.5). Biphenyl-4-hydroxylase activity 
may increase with length of gestation, but this did not appear to be 
the case with biphenyl-2-hydroxylase activity. The rates of placental 
hydroxylation were comparable in different species.
Fig. 4.5 Hydroxylation of biphenyl by human placenta and foetal liver
at different periods of gestation
Tissue Foetal Age 
(wks)
Biphenyl-4-hydroxylase
activity
Biphenyl-2-hydroxylase 
activity
Placenta 15 CD 0.05 < 0.01
Placenta 16 (1) 0.07 0.03
Placenta 19 CD 0.08 0.01
Placenta 22 (2) 0.08 + 0.02 0.03 + 0.01
Placenta 4° (4) 0.07 + 0.02 0.01
Foetal Liver 16 (1) 0.25 0.05
Foetal Liver 19 (1) 0.14 0.74
Foetal Liver 22 (1) 0.13 0.01
Enzyme activity expressed as ymol/g.wet wt/h. _+ S.D.; 
Figures in parenthesis represent the number of subjects.
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Foetal liver hydroxylated biphenyl in the ortho- and para- 
positions more rapidly than did placenta, but the activity was 
independent of the gestational period. The order of biphenyl 
hydroxylase activities of foetal liver was rat < man < phenobarbital 
treated rabbit.
f) Effect of dialysis on the hydroxylation of biphenyl
Microsomes of full-term human placenta (268 g) isolated after 
homogenizing in half a volume (w/v) of 1.15V KC1 (containing 0.05 M 
phosphate buffer, pH 7.0 and 0.04 M nicotinamide), were divided into 
eight pellets, one group of three was stored at -15°. The remaining 
five were resuspended in original buffer (40 ml) and aliquots (10 ml) 
transferred to visking tubing and sealed. Individual sacs were 
dialysed for 5 h. at 4° against one of the following: 0.1 ^ 
succinate buffer, pH 4 or 5, or 0.1 ^ phosphate buffer, pH 6 or 7 
(2.5 litres), the media being changed after 150 min.
After dialysis, microsomal preparations were resedimented, 
rinsed with 1.151 KC1, resuspended in the same (7 ml) and used for 
the hydroxylation of biphenyl along with undialysed microsomal 
preparations. The incubate consisted of:-
NADP (4.3 ymol/8.0 ml) 0.1ml
G-6-P dehydrogenase (1 Unit/ml) .. 0.5 ml
G-6-P (37.2 pmol/4 ml) .. .. 0.5 ml
Biphenyl (12 pmol/ml) .. .. 0.5 ml
Microsomal preparation (in 1-.15V KC1) 0.3 ml
MgC^ (80.4 pmol/ml) . . . . 0.1ml
Total volume = 2.0 ml
The pH of the reaction mixture was varied by dissolving cofactors in 
0.1 M phosphate buffer, pH 6.8 or 7.0, and 0.1 M tris-HCl buffer, 
pH 7.4, 7.8 or 8.2. Microsomal protein concentrations were:-
pH used for dialysis mg, protein/incubate
4 4.3
5 5.1
6 3.7
7 3.0
Control 5.1
160
No biphenyl hydroxylation was apparent with dialyzed microsomes, 
and only biphenyl-4-hydroxylase activity was detectable with control 
microsomal preparations (Fig. 4.6), particularly at alkaline pH 
values.
Fig. 4.6
pH of incubate Biphenyl-4-hydroxylase activity 
(jumol/g/h)
6.8 0.05
7.0 0.05
7.4 0.05
7.8 0.06
8.2 0.06
(ii) Reduction of p-nitrobenzoic acid
a) p-Nitrobenzoic acid reduction activity in the Wistar/albino rat.
Placental reduction of p-nitrobenzoic acid, though undetectable at 
15-17 days, may increase towards full-term (Fig.4.7), whereas that of 
maternal liver declines, such that at parturition the former exhibited 
a total capacity equalling 51 of that of the latter. Foetal liver 
exhibited a higher rate of reduction than observed in placenta, though 
the overall pooled capacity was less. Phenobarbital increased the 
rate of reduction only in the maternal liver, and by 20% on a unit 
weight basis (Fig.4.8). 3-Methylcholanthrene elevated the total 
p-nitrobenzoic acid reductase activity by virtue of liver enlargement, 
but was without effect on foetal liver and placenta.
Fig. 4.8 Effect of 3-Methylcholanthrene and phenobarbital 
administration at full-term on maternal liver 
p-nitrobenzoic acid reductase activity
Animal wt. 
(g)
Maternal 
liver wt. 
(g)
Pre treatment Rate of p-aminobenzoic acid 
formation
ymol/g/h ymol/organ/h
313 + 8 (4) 
344 + 7 (S) 
376 + 13 (5)
9.4 + 0.3 
12.9 +0.4 
11.2 + 0.4
3-MC
Phenob.
0.59 + 0.16 
0.61 + 0.14 
0.71+0.19
5.55 + 1.52 
7.87 + 1.81 
7.95 + 2.13
Figures in parejbiesis represent the number of animals: Mean > S.D.
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b) Localization of p-nitrobenzoic acid reductase activity 
in rat placenta
Foetal liver and placental subcellular fractions were supplemented 
with those of maternal liver. The minimal nitroreduction with placental 
and maternal liver microsomal preparations may be due to the deficiency 
in glucose-6-phosphate dehydrogenase activity, since reduced NAD and 
NADP are necessary for enzyme activity. The inclusion of placental
105,000 g.av. supernatant with the microsomal incubation did not 
enhance reduction. The maternal liver 105,000 g.av. supernatant 
readily reduced p-nitrobenzoic acid, whereas that of the placenta did 
not. The hepatic soluble fraction increased the nitroreduction of 
maternal liver microsomes by a margin higher than can be explained 
by the former’s own activity. Supplementing hepatic microsomes with 
the placental 105,000 g.av. supernatant also increased p-nitrobenzoic 
acid reductase activity, but less effectively than with the maternal 
liver soluble fraction.
The maternal liver 10,000 g.av. supernatant exhibited a rate of 
nitroreduction 32 fold that observed in the placenta. The diminished 
nitroreduction of the maternal liver 10,000 g.av. supernatant in the 
presence of the placental soluble fraction appeared to be due to an 
interaction with the hepatic microsomes only. The elevated p-nitro­
benzoic acid reductase activity of foetal liver 10,000.g.av. super­
natant in the presence of maternal liver soluble fraction is because 
of an additive effect of the latter's capacity for reduction.
c) p-Nitrobenzoic acid reductase in the New Zealand white rabbit
The basal level of p-nitrobenzoic acid reductase activity in the 
control liver was considerably less than that of full-term rabbits, 
though the latter was lowered following phenobarbital treatment. This 
may be due to individual variations as animals were purchased from 
an outside supplier and their backgrounds were therefore unknown.
Rabbit placentae reduced p-nitrobenzoic acid at twice the rate observed 
in the rats, but this activity was abolished after phenobarbital 
administration. The latter did not prevent nitroreduction by foetal 
liver, which proceeded at a rate comparable to that of non-pregnant adult 
rabbit liver.
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Fig 4.10 Reduction of p-nitrobenzoic acid in the pregnant
New Zealand white rabbit
Animal wt. 
(kg)
Organ Organ wt. 
(g)
Foetal
age
Pretreat­
ment
Rate of 
acid
1 ■" 1 ■ —— . ' ' t
p- aminobenzoic 
formation
(days) ymol/g/h pmol/organ(s)/h
4.0 (1) Maternal
Liver
140.3 0 ■ - 0.30 42.2
6.0 (2) Maternal
Liver
131.0 31 - 1.63 213.5
4.3 (1) Maternal
Liver
102.7 30 Phenobarbital 0.96 98.6
4.3 (1) Foetal
Liver
5.6 30 PIlenobarbital 0.34 1.9
6.0 (2) Placenta 26.0 31 - 0.11 2.9
4.3 (1) Placenta 21.8 30 PI^ enobarbital<: 0.01 < 0.1
Figures in parenthesis represent the number of animals
d) p-Nitrobenzoic acid reductase activity in human placenta and 
and foetal liver
Throughout the gestational period studied, human placenta and 
foetal liver exhibited comparable rates of nitroreduction (Fig.4.11).
The protein content of foetal liver 10,000 g.av. supernatant was, 
however, marginally higher than that of placenta, though increasing 
this did not produce a corresponding increase in nitroreductase activity.
Fig.4.11. Reduction of p-nitrobenzoic acid in the human placenta 
and foetal liver at different periods of gestation
Organ Foetal Age 
(wks)
ymol p-Aminobenzoic 
acid/g of tissue/h.
mg Protein/ml. of 
tissue fraction
Placenta 15 CD 0.24 0.51
Placenta 16 CD 0.36 1.83
Placenta 19 CD 0.17 2.89
Placenta 22 C2) 0.21 + 0.07 11.90
Placenta 40 (4) 0.09 +0.02 6.10
Foetal Liver 15 CD 0.36 5.12
Foetal Liver 16 CD 0.14 0.59
Foetal Liver 19 CD 0.22 1.20
Foetal Liver 22 CD 0.29 6.00
Figures in parenthesis represents number of experiments; 
Mean + S.D.
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Placental reduction of p-nitrobenzoic acid occurred more readily with 
preparations from early gestation, but foetal liver did not show such a 
pattern. The omission of FMN prevented detection of p-aminobenzoic acid 
with human tissue, but not with rat and rabbit placentae.
Hietbrink and Dubois (1964) observed that some of the p-aminobenzoic 
acid produced in vitro exists in a bound form which requires acid treatment 
before diazotization. On terminating human placental and foetal liver 
incubations with 25V (w/v) trichloroacetic acid (1 ml), aliquots (2 ml) of 
supernatant were removed for the Bratton and Marshall reaction, but one was 
first hydrolyzed with conc. (0.3 ml) in a boiling water bath for
30 min. Since the p-aminobenzoic concentration was identical in both
aliquots, it was assumed that the binding phenomena was not apparent with 
human placental and foetal liver incubations.
(iii) Metabolism of zoxazolamine
Human placental metabolism of zoxazolamine was assessed by two methods.
a) Extraction procedure of Conney, Trousof and Bums (1960).
The effect of 1.51 (V/v) isoamyl alcohol on the efficiency of
zoxazolamine extraction by 1,2-dichloroethane was investigated, since 
it is reported to reduce adsorption onto glassware and aid disruption 
of hydrophobic bonding in proteins. The recovery of zoxazolamine from 
placental incubates is shown in Fig. 4.12. Isoamyl alcohol marginally
Fig. 4.12 Effect of isoamyl alcohol on the extraction of
zoxazolamine by 1,2-dichloroethane
Zoxazolamine (yg) Extraction Procedure
1,2-dichloroethane 1,2-dichloroethane +1.51 
isoamyl alcohol
O.D. at 278 nm % Recovery O.D. at 278 nm % Recovery
50
50
0.218]
0.222j 85,8
0.218 7 , 
0.217J 84-6
100
100 0:335] 80-°
0.326] 77 ? 
0.317J //.z
reduced zoxazolamine recovery. When n-heptane was used for drug 
extraction, according to the method of Juchau, et al (1965), no
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emulsions were formed and less interfering background material was 
extracted (see accompanying spectra).
b) Zoxazolamine metabolism by rat liver and human placenta.
Full-term human placenta (530.8 g) and adult female Wistar/ 
albino rat liver were homogenized according to the method of Juchau 
et al (1965). Placental microsomes (^12 g wt wt.) and whole liver 
homogenate were incubated in quadruplicate for 60 min. at 37° under 
oxygen in a modified reaction mixture of Conney, Trousof and Bums (1960).
Unchanged zoxazolamine, determined according to the method of 
Juchau, et al (1965), indicated a rate of hepatic metabolism 
equivalent to 0.77 ymol. drug/g. of tissue/h. but did not indicate 
any placental metabolism. Since zoxazolamine weakly absorbs at 
278 nm (Fig. 2.2), quadruplicate incubates were necessary to establish 
differences between control and experimental recoveries. Snail 
changes in extinction significantly effected the calculated drug 
recoveries. Placental microsomal zoxazolamine metabolism was also 
undetectable using the complete assay procedure of Juchau, et al (1965).
c) Metabolism of zoxazolamine by rat liver 10,000 g.av.
The 10,000 g.av. supernatant of adult female rat liver was 
incubated as in the previous experiment, and the rate of zoxazolamine 
metabolism determined as 0.43 ymol/g. of liver/h. Sedimentation of 
fragments of endoplasmic reticulum probably account for the lower rate
G-6-P (0.03 M) •> .. ..
NADP (3.9 M) .. .. ..
Nicotinamide (0.6 M) ..
MCI (2.0 M) .. ' ..
MgCl2 (0.1 M) V  .. . .
Potassium phosphate buffer, pH 7.4 (0.1 M) 
Zoxazolamine (0.6 mM)
Tissue Preparation ..
G-6-P-dehydrogenase (0.5 Units)
0.2 ml 
0.1 ml 
0.1 ml 
0.1 ml 
0.1 ml 
0.5 ml. 
0.5 ml 
1.0 ml 
0.4 ml
Total Volume 3.0 ml
supernatant.
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of metabolism than was observed with whole homogenate. Fig. 4.13 
demonstrates the small differences in extinction between blank and 
experimental incubates.
Fig. 4.13
Incubate O.D. at 278 nm.
Blank 1 0.270
n 2 0.268 0.271 + 0.002*
ft 3 0.268
I 1 4 0.278
Experimental 1 0.295
n 2 0.277 : 0.289+0.006*
11 3 0.303 '
it 4 0.284 =
* S.E.M.
d) Further studies on hepatic metabolism of zoxazolamine.
The rate of zoxazolamine metabolism in adult female rat liver 
was 0. 863 ymol. of drug/g. of liver/h., when the incubation of 
procedure of Conney, Trousof and Bums (1960) was used in conjunction 
with the extraction procedure of Juchau et al (1965).
e) Placental zoxazolamine metabolism and magnesium ion
concentration.
Full-term human placental microsomes were collected and 
incubated as described in experiment b). The levels of MgC^ 
incorporated into the reaction mixtures were 6, 8, 10, 12 and 14 pmol. 
Following a 60 min. incubation, zoxazolamine was estimated according to 
the method of Juchau et al (1965) where it was shown that no 
placental metabolism had occurred. The same result was obtained with 
whole placental homogenates.
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(iv) N-Demethylation of ethylmorphine.
a) N-Demethylation o£ ethylmorphine by human placenta.
1) Full-term, human placenta.
The ability of two full-term human placentae to N-demethylate 
ethylmorphine was examined using the 800 g.av. supernatant (Fig. 4.14). 
The persistent difference between the extinctions of blank and 
experimental samples, which did not increase with length of incubation, 
was considered to be due to the absence of substrate in the former. 
Parallel assays, using female rat liver 800 g.av. supernatant, 
demonstrated that N-demethylation could be measured under these 
experimental conditions. A mean rate of metabolism equivalent to 
3.1 ymol. HCHO released/g. of liver/h. was found in the liver. Human 
placental N-demethylase activity was therefore undetectable at the 
limit of sensitivity of the assay, equivalent to 0.01 ymol. HCHO/g. 
liver/h.
Fig. 4.14 Full-term human placental ethylmorphine N-demethylase activity
Incubation Incubation Time (min.) Extinction at 412 nm.
Expt. 1 Expt. 2
Control 10 0.090 0.061
Expt. i t 0.170, 0.090 0.071, 0.080
Control 20 0.091 0.060
Expt. i t 0.107, 0.150 0.070 , 0.062
Control 30 0.089 0.065
Expt. ft 0.092, 0.090 0.067, 0.061
Control 40 0.090 0.060
Expt. i t 0.090, 0.130 0.065, 0.068
Control 50 0.091 0.060
Expt. >• 0.101, 0.098 0.071, 0.070
2) Effect of pH and Mg concentration on human placental
N-demethylase activity.
A full-term human placenta (489 g) was homogenized in 1.151 KC1 
and the whole homogenate, 10,000 g.av. .supernatant, microsomes and 
soluble fraction collected. The protein concentrations of these enzyme 
preparations were:-
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Whole homogenate = 42 mg/ml
10,000 g.av. supernatant = 40 mg/ml
Microsomal preparation = 2 4  mg/ml
Each fraction was incubated in duplicate under 25 different reaction 
mixture conditions.
Buffer (0.15 M) pH
MgCl2 (pmol) 6.8(P04) 7.0(P04) 7.4(tris-HCl) 7.8 (tris-HCl) 8.2(tris-HCl)
10 ti i• ii ii ii
12.5 ?» »• ii ii M
15 ii ii ti M it
17.5 M it ii M M
?n ti i• ii n ii
The substrate concentration was increased from 4 to 15 '.pmol. In
addition to these incubations, a further five were carried out using
the 105,000 g.av. supernatant (0.5 ml) in place of the exogenous
glucose-6-phosphate dehydrogenase (0.5 ml). This was only effected with
++
microsomal incubations at pH 7.4, where the Mg concentration was varied. 
Blanks for each subfraction were prepared by adding the substrate after 
the additions of zinc sulphate and barium hydroxide/sodium tetraborate 
solutions which stop the reaction. Formaldehyde standards were carried 
through the assay as described in Materials and Methods. The reactions 
were carried out under air at 37° for 40 minutes.
The release of HCHO was not apparent in any of these incubations, 
even when the placental soluble fraction was used as an exogenous 
source of glucose-6-phosphate dehydrogenase. N-Demethylase activity was 
therefore considered insignificant. Mitochondrial (0.050 nmol/mg of 
protein) and microsomal (0.015 nmol/mg of protein) cytochrome P-450 
were readily measurable in this placenta.
b) N-Demethylation of ethylmorphine by rabbit placenta.
1) Effect of phenobarbital and 3-methylcholanthrene treatment 
on rabbit placental N-demethylation
Microsomal preparations (6 mg protein/ml) from control, 
phenobarbital-treated and 3-methylcholanthrene-treated rabbits in
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midpregnancy were assayed for ethylmorphine N-demethylase activity 
(Fig. 4.15). In contrast to the placental deficiency of 
N-demethylation, the activity of the foetal liver could be stimulated 
with phenobarbital, and to a lesser extent with 3-methylcholanthrene, 
to levels which were readily measurable. Phenobarbital enhanced the 
rate of maternal liver N-demethylation by 651, whereas 
3-methylcholanthrene did not exert a significant effect.
Fig. 4.15 N-Demethylation of ethylmorphine in the New Zealand white rabbit at
mid-pregnancy
Animal Organ Organ wt 
(g)
Foetal Age 
(days)
Ethylmorphine N-Demethylase 
Activity 
(nmol HCHO/mg protein/h)
Control Placenta 29.0 < 0.01
(3.50 kg) Maternal Liver 48.0 23 10.41
Foetal Liver 6.8 < 0.01
3-MC Placenta 10; 0 < 0.01
(4.45 kg) Maternal Liver 52.0 21 10.98
Foetal Liver 1.2 0.24
Phenobarb­ Placenta 53.0 < 0.01
ital Maternal Liver 69.0 23 17.19
(4.4 kg) Foetal Liver 6.6 0.44
(v) O-Demethylation of p-nitroanisole
a) O-Demethylation of ]D-nitroanisole by rat liver.
Two assay procedures, considered for use with placental 
preparations, were previously examined with adult female rat liver 
microsomes.
1) Netter procedure
Fig. 4.16 represents a chart recording produced by this 
spectrophotometric technique. The release of £-nitrophenol from 
£-nitroanisole was linear for 20 min, and the maximal rate of 
O-demethylation occurred at the highest substrate level (306 yg).
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Fig. 4,17 p-Nitroanisole O-demethylase activity in rat liver at different
substrate concentrations
Substrate level (pg) £-Nitroanisole O-demethylase activity 
(nmol of jD-nitrophenol/ml of incubate/min)
306.0 1.80
224.2 1.34
142.8 1.52
61.2 0.90
2) Nash procedure
The rates of O-demethylation, measured by the release of HCHO, 
were low with the Nash procedure (Fig. 4.18) since incubations were 
for 60 min though the reaction was only linear for 20 min. The 
highest substrate level also produced the highest rate of 
O-demethylation. The measurement of jD-nitrophenol release was chosen 
for placental studies since it was sensitive, convenient and suitable 
for kinetic studies.
Fig. 4.18 £-Nitroanisole O-demethylase activity in rat liver at different
substrate concentrations
Substrate level (pg) p-Nitroanisole O-demethylase activity 
(nmol of p-nitrophenol/ml of incubate/min)
306.0 0.69
224.2 0.63
142.8 0.63
61.2 0.42
b) O-Demethylation of p-nitroanisole by full-term human placenta.
1) Netter Procedure
Freshly prepared placental microsomes , incubated with 
£-nitroanisole (306 pg) but not semicarbazide, did not increase 420 nm 
absorbance due to the release of p-nitrophenol. A repeat experiment 
with a second placenta (provided by a patient smoking 20 cigarettes a 
day), but employing scale expension of 0 - 0.2 absorbance, also did 
not demonstrate N-demethylase activity (Fig. 4.19). Since a ten-fold 
increase in assay sensitivity could not detect £-nitrophenol formation, 
the full-term human placenta was considered deficient in significant 
levels of microsomal p-nitroanisole O-demethylase activity.
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c) O-Demethylation of p-nitroanisole by Wistar/albino rat 
testes and liver
The rates of testicular and hepatic O-demethylation have been 
expressed as nmol of £-nitrophenol produced/mg of protein/h, nmol/g of 
tissue and nmol/organ/g of body weight/h.
Rat testicular O-demethylation of £-nitroanisole per mg 
microsomal protein was equivalent to 4.71 of that observed in rat 
liver, but whereas phenobarbital enhanced the latter’s activity 
by 3001, the former was unchanged. The increase in liver 
0-dealkylation on the basis of nmol £-nitrophenol/organ/g body 
wt/h was equivalent to 4451.
In addition to monitoring hepatic and testicular 0-dealkyl at ion, 
the general response of the tissues to enzyme induction was studied 
(Fig. 4.22).
Fig. 4.22 Effect of phenobarbital on microsomal protein concentration
Organ Mean Organ wt 
■(g).
Pretreatment Microsomal Protein 
(mg/g tissue)
Liver 22.3+1.6 - 19.2 + 1.8
Liver 23.3 + 1.2 Phenobarbital 26.2 + 2.4
Testes 6.1 + 0.1 - 2.9 + 0.4
Testes 5.9 + 0.1 Phenobarbital 3.2 + 0.6
Mean + S.D.
The percentage induction of hepatic microsomal protein per g of tissue 
was 36.5$ and for testicular protein was 10.2$. The percentage increase 
in the tissue weight/body weight ratio for these two organs was less 
marked (Fig. 4.23). The proliferation of the hepatic endoplasmic 
reticulum following phenobarbital administration corresponded with 
the increase in £-nitroanisole O-demethylase activity. Similarly, the 
absence of testicular enzyme induction was accompanied by no increase 
in microsomal protein.
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Fig. 4.23 Effect of phenobarbital pretreatment on tissue
weight to body weight ratio in the rat
Organ Ratio of tissue wt Control (a)
(g)/body wt (g) as % 
Experimental (b)
b/a x 100
Liver 4.00 4.07 1.02
Testes 1.10 1.04 0
(vi) N-Demethylation of £-chloro-N-methylaniline
a) N-Demethylation of £-chloro-N-methylaniline by full-term 
human placentae
The 10,000 g.av. supernatant of human placenta, obtained from a 
patient who regularly smoked 15 cigarettes a day throughout pregnancy, 
was incubated as described previously. Extinction values subsequently 
recorded at 445 run are shown below.
Fig. 4 .24 £-Chloro-N~methylaniline N-demethylase activity
in full-term human placenta
Sample Enzyme 
Vol.(ml)
Incubation 
Time (min)
O.D. at 455 nm
Experimental Incubate 0.2 20 0.73
n it 0.2 20 0.74
ft tt 0.2 40 0.75
tt tt 0.2 40 0.70
tt tt 0.2 60 0.73
tt tt 0.-2 60 0.71
tt tt 0.3 60 1.20
tt tt 0.3 60 1.23
Blank Incubate 0.2 20
tt tt 0.2 ■40 -
tt tt 0.2 60 -
£-Chloroaniline (4 nmol) 0.2 60 0.11
" (10 nmol) 0.2 60 . 0.27
" (16 nmo!.) 0.2 60 0.43
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T h e  increment between blank and experimental incubates did not change 
with the period of incubation, but was related to the volume of 
10,000 g.av. supernatant. The acconpanying absorption spectra show that 
those of control (boiled) and experimental incubate were alike,but dissimilar 
to that of £-chloroaniline standard. it was concluded that the 
Ehrlich’s reagent used in the assay procedure failed to completely 
denature placental protein, and in particular haemoglobin.
As a possible alternative measurement procedure, aliquots (1 ml) 
of supernatant following centrifugation of incubates (2.0 ml) treated 
with 25% trichloroacetic acid (0.5 ml) were subjected to the Bratton 
and Marshall reaction. Extinctions at 545 nm suggested p-chloro-N- 
methylaniline also gave the colour reaction, which was confirmed by a 
second experiment. This assay modification was therefore no longer 
considered since low placental N-demethylase activity would be difficult 
to determine in the presence of such a high blank value. Other methods 
considered included the use of trichloroacetic acid instead of ^ SO^, 
but £-dime thy laminobenzaldehyde was not soluble in this reagent.
Titration with perchloric acid, and subsequent dilution with water 
was attempted, as was also determination of the acid requirement to 
reduce the pH necessary for full denaturation and then adding Ehrlich’s 
reagent under less acid conditions. The HCHO release was studied with 
the Nash reaction. The problem was eventually resolved by (i) washing 
placentae with saline to remove blood, (ii) using a microsomal 
suspension, and (iii) by boiling incubates prior to the addition of 
Ehrlich’s reagent.
Fig. 4.25
Incubate O.D. at 545 nm
£-diloro-N-methylaniline (3 ymol) 
£-chioro-N-methy 1 ani 1 ine (3 ymol)
0.123
0.120
0.258
0.262
0.560
0.775
£-chloroaniline (0.1 ymol)
£-chloroaniline (0.1 ymol)
£-chloroaniline (0.2 ymol)
£-chloroaniline (0.3 ymol)
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1) N-Demethylation of p-chloro-N-methylaniline in microsomal
preparations of human placenta
N-Dealkylation of £-chloro-N-methylaniline in five human 
placentae was studied. None of the subjects had recent histories of 
prolonged drug therapy, though one admitted to smoking about 10 
cigarettes a day, and another 15. Microsomal preparations, 
incubated for up to 2h, produced no measurable yield of 
2“Chloroaniline. A placental preparation from pig was also deficient 
in significant levels of N-demethylase activity.
b) N-Demethylation of £-chloro-N-methylaniline by Wistar/
albino rat placentae
The rate of rat placental N-demethylase activity was less than 
3.4% of that of the maternal liver at full-term (Fig. 4.26). 
Phenobarbital administration increased hepatic metabolism by 31% 
but placental N-dealkylation was unaffected. The decline in pooled 
placental weight may in part be due to the inducer, but is mainly 
determined by the number of foetuses.
Fig. 4.26 Effect of phenobarbital pretreatment on £-chloro-N-methylaniline 
N-demethylase activity in Wistar/albino rat placenta and 
maternal liver at full-term ~
Organ (s) Organ wt (g) N-Demethylase activity 
(nmol/mg microsomal protein/h)
Control Phenobarbital
Placenta (6) 
Placenta (6) 
Maternal Liver (6) 
Maternal Liver (6)
18.0+2.7
11.6+1.8
16.6+1.4
18.0+1.7
6.2+1.4
184.1+10.2
7.4+2.1 
241.3+14.1
Mean +_ S.D.; Figures in parenthesis represent the number of animals.
1) Protein Induction
Variations in protein content of subcellular fractions following 
phenobarbital treatment is shown in Fig. 4.27. On a unit weight basis,
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the microsomal protein content of rat full-term placentae was 
equivalent to 18.4% of that of the maternal liver. Phenobarbital 
increased the placental 10,000 g.av. supernatant protein/g of tissue 
by 105% and microsomal protein/g of tissue by 97%. This proliferation 
in endoplasmic reticulum was countered by a reduction of pooled 
placental weight. Liver enlargement (8.75%) was accompanied by an 
increase in total microsomal protein (23%) following phenobarbital 
administration.
c) N-Demethylation of p-chloro-N-methy lanil ine by Wistar/albino
rat testes
Testicular microsomal preparations N-dealkylated p-chloro-N- 
methylaniline at a marginally lower rate than was observed in 
placentae, and did not respond to 3-methylcholanthrene or isosafrole 
pretreatment (Fig. 4.28). The N-demethylation did not proceed as 
rapidly in male livers as was observed with hepatic tissue from 
pregnant rats. The rate of N-dealkylation in 5-6 week old male rats 
was enhanced 48% by 3-methylcholanthrene pretreatment and 168% by 
isosafrole, on a microsomal protein basis.
1) Protein Induction
On the basis of the microsomal protein content per gram of 
tissue, 3-methylcholanthrene increased that of maternal liver by 27% 
and testes by 20.5%. In contrast, isosafrole was without such effect 
on testicular microsomal protein but elevated that of liver by 51.5%. 
Isosafrole also increased the liver weight/body weight ratio (Fig. 4.30). 
It is possible to equate the induction by phenobarbital of placental 
microsomal protein with the 3-methylcholanthrene induction of 
testicular microsomal protein since neither is associated with enhanced 
N-dealkylation.
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Fig. 4.29 Effect of 3-methylcholanthrene and isosafrole pretreatment on the 
microsomal protein content of rat liver and testes
Organ Mean Organ 
Weight (g)
Pretreatment Microsomal protein 
(mg/g tissue)
Liver 11.2 . - 14.8
Liver 8.4 3-methylcholanthrene 18.8
Testis 3.2 - .2.9
Testis 2.8 3-methylcholanthrene 3.5
Liver 10.5 — 18.8
Liver 4.8 Isosafrole 28.5
Testis 2.3 - 3.5
Testis
■
1.6 Isosafrole 3.4
Fig. 4.30 Effect of 3-methylcholanthrene and isosafrole pretreatment on
tissue weight to body weight ratio in the rat
Tissue Ratio of organ wt/body wt (g^ as %
Control
(a)
3-methylcholanthrene
(b)
b/a x 100 Control
(c)
Isosafrole
(d)
d/c x 
100
Liver 4.02 3.28 0 4.38 5.20 18.7
Testis 1.15 1.09 0 1.92
1.71 0
The N-demethylation of p-chloromethylaniline by testicular 
microsomes occurs at a rate marginally inferior to that observed in rat 
placenta. However, similar to the latter, the enzyme activity did not 
appear to be induced. Isosafrole and 3-methylcholanthrene did not 
exert any affect on testicular dealkylation. The N-demethylation did 
not proceed as rapidly in the male livers as was observed with hepatic 
tissue from pregnant rats in the previous experiments. This may be 
due to the difference in the assay.
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(vii) Metabolism of benzo[a]pyrene '
a) Human placental benzo[a Jpyrene hydroxylase activity
In accordance with the assay procedure of Welch et al (1969), 
the ability of five full-term human placentae to hydroxylate 
benzo[a]pyrene is shown below (Fig. 4.31). The findings corroborate 
previous work (Welch et al, 1969; Nebert, Winkler and Gelboin, 1969), 
indicating that cigarette smoking induces benzo[a]pyrene hydroxylase 
activity, though the number of cigarettes smoked could not be equated 
with the level of metabolism. The diabetic subject, A.L., did not 
exhibit the highest rate of hydroxylation though she admitted to 
smoking at least 30-35 cigarettes a day. Placental weight is often 
reduced in diabetes, but the capacity for steroid hydroxyiations are not 
diminished. On a weight basis, therefore, subject A.L. may have shown 
a higher benzo [ a] pyrene hydroxylase activity than if she were not 
diabetic. Pre-operative medication may limit benzo[a]pyrene hydroxylation 
though it is difficult to ascertain from such a small study.
Fig. 4.31 Effect of cigarette smoking on benzorajpyrene hydroxylase
activity in human placenta at full-term
Patient Age
(yrs)
Race Preoperative
Medication
Cigarettes smoked 
daily during 
pregnancy
3-Hydroxyb enzo 
[a]pyrene formed 
by placenta 
(ng/g tissue/h)
A.A. 27 Caucasian Pethidine
Valium
Entonox
Syntocinon
0 <100
B.S. 25 Asian Pethidine 0 <100
A.L. 21 Caucasian Atropine
(Diabetic
receiving
Insulin)
30-35 2,580
C.L. 33 Caucasian None 20 5,241
M.G. 23 Caucasian None 5 1,268
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The formation of 3-hydroxybenzo[a]pyrene, with whole placental 
homogenate from subject A.L., proceeded linearly for 15 min. and 
thereafter declined (Fig. 4.32). All subsequent incubations were 
carried out for 15 min. only. It was possible to store full-term 
human placentae at -15° for two weeks without any apparent loss of 
hydroxylating activity.
b) Wistar/albino rat benzo [al pyrene hydroxylase activity
The benzo[a]pyrene hydroxylase activity of steroidogenic tissues, 
following 3-methylcholanthrene pretreatment, was assessed according to 
the method of Juchau (1971). Pregnant rats were sacrificed on the 
19th day of gestation.
Fig. 4.33 Organ weights of rats on day 19 of gestation following
3-methylcholanthrene pretreatment
Animal Animal Wt 
(g)
Liver Wt 
(g)
Pooled Placental 
Wt (g)
Ovaries
(g)
Testes
Cg)
Adrenals
(g)
Control Female 240 9.2 1.1 0.7 - 0.15
3-MC Female 260 11.9 4.2 0.6 - 0.20
Control Male 355 12.1 - - 3.43 0.09
3-MC Male
• '
400 13.7 - - 3.61 0.16
The adrenals, ovaries and testes were, where possible, homogenized in 
3.5 volumes (w/v) of 0.25 M sucrose solution and this preparation was 
used as the enzyme source. The exceptions were the control female 
ovary homogenate which was made up to 1.2 ml, as was that of 
experimental female adrenals; the control male adrenal homogenate 
was diluted to 1.3 ml and the 3-methylcholanthrene-treated to 1.4 ml.
Relative to steroid producing organs studied, liver was most 
active in its capacity to hydroxylate benzo[a]pyrene (Fig. 4.34). 
Marked induction of this enzyme was found only in the liver among the 
tissues studied.
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Benzo [a]pyrene hydroxylase activity was lowest in the rat placenta, 
and a small increase was found with 3-methylcholanthrene treatment.
Of the four steroidogenic tissues investigated, the ovaries exhibited 
the highest basal rate of benzo[a]pyrene hydroxylation and no induction 
was observed following 3-methylcholanthrene treatment. The adrenals 
also proved active in hydroxylating benzo[a]pyrene, particularly in 
male rats. Testicular hydroxylation was comparable to that of the 
placenta.
c) New Zealand White rabbit benzofaIpyrene hydroxylase activity
A comparable study to that reported in the rat was also 
carried out in New Zealand White rabbits. In this investigation, 
benzo [a ]pyrene hydroxylase activity was studied in steroid synthesizing 
organs of the pregnant animal only. 3-Methylcholanthrene pretreatment 
was carried out on days 29 and 30 of gestation, and the experiments 
completed the following day.
Fig. 4.35 Organ weights of rabbits on day 31 of gestation following
5-methylcholanthrene pretreatment
Animal Animal Wt 
(kg)
Liver Wt 
(g)
Pooled Placental 
Wt (g)
Ovaries
(g)
Uterus
(g)
Adrenals
(g)
Control 4.5 45.1 38.2 3.7 33.4* 0.4 (one)
3-MC
Treated 4.6 48.3 48.0 2.8 39.0* 0.7
* = A Portion of the organ.
Tissue homogenization was effected with a Potter homogenizer, 
except for the uterus, where it was necessary to use the Polytron Ultra 
Turrax. Two volumes of 0.25 M sucrose were used for tissue 
homogenization. It was found necessary to dilute the adrenal and 
ovarian homogenates with a further aliquot (5 ml) of sucrose solution. 
The final tissue preparations (whole homogenates in the case of ovaries, 
uterus and adrenals) were stored overnight at -15°. The rate of 
benzo [a]pyrene hydroxylation determined are shown in Fig. 4.36.
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In general the levels of benzotal pyrene hydroxylase activity 
measured in the New Zealand White rabbit are lower than those observed 
with Wistar/albino rats. The maternal liver was pre-eminent in 
hydroxylating activity, and responded markedly to 3-methylcholanthrene 
induction. The placental, ovarian and adrenal preparations from the 
control rabbit were unable to significantly hydroxylate benzo{a] pyrene. 
Following 3-methylcholanthrene treatment, activity was detectable in 
placental and ovarian homogenates but at a very low level. Control 
uterine preparations hydroxylated benzo [a] pyrene whereas those from 
3-methylcholanthrene treated animals did not. This most probably 
reflects differences in the efficiency of tissue disruption, since the 
uterus of the control rabbit was less particulate than that of the 
3-methylcholanthrene treated animal. These findings are not the same 
as those for rat, particularly since no adrenal hydroxylation was 
observed and the ovarian system respondecj to 3-methylcholanthrene 
administration. -
(viii) Hydrolysis of phenolphthalein glucuronide
a) Human placental hydrolysis of phenolphthalein glucuronide
1) pH Optimum
Particulate fractions were incubated for 60 min at 37° under 
varying pH conditions. Peak 3-glucuronidase activity was achieved at 
pH of 4.4 (Fig. 4.37). The 10,000 g.av. supernatant exhibited a higher 
rate of hydrolytic activity on a protein basis than did the 600 g.av. 
supernatant.
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Fig. 4.37 pH Optimum for full-term human placental 3-glucuronidase activity
Subcellular Fraction Buffer
(0.1M)
PH 3-glucuronidase activity 
(yg of phenolphthalein produced/ 
mg protein/h)
10,000 g.av. Supernatant Acetate 4.0 1.32
600 " tt Acetate 4,4 1.28
10,000 M tt Acetate 4.4 1.38
it ii tt Acetate 5.5 0.82
ii ii n Phosphate 6.8 < 0.01
it it tt Phosphate 7.0 < 0.01
ii ii ti tris-HCl 7.4 < 0.01
ii it tt tris-HCl 7.8 < 0.01
it tt tt tris-HCl 8.2 < 0.01
2) Subcellular localization of 3-glucuronidase activity
Isolated subcellular fractions from 94 g of placenta were 
all resuspended in 30 ml of 0.25 M sucrose, except for the 
600 g.av. (10 min) pellet where 150 ml was used. The 3-glucuronidase 
activity of these preparations were similar, though the specific 
hydrolytic activity of the 10,000 g.av. sediment was significantly 
lower than conparable fractions (Fig. 4.38). In previous 
experiments (Chapter Three) electron microscopy had confirmed 
the isolation of intact mitochondria and homogenous microsomal 
preparations (Fig. 3.39-42).
Fig. 4.38 Subcellular distribution of full-term human placental 
3-glucuronidase activity
Subcellular
Fraction
yg of Phenolphthalein 
formed
yg of Phenolphthalein 
mg protein/h
600 g.av. Sediment 53.6 7.08
4,000 g.av. Sediment 40.5 8.18
10,000 g.av. Sediment 11.7 3.74
105,000 g.av. Sediment 30.2 8.52
Soluble Fraction 45.0 8.13
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Homogenizing in 0.25 M sucrose minimises the disruption of sub- 
cellular components, but does not remove haemoglobin as effectively 
as does 1.151 KC1. The presence of haemoglobin exaggerates protein 
measurements. 3-Glucuronidase activity has therefore been 
expressed in terms of subcellular fraction per g wet wt. placenta.
In Fig. 4.39, 3-glucuronidase activity was largely associated 
with the 600 g.av. sediment and 105,000 g.av. supernatant, which 
together indicated inadequate homogenization. Since considerable 
hydrolysis occurred with the placental soluble fraction, homogenization 
may have been effected with only a portion of the placenta, and 
possibly through mechanical damage released 3“glucuronidase from 
lysosomes and possibly microsomes. Soluble 3-glucuronidase activity 
may be mediated through "light" microsomes.
Fig. 4.39 Subcellular distribution of full-term human placental 
3-glucuronidase activity
Subcellular
Fraction
pg of Phenolphthalein 
released/g/h
% Total activity
600 g.av. Sediment 342.0 42.4
4,000 g.av. Sediment 51.7 6.4
10,000 g.av. Sediment 14.9 1.9
105,000 g.av. Sediment 38.6 4.8
Soluble Fraction 360.0 44.6
(ix) Formation of 4-methylumbelliferone glucuronide
a) UDP-glucuronyl transferase activity in the Wistar/ albino rat
The small amount of UDP-glucuronyl transferase activity 
present in the rat placenta appeared to increase with gestation and 
could not be stimulated with phenobarbital or 3-methylcholanthrene 
treatment (Fig. 4.40). The total conjugating capacity at full-term 
represented only 0.4$ of that of the maternal liver (Fig. 4.41). 
Glucuronidation in the foetal liver at full-term was also unaffected
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by enzyme inducers, and exhibited a basal rate of conjugation more 
than thirteen-fold that observed with placenta. On a unit weight 
basis, maternal liver UDP-glucuronyl transferase activity was 100 
times greater than that of placenta and over 10 times that of foetal 
liver. 3-Methylcholanthrene enhanced the rate of conjugation by 
33.31, whereas phenobarbital increased it by only 4.71
Fig. 4.41 UDP-Glucuronyl transferase activity of rat placentae and
foetal livers expressed as a percentage of that of the maternal liver
Pooled organs 
of each litter
Foetal Age 
(days)
Rate of 4-methylumbelliferone Conjugation 
C% maternal liver)
ymol/g/h pmol/organ (s) /h
Placentae 15-17 0.4 0.1
Placentae 18-20 0.6 0.4
Placentae 21 0.7 0.4
Placentae* 21 0.3 0.2
Placentae** 21 0.5 0.3
Foetal Livers 21 8.6 1.5
Foetal Livers* 21 6.0 0.9
Foetal Livers** 21 5.8 1.2
* 3-methylcholanthrene; ** phenobarbital pretreatment
b) UDP-glucuronyl transferase activity in the New Zealand White 
Rabbit
The full-term rabbit placental rate of conjugation was 22% 
of that found in the rat (Fig. 4.42). Unlike the latter, however, 
it was induced by phenobarbital to a level of 11% above normal 
and the total capacity for glucuronidation equalled 1.31 of that 
of the maternal liver. Induction may have been the cause of the 
high foetal liver UDP-glucuronyl transferase activity. Surprisingly 
there was a high rate of glucuronidation in maternal liver compared 
with that of phenobarbital treated and non-pregnant rabbits. If 
this is disregarded, however, the administration of phenobarbital 
clearly raised maternal liver activity by 1001 over that of the
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non-pregnant rabbit. The conjugating capacity of pooled foetal livers 
represented 7.1% of that of the maternal liver from the phenobarbital 
treated animal.
Fig. 4.42 4-Methylumbelliferone glucuronidation in the rabbit
at full-term following phenobarbital pretreatment
Animal 
wt (kg)
Organ Organ 
wt (g)
Foetal
Age
Pretreatment Rate of 4-methylumbeli- 
iferone conjugation
(days)
; ! ymol/g/h y mol/organ(s)/h
4.0 (1) Non-pregnant
liver 140.3 0 Phenobarbital 2.91 407
6.0 (2) Maternal
liver 131.0 31 8.84 1145
4.3 (1) Maternal
liver 102.7 30 Phenobarbital 5.82 595
4.3 (1) Foetal
liver 5.6 30 Phenobarbital 7.61 42.5
6.0 (1) Placenta 26.0 31 0.15 3.9
4.3 (1) Placenta 21.8 30 Phenobarbital 0.36 7.9
c) UDP-glucuronyl transferase activity in the human placenta 
and foetal liver
Human placenta was virtually devoid of glucuronidation during the 
period of gestation studied (Fig. 4.43). Human foetal liver exhibited 
a corresponding deficiency in UDP-glucuronyl transferase activity, 
though the level appeared elevated towards the end of the second trimester.
Fig. 4.43 4-Methylumbelliferone glucuronidation in human placenta 
and foetal liver at different periods of gestation
Organ Foetal Age 
(weeks
Rate of 4-methylumbelliferone conjugation 
(ymol/g/h)
Placenta 15 a) < 0.01»» 16 a) 0.01
it 19 a) 0.01
M 22 (2) 0.02
11 40 (4) 0.01
Foetal liver 16 (1) 0.01
it it 19 (1) 0.01
M II 22 (1) 0.05
Figures in parenthesis represent the number of experiments
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C. SUMMARY
The capacity of the placenta, foetal liver, maternal liver and 
several steroidogenic tissues from different species to perfoim a 
variety of xenobiotic biotransformations were investigated at different 
stages of gestation and following pretreatment with enzyme inducers.
In contrast to the rabbit placenta, that of humans hydroxylated biphenyl 
in both the 2- and 4-positions, whereas rat preparations exhibited only 
biphenyl-4-hydroxylase activity. The latter was found in association 
with the soluble fraction (Fig. 4.2) and was not increased after 
phenobarbital or 3-methylcholanthrene treatment. Dialysis of human 
placental microsomes for 5 h. abolished ortho- and para-hydroxylase 
activity. The reduction of p-nitrobenzoic acid in the rat, which was 
also associated with the soluble fraction, appeared to increase with 
gestation such that at full-term, pooled placental activity equalled 5% 
of that exhibited by maternal liver (Fig. 4.7). Rabbit and human 
placentae exhibited marginally higher rates of nitroreduction, though 
animals pretreated with phenobarbital and 3-methyl cholanthrene did not 
show increased activity.
Zoxazolamine metabolism and 0-demethyl at ion of p-nitroanisole was 
not present in measurable levels when human placental preparations were 
assayed. Ethylmorphine N-demethylase activity was also not detectable 
with human placentae, but was apparent in rabbits following phenobarbital and 
3-methyl cholanthrene treatment (Fig. 4.15). Similarly,the N-demethylation of 
p-chloro-N-methylaniline was shown with rat placentae but not with those 
of humans or pigs. Following phenobarbital administration there was a 
97% increase in microsomal protein per g. of rat placenta though there 
was no corresponding elevation of N-dealkylation.
Placental homogenates from subjects with a history of cigarette 
smoking during pregnancy were found to contain measurable benzo!a]pyrene 
hydroxylase activity, but the level did not appear to be related to the 
number of cigarettes smoked (Fig. 4.31). Pretreatment with 3-methylcholan- 
threne resulted in detectable benzo [a]pyrene hydroxylation with rabbit 
placenta (Fig. 4.36), and enhanced enzymic activity in rat placenta (Fig.4.34). 
The placental enzyme was associated with the 1,000 g.av. sediment.
199
The most active placental enzyme was 3-glucuronidase. The subcellular
distribution in the human placenta of the observed hydrolytic 
activity could not be readily assessed. The minimal level of glucuronidation 
in the rat placenta appeared to increase with gestation (Fig. 4.40) but could 
not be stimulated with 3-methylcholanthrene or phenobarbital. The human 
placenta poorly conjugated 4-methyl-umbelliferone (Fig. 4.43) whereas that 
of the rabbit seemed to increase after phenobarbital treatment (Fig. 4.42).
In general, on a unit weight basis, the rate of placental drug-metabolizing 
activity in all species studied was approximately one hundredth of that shown 
in the maternal liver. The subcellular location of placental detoxicating 
activity and the cofactor requirements observed distinguishes these systems 
from those of maternal liver, and suggests that different mechanisms may 
be involved.
Biological transfoimations found in foetal liver were comparable to 
those of placenta, though in general the activity was marginally higher.
Foetal liver biphenyl-4-hydroxylase activity in the rat 10,000 g.av. 
supernatant was enhanced in the presence of maternal liver soluble fraction 
but only by an increment already shown present in the latter (Fig. 4.2).
Ortho- and para-hydroxylation was apparent with both human and rabbit foetal 
liver preparations (Fig. 4.5; 4.4). Nitroreduction may increase with 
gestation in the human foetal liver, but phenobarbital did not influence 
activity in rat and rabbit foetal liver. 3-Methyl cholanthrene was also 
without effect on rat foetal liver nitroreductase activity. Human foetal 
liver was largely deficient in 4-methylumbelliferone glucuronidation 
(Fig. 4.43), whereas the phenobarbital-treated rabbit exhibited high 
activity (Fig. 4.42). In rat, the administration of 3-methylcholanthrene 
or phenobarbital did not alter foetal liver UDP-glucuronyl transferase 
activity. N-demethyl at ion of ethylmoiphine was only apparent in 
3-methylcholanthrene or phenobarbital pretreated rabbit foetal livers 
(Fig. 4.15). Since placental weight usually exceeded pooled foetal liver 
weight, a greater total capacity for detoxification was associated with 
the foimer.
The capacity of the maternal liver to effect different biochemical 
transformations did not appear to be markedly altered during pregnancy.
2 0 0
The reduction in drug-metabolizing acitivity per g. of liver was often 
countered by an I increase in liver weight. The ratio of liver to body 
weight, however, probably changes during pregnancy (Neale, 1970). The 
high biphenyl-4-hydroxylase activity was particularly enhanced following 
phenobarbital treatment, whereas the minimal biphenyl-2-hydroxylase 
acitivity was readily measurable after 3-methylcholanthrene treatment.
The £-nitrobenzoic acid reductase activity in the rat maternal liver 
on a unit weight basis and whole organ basis appeared to decline 
towards full-term (Fig. 4.7). Phenobarbital and 3-methylcholanthrene 
increased total | nitroreductase activity at full-term, in part by liver 
enlargement. Comparable studies with rabbit liver produced inconsistent 
data (Fig. 4.10). Under the experimental conditions employed for 
placental studies, zoxazolamine metabolism was apparent in maternal liver, 
as was £-nitroanisole O-dealkylation. Phenobarbital treatment increased 
the rate of the latter by 30% and the microsomal protein content per g. 
of tissue by 36.5% (Fig. 4.22). It also elevated the rate of rabbit maternal 
liver ethylmorphine N-demethylase activity by 65% (Fig. 4.15). N-demethylation 
of £-chloro-N-methylaniline was increased with phenobarbital treatment by 
31% on a mg. of protein basis, which was accompanied by a 8.75% increase 
in liver weight and a 23% rise in total microsomal protein content (Fig. 4.27). 
The administration of 3-methylcholanthrene significantly elevated rat and 
rabbit maternal liver benzofa]pyrene hydroxylase activity (Fig. 4.34;4.36).
The total rate of glucuronidation in the rat maternal liver was not markedly 
altered from day 15 - 21 of gestation. Pretreatment with 3-methylcholanthrene 
resulted in higher UDP-glucuronyl hydroxylase activity than was apparent with 
phenobarbital (Fig. 4.40). On a unit weight basis, the rabbit exhibited 
a lower rate of conjugation (Fig. 4.42). Enzymes responsible for these bio­
transformations were found in maternal liver in association with the 
microsomal fraction, and to a lesser extent in the soluble fraction.
Particulate fractions of rat testes hydroxylated biphenyl and 
N-dealkylated £-chloro-N-methylaniline at comparable rates to those shown 
for full term placenta. Isosafrole and 3-methylcholanthrene did
not influence the testicular N-dealkylation, although the latter increased 
the microsomal protein content per g. of tissue by 20.5%. O-Dealkylation 
of £-nitroanisole occurred at a rate equal to 4.7% of that of the maternal
2 0 1
liver on a mg. of protein basis (Fig. 4.20). Phenobarbital administration 
elevated the microsomal protein content per g. of testes by 10.21 but 
this was not accompanied by enhanced 2-nitroanisole O-demethylation. The 
minimal rat testicular benzo[a]pyrene hydroxylase activity was not 
influenced by 3-methylcholanthrene administration, and neither was that 
of ovaries, and male and female adrenals (Fig. 4.34). In the rabbit, 
benzo[a]pyrene hydroxylation was detectable in ovaries following 
3-methylcholanthrene treatment, but was present in uterus of the 
untreated animal only. No adrenal benzo[a]pyrene hydroxylase activity 
was detected in pregnant rabbit (Fig. 4.36).
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INTRODUCTION
Cytochrome P-450 is the terminal component of an enzyme system 
of hepatic endoplasmic reticulum that oxygenates drugs and endogenous 
steroid hormones (Emster and Orrenius, 1965). Drugs may be metabolized 
by the other tissues of the body besides liver (Mason, 1957) and 
recent investigations have suggested that such activity is to be found 
in placental tissues (Mirkin, 1970) thus possibly compensating for the 
low levels of drug metabolizing activity of the foetal liver (Fouts 
and Adamson, 1959). The levels of placental drug-metabolizing activity 
reported are modest and the concentration of cytochrome P-450 present 
is correspondingly low (Meigs and Ryan, 1968). This contrasts with 
the high level of enzymes present in placenta that aromatize steroids. 
This steroid-aromatizing system involves a series of oxygenations at 
C-19 and C-l, which are dependent on NADPH and molecular O2 for activity 
(Ryan, 1959; Akhtar and Skinner, 1968). This apparent anomaly was 
investigated to ascertain whether and to what extent the steroid- 
aromatizing enzyme system is mediated through cytochrome P-450 and to 
seek the reason for the low level of drug-metabolizing activity found 
in the placenta.
Assay procedures were developed to monitor in vitro oestrogen 
synthesis and to characterize the oxygenation process in different 
species. Detailed investigations were undertaken on human placental 
aromatization, incorporating solubilization, inhibition and binding 
studies.
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RESULTS
A. Aromatization in the Human Placenta
i (i) Preliminary Studies
Initial rates of aromatization observed with full-term human 
placental microsomal preparations were modest. The conversion of 
androstenedione to oestrone in a placenta previously stored for 2 hr. 
at -15° was 8.91, whereas in a second organ stored for 5 hr. the 
rate was 6.11, during a 60 min. incubation. The formation of oestrone 
no longer proceeded linearly beyond 1 hr. (Fig. 5.1).
Fig. 5.1 The Conversion of Androstenedione to Oestrone with Time 
By Human Placental Microsomal Preparations
9060
Incubation Time (min.)
-• = Placenta stored at -15° for 2 hr.
-a = Placenta stored at -15° for 5 hr.
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(ii) Subcellular distribution of the aromatization complex
In addition to microsomes, the placental mitochondrial fraction 
has been implicated as a second site of oestrogen biosynthesis (Shaw, 
et al, 1969; Aleem et al, 1970). Particulate fractions were therefore 
prepared as described earlier, and except for microsomes were resuspended 
in their original volumes with 0.05 ^ phosphate buffer, pH 7.1, follow­
ing one washing in this media. The relative rates of aromatization 
in these subcellular fractions during a 60 min. incubation are shown in 
Fig. 5.2.
Fig. 5.2 Subcellular distribution of the human placental
j aromatization complex
Particulate
Fraction
% Conversion nmol, of oestrone 
/mg. of protein/h
ymol. of oestrone 
/placenta/h.
Soluble
fraction 1.01 0.096 1.183
Microsomal
preparation 12.60 1.194 2.255
Mitochondrial
preparation 0.86 0.266 0.116
Lysosomal
preparation 7.66 2.274 1.161
Nuclear
preparation 2.16 0.281 7.808
The microsomal preparation effected the highest oestrone formation, but 
contained more protein (= 30 g wet wt.) than comparable fractions. In 
terms of specific activity on a protein basis, the lysosomal rate of 
aromatization was greater than that of microsomes. The highest conversion 
per total subcellular fraction per placenta was found with the 600 g. av. 
sediment, with that of the 105,000 g.av. second. Aromatization associated 
with nuclear and cellular debris probably reflects inadequate homogenization. 
The oestrogen biosynthesis in the soluble fraction was possibly due to 
the presence of '’light” microsomes which did not sediment at 105,000 g.av. 
for 60 min.
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(iii) Effect of nicotinamide in the homogenizing media on the 
subcellular distribution of the aromatization complex
Mann and Quastel (1941) introduced nicotinamide into the 
incubation media as an inhibitor of pyridine nucleotidase activity. 
Schenkman, Ball and Estabrook (1967) found nicotinamide competitively 
inhibits aminopyrine demethylation and also inhibits aniline hydroxylase 
by some mixed type, of action. The subcellular distribution of the 
placental aromatization complex was therefore reinvestigated in the 
absence of nicotinamide. The conversion of androstenedione to oestrone 
in all particulate fractions was markedly reduced (Fig. 5.3), representing 
approximately one tenth those previously observed (Fig. 5.2). The 
distribution pattern, however, was essentially the same with aromatization 
activity being concentrated in the microsomal and lysosomal fractions.
The high level of activity associated with the soluble fraction may 
reflect microsomal contamination.
Fig. 5.3 Subcellular distribution of the human placental aromatization
complex in the absence of nicotinamide
Particulate
Fraction
% Conversion nmol of oestrone 
/mg of protein/h
ymol of oestrone 
/placenta/h
Soluble
fraction 0.22 0.011 0.135
Microsomal
preparation 1.16 0.458 0.081
Lysosomal
preparation 1.51 0.299 0.058
Mitochondrial
preparation 0.40 0.096 0.015
Nuclear
preparation 0 0 0
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(iv) Homogeneity of subcellular fractions
Marker enzymes were used to assess the homogeneity of subcellular 
fractions (Fig. 5.4). Despite the washing of particulate fractions, 
the distribution of these marker enzymes suggested considerable cross­
contamination. Results with acid phosphatase indicated that lysosomes 
remained intact and their contents did not diffuse out. The high levels 
of succinate dehydrogenase and glucose-6-phosphatase activity observed 
with the lysosomal fraction suggested considerable contamination with 
microsomes and mitochondria. Inadequate homogenization may result in the 
sedimentation of aggregates of endoplasmic reticulum at lower g. forces 
than normally required. The distribution of glucose-6-phosphatase 
supports this suggestion and may explain the lysosomal aromatization.
(v) The conversion of androstenedione to oestrogens by human 
placental microsomal preparations
a) Preliminary study
Placental microsomal fractions were prepared and incubated 
as described. Following isotope dilution with oestrone (500 yg), 
the incubates were extracted and the steroids resolved on t.l.c. 
(silica gel Hp 254 + 355). acetone/chloroform (15:185 ^/v).
Since lack of definition was obtained using a t.l.c. radioactive 
plate scanner and a spark chamber, bands (1 cm) of silica gel 
were eluted with methanol (5 ml) and aliquots (0.1 ml) removed 
for liquid scintillation counting. The radioactivity of each 
band was recorded on a histogram as a percentage of the total 
activity on each t.l.c. plate (Fig. 5.5). Methanolic extracts 
of bands exhibiting peak radioactivity were pooled, and isotope 
dilution with oestradiol-173 (100 yg) and oestriol (100 yg) 
completed. Steroids were then resolved on t.l.c. in benzene/ 
ethyl acetate (2:1 v/v) and then cyclohexane/ethyl acetate 
(1:1 v/v). The major androstenedione metabolite was oestrone, 
representing a 32.5% conversion. Tritium was found in association 
with the oestradiol-17$ band and a trace amount with that of 
oestriol. A tritiated A^-3-oxo steroid was also apparent which 
may have represented 19-hydroxy-androstenedione.
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b) Further studies
Following a 90 min. incubation, isotope dilution was 
completed with 500 pg of oestrone, oestradiol-173 and oestriol.
The incubates were extracted with diethyl ether/ethanol (3:1 v/v), 
and the oestrogens partitioned between the organic phase and 
1 M NaOH (2 x 10 ml). The pH of the alkaline extracts was 
adjusted to 8-8.5 and oestrogens re-extracted into ether (2 x 25 ml). 
Steroids were resolved on t.l.c. in cyclohexane/ethyl acetate 
(1:1 v/v) and then eluted with ether/chloroform (5:1 v/v). The 
separation of oestriol from residual androstenedione was achieved 
on t.l.c. in the system, ethyl acetate/n-hexane/acetic acid/ethanol 
(72:13.5:10:4.5 v/v) using silica gel Hp + 355* Oestrone and 
oestradiol-178 were purified on t.l.c. in chloroform/ethanol 
(97:3 v/v). From the specific activities of the oestrogens,the 
percentage conversion from androstenedione was determined and 
the mean of quadruplicate incubates shown below (Fig. 5.6).
Fig. 5.6 The conversion of androstenedione to oestrogens by human
placental microsomal fractions
Metabolite of Androstenedione % Conversion
Exogenous G-6-P-D Placental G-6-P-D 
(Soluble fraction)
Oestrone 10.98 9.01
Oestradiol-173 0.29 0.19
Oestriol 0.16 0.34
Oestrone was the major oestrogen metabolite, though trace 
amounts of oestradiol-173 were also present. The placental
105,000 g.av. supernatant was almost as effective as the exogenous 
G-6-P dehydrogenase in supporting aromatization.
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(vi) Effect of Mg on human placental aromatization
HoHanderand Hollander (1960) reported that a 10 mM concentration of
++
Mg is the optimal cofactor requirement for placental aromatization. In 
checking this level, it was not possible to employ MgSO^ since SO  ^
were found to inhibit the exogenous G-6-P-dehydrogenase activity (obtained 
from Torula yeast). Therefore, MgCl^, stored in a desiccator as it is 
hydroscopic, was utilized as the cofactor. Freshly prepared microsomal 
fractions, obtained from two full-term placentae, were incubated under 
varying Mg concentrations for 60 min. The pH optima determined were
11.0 mM and 10.0 mM respectively (Fig. 5.7).
a) Effect of time on the Mg requirement for human placental 
aromatization
In the presence of 10, 11 and 12 mM MgC^, the progress of
aromatization was followed at 15, 30, 45, 60 80 and 100 min. The
reaction mixture volume for these experiments was maintained at 5.0 ml. 
++
The Mg concentration did not effect the linearity of the aromatization
++
curve. Oestrone synthesis occurred more readily at a Mg concentration 
of 10 nM (Fig. 5.8).
++
Fig. 5.7 Effect of Mg on human placental aromatization
bO
2.0
Concentration of MgC^ (mM)
+■— « = first placenta studied 
▲— —a = second placenta studied
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(vii) Effect of solubilizing agents on human placental aromatization
a) Effect of steapsin and deoxycholate 
A portion (192.5 g) of human term placenta (445.0 g) was 
homogenized in two volumes (W/v) of 0.25 M sucrose (containing
0.05 M phosphate buffer, pH 7.0) and the 800 g.av. (10 min.) 
supernatant incubated in the presence of either steapsin (pancreatic 
lipase) or sodium deoxycholate for 120 min. The reaction mixture 
consisted of:-
800 g.av. supernatant ......
Androstenedione (0.66 ymol) ...
NADP (5.2 ymol) ... ......
G-6-P (26 ymol) ... ......
G-6-P-dehydrogenase (0.5 Unit)
Steapsin or deoxycholate*
Total Volume
= 0.11 (W/v) solns.
3 ml 
Dried under N, 
0.5 ml 
0.5 ml 
0.5 ml 
0.5 ml
5 .0 ml
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The oestrone recovery from steapsin digested incubates was 
very low, and thus prevented the determination of the rate of 
oestrone biosynthesis. Deoxycholate treated preparations exhibited 
a rate of aromatization (0.015 nmol of oestrone/mg of protein/h) 
which was 28.6% of that of control incubates (0.051 nmol/mg/h).
b) Effect of lipase and papain
Freshly prepared human placental microsomes were resuspended 
in either 0.1 M phosphate buffer, pH 6.9 (2 ir^.1 reduced glutathione) 
or 0.1 M phosphate buffer, pH 7.4 to a protein concentration of
17.5 mg/ml or 19.6 mg/ml respectively. Aliquots (15 ml) were, removed 
for 15 min. incubations at 37.5° under ^  For papain experiments, 
the proteolytic enzyme (174.9 mg) was dissolved in 0.1 M phosphate 
buffer, pH 6.9 (20 ml), and for lipase studies, the enzyme (196 mg) 
was dissolved in 0.1 M phosphate buffer, pH 7.4 (20 ml). On warming 
preparations to 37.5°, aliquots (1.5, 3, 9 and 15 ml) of the 
digesting enzymes were added to those microsomal resuspensions in 
the same buffer. Thus the percentage (w/w) of digestive enzymes 
to microsomal protein was:-
i) 28.57%, ii) 17.14%, iii) 5.71%, iv) 2.85%.
Following incubation (2 h) and centrifugation, the 105,000 g.av. 
(60 min) supernatants were not found to aromatize androstenedione to 
oestrone in measurable levels.
c) Solubilization according to the method of Gaylor 
and Mason (1968)
Gaylor and Mason (1968) achieved considerable purification of 
an oxidative sterol demethylating system which was not cytochrome 
P-450 mediated. The procedure depended on solubilizing extraneous 
microsomal material with a Triton detergent, then bringing the enzyme 
into a soluble form with deoxycholate treatment followed by further 
purification on an anion exchange column.
A portion (100-200 g) of full-term placenta was minced at 4°, 
and washed repeatedly with ice-cold 0.9% (W/v) NaCl over muslin 
cloth to remove excess blood. It was then homogenized in two
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volumes (W/v) of 0.1 M phosphate buffer, pH 7.1 containing 30 mM 
nicotinamide and 1 nM reduced glutathione. The microsomal pellets 
were resuspended in 251 of the 10,000 g.av. supernatant volume 
and treated with an equal volume of 10$ (W/v) Triton W.R.-1339 for 
10 min. in a shaking water bath at 37°. On cooling to 4°, an 
equal volume of ice-cold 0.1 M phosphate buffer, pH 7.1 was added 
and microsomes resedimented. The pellets were stored at -15° 
under 50$ (v/v) glycerol in 0.1 M phosphate buffer, pH 7.1 
(30 mM nicotinamide and 1 mM reduced glutathione).
Micrbsomal pellets were resuspended in 0.1 M tris-HCl buffer, 
pH 7.1 (containing 2 nU glutathione) and incubated under N2 for 
20 min. atj 25° with 0.5 mg of sodium deoxycholate per mg of protein. 
The volume was kept to a minimum since the incubate was applied to a 
sephadex G-25 column (30 g of sephadex G-25 was hydrated and 
equilibrated with water). A flow rate of 4 ml/min. was maintained. 
Phosphate buffer, pH 7.1, nicotinamide and glutathione were added 
to collected fractions to yield final concentrations of 0.1
0.03 M andj 2 nM respectively. The column was packed to a height of 
14 cm and 4 cm in diameter and the deoxycholate was separated from 
the major protein fraction at 4°. Aliquots (5 ml) were collected 
from the column automatically and protein detected by absorbance
at 280 nm.
Protein fractions were pooled and centrifuged at 105,000 g.av. 
for 60 min. The soluble protein content was collected by freeze- 
drying rather than (NH^^SO^ precipitation. Gaylor and Mason (1968) 
subjected this protein to further column chromatography using DEAE- 
sephadex A50, and concentrated the purified enzyme preparation by 
ultrafiltration.
In Fig. 5.9, a flow diagram describes in detail the steps 
taken in trying to solubilize the placental aromatization complex.
1. Following the left column of the flow sheet, four freshly 
prepared microsomal pellets were treated with Triton WR-1339 
and then resuspended in 0.1 M tris-HCl buffer, pH 7.1
(16 ml) containing 2 mM reduced glutathione. Three aliquots 
(5 ml) were removed and treated separately. The first aliquot
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was incubated with deoxycholate as described above. The 
second was treated with the same amount of surfactant but 
only during a 5 min. homogenization. The final preparation 
was subjected to both homogenization and incubation in the 
presence of deoxycholate.
2. TWenty-four hours were required to freeze-dry approximately 
100 ml of 105,000 g.av. (60 min.) supernatant, which was found 
to be devoid of protein.
3. Preliminary sonication studies were shown to denature protein. 
Frequent cooling of the soniprobe was necessary during a period 
of 5-8 min. sonication. The treatment released microsomally 
bound haemoglobin.
4. Haemoglobin, cytochrome b^, cytochrome P-450 and P-420 contents 
were; determined in five microsomal pellets which had undergone 
different treatments. In the flow sheet, the dilution factor 
of these resuspended microsomes is given as an aliquot to 
which a known volume of the phosphate buffer was added.
5. The reaction mixture of the aromatization assay was modified 
to: -
Androstenedione (2yCi/0.33 ymol) ........... 0.1 ml
G-6-P (13 ymol)     ... 0.25ml
NADP (2.5 ymol) ...... ... ......... 0.25ml
G-6-P-Dehydrogenase (0.5 unit) ... ...... 0.5 ml
Microsomal preparation ... ... ... ......  1.0 ml
MgC^ (25 ymol) ...... ..... ... ... ... 0.4 ml
Total volume 2.5 ml
Sonication and deoxycholate treatment did not solubilize the 
human placental aromatizing system. However, the method of Gay lor 
and Mason (1968) enabled a partial purification of the enzyme complex 
since Triton WR-1339 solubilized some microsomal lipid and to a 
lesser extent protein. Similarly, following deoxycholate treatment 
and filtration on Sephadex G-25 the microsomal preparations exhibited 
a higher specific activity (2.44 nmol oestrone/mg protein/h) than 
did the original (1.553 nmol/mg/h). This difference may reflect the
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Resuspended 
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presence of haemoglobin in the original. The rate of aromatization 
shown by Triton-treated microsomal preparations was, however, 
reduced (1.257 nmol/mg/h) suggesting that deoxycholate effected 
a significant purification. Cytochrome P-450 was present through­
out only as its inactive derivative, P-420 but this did not 
prevent aromatization. Cytochrome bj- was not found in detectable 
concentrations.
(viii) Effect of CO on human placental aromatization
A simple technique for producing gaseous mixtures of known content 
was devised. To each of three gas cylinders containing O2, ^  and CO 
respectively, was attached a conical flask containing water, through which 
the gases were bubbled. By counting the bubbles, the flow rate was 
determined and adjusted accordingly. Having attained the requisite 
flow rate for each gas, the cylinders were connected to a three way 
junction which in turn led into a boiling tube with a side-arm. Within 
this was a rotating magnetic stirrer which served to mix the gases before 
they left the side-arm for the incubation tubes. The gases flowed into 
the top of the boiling tubes and left via the side-arm to the adjacent 
incubate. Reaction mixtures were not shaken during incubation. Pre­
flushing with the mixed gases was carried out for 15 min. at 04°.
A preliminary study, where the oestrone yield was low (41 conversion), 
suggested that high levels of CO may inhibit aromatization. This finding 
could not be repeated. Using conical flasks (50 ml) for incubations,
CO was not found to significantly modify the rate of aromatization (Fig. 5.10)
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Fig. 5.10 Effect of CO on human placental aromatization
Gaseous Mixture Microsomal Aromatization
nmol of oestrone/mg of protein/ h . % Conversion in 30 min.
Air 1.712 14.2
30% CO
65% N2 1.490 12.4
5% 02
60% CO
35% N2 1.420 11.8
5% 02
90% CO
5% N2 1.549 12.9
5% 02
'
The incubates exposed to 901 CO demonstrated a higher rate of 
oestrone production than did comparable preparations incubated in the 
presence of 301 and 601 CO. Because of the manipulations of the gassing 
apparatus the reaction mixtures were not incubated simultaneously and 
this may explain differences in rates of aromatization. Clearly, however, 
the presence of CO did not markedly alter the production of oestrone from 
androstenedione.
a) Methylation of oestrone
The purity of oestrone isolated from t.l.c. was examined by 
methylation according to the method of Brown (1955). Aliquots 
(5 ml) were taken from purified oestrone extracts (10 ml) produced 
in the CO inhibition experiments and dried in N2 at 37°. The 
residues were taken up in 1.6% (W/v) NaOH (2 x 25 ml) and transferred 
to stoppered reagent bottles (100 ml) containing H^BO^ (0.9 g). The 
bottles were placed in a water bath at 37° and dimethyl sulphate 
(1 ml) added with a safety pipette. Samples were then incubated
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at 37° for 30 min., after dissolving H^BO^. This procedure 
was repeated by adding more dimethyl sulphate (1 ml) together 
with 201 (W/v) NaOH (2 ml), and incubating for a further 30 min. 
Dimethyl sulphate became miscible on vigorous shaking. The 
methylated fraction was divided in half (approx. 25 ml) and one 
sample was extracted with petroleum ether (2 x 10 ml) which was 
then dried under ^  The residue was taken up in CHCl^ and run 
on t.I.e. (Hp 254 + 365) in ethyl acetate /benzene (1:9 v/v) along 
with the oestrone-3-methyl ether standards. Methylated oestrone 
was eluted with CHCl^ (2x4 ml) and the extract made up.to. 10 ml. 
Aliquots (0.4 ml) were removed for liquid scintillation counting 
and also (0.8 ml) for Ittrich’s modification of the Kober reaction 
(Fig. 5.11).
Fig. 5.11 Oestrone-3-methyl ether standard curve
5.0:
4.0-
3.0
2.0
1.0
74 6 852 30 1
Concentration of oestrone-3-methyl ether (yg/3 ml)
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Tabulated below are the specific activities of the methylated 
derivatives expressed as a percentage of that of the original 
oestrone (Fig. 5.12).
Fig. 5.12 Purity of isolated oestrone as examined by methylation
Incubate
(duplicates)
Oestrone
(dpm/ymol)
(a)
Oestrone-3-methyl ether 
(dpm/ymol)
(b)
b 7 x 100 . /a
In air 651, 880 539, 526 83 '
In 30% CO 571, 682 572, 730 100 > 98 ± 5%
In 60% CO 546, 387 571, 679 105
In 90% CO 593, 792 629, 862 106 .
The results presented above indicated that isolated oestrone 
following separation on t.l.c. was relatively pure. Methylation 
of oestrogens was routinely carried out whenever the purity was 
questionable.
(ix) Effect of alternative substrates on aromatization of 
androstenedione
Androstenedione was incubated with human placental microsomes in 
the presence of up to equimolar concentrations of aniline, zoxazolamine 
and cytochrome c1. The formation of oestrone was markedly reduced 
(up to 90%), particularly when cytochrome c was added. Efforts to 
produce Lineweaver-Burk plots and define the nature of inhibition was 
found to be difficult since there was considerable variation in the 
effects of these compounds.
(x) Development of an aromatization assay suitable for kinetic studies
The development of an assay to monitor in vitro oestrogen biosynthesis 
was undertaken to elucidate the nature of this hydroxylation process. A 
major way of achieving this has been through the use of inhibitors of 
known enzymic processes. The assay procedure described in Materials and 
Methods was found unsuitable for kinetic studies and therefore a new
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method was devised. Since the aromatization complex could not be 
solubilized, the new assay procedure was developed as described below.
a) Aromatization with varying protein and substrate 
concentrations
Stored microsomal pellets were resuspended and washed in
0.05 M phosphate buffer, pH 7.1 and diluted to a protein 
concentration of 19.6 mg/ml. The reaction mixture consisted 
of:-
NADP (2.6 ymol) ... ... ... ... .... ...
G-6-P (13 ymol) ... ... ... ....... ... ...
G-6-P-Dehydrogenase (0.5 Unit) ... ... ...
MgCl2 (25 ymol) ... ....... ... ... ... ...
Androstenedione (0.350, 0.525, 0.700 ymol)......
Microsomal preparation
(1.0, 0.75, 0.5 and 0.25 ml) ...
Total volume
Following pre-incubation for 15 min at 37°, the substrate was 
added and the mixture incubated for 60 min. under O2. Twelve 
experimental incubates were prepared (each with a blank containing 
boiled microsomal protein) as follows: at four protein levels
(4.9, 9.8, 14.7 and 19.6 mg) the androstenedione incubated was 
varied between 100, 150 and 200 yg
At the lowest protein concentration (4.9 mg), the rate of 
oestrone synthesis, equivalent to 17 nmol/h, did not change over the 
whole substrate range, suggesting that the enzyme source was a 
limiting factor. On increasing microsomal protein (9.8 mg) , 
aromatization occurred most rapidly (50 nmol oestrone/h) at the 
lowest androstenedione level (0.35 ymol) indicating possible 
substrate inhibition at higher concentrations. With 14.7 mg 
of microsomal protein, maximal activity (53 nmol oestrone/h) 
was apparent with 0.525 ymol of substrate, and at the highest 
enzyme level (19.6 mg) aromatization was maintained at 74 nmol 
of oestrone/h.
0.25 ml 
0.25 ml 
0.50 ml 
0.30 ml
0.10 ml
1. 00 ml 
2.4 ml
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At a substrate level of 0.35 ymol, the rate of aromatization 
with increasing protein concentration increased linearly to 74 nmol 
of oestrone/h. When a microsomal protein level of 19.6 mg was used, 
a linear increase in aromatization was no longer observed at substrate 
levels of 0.525 and 0.700 ymol, particularly with the latter.
b) Aromatization with varying substrate concentrations
Employing the reaction mixture just described, the rate of 
aromatization by 10 mg of microsomal protein was studied over the 
androstenedione range 0.035-0.700 ymol. The enzyme activity shown 
in Fig. 5.13 is based on triplicate incubations.
Fig. 5.13 Effect of varying androstenedione concentrations on
human placental aromatization
Substrate
(ymol)
■■ — i
Rate of Aromatization 
(nmol oestrone/10 mg protein/h)
0.035 *2.2 ±0.5
0.105 1.9 ± 0.4
0.210 1.9 ± 0.2
0.315 2.2 ±0.4
0.420 2.2 ± 0.2
0.525 1.8 ± 0.2
0.700 2.2 ± 0.6
* Mean ± S.D.
The rate of aromatization per mg of protein did not significantly 
change over the range of substrate concentrations examined. Since 
tissue to substrate ratio of 10,000-5,000 to 1 are often employed 
in steroid incubations in vitro, it was assumed that the andro­
stenedione concentration required reducing below 0.035 ymol.
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c) Aromatization with varying substrate concentrations
Freshly prepared microsomal preparations (10 mg of protein) 
were incubated in triplicate for 60 min under air, following a 
15 min pre-incubation at 37°. The results are tabulated below.
Fig. 5.14 Effect of varying androstenedione concentrations on
human placental aromatization
Substrate
(nmol)
nmol oestrone formed/10 mg protein/h V Conversion
3.5 *1.31 ± 0.07 35.5
10.5 1.08 ± 0.07 9.7
17.5 0.97 ± 0.11 5.2
24.5 0.97 ± 0.04 3.7
31.5 0.91 ± 0.04 2.7
* Mean ± S.D.
As in the previous experiment, the total yield of oestrone did 
not significantly alter with differing substrate levels. This 
may have been due to a cofactor requirement. As aromatization is 
possibly mediated through a multienzyme complex where one reaction 
is the rate-limiting step, it was necessary to reduce the andro­
stenedione level still further until this became the limiting 
factor.
On the basis of these experiments a number of proposals 
were made.
1. The substrate concentration should be lowered ten fold, using 
the widest substrate range possible.
2. Incubation time should be reduced to 15 min with a 10 min
pre-incubation.
3. It would be necessary to use only tritiated androstenedione
at these substrate levels. Interference from endogenous 
steroids might be reduced to a minimum by pre-incubating, 
though dialysis or millipore filtration might be necessary.
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4. The enzyme protein level of 10 mg was considered high, and 
may require reducing, though this would be dependent on the 
specific activity of the tritiated androstenedione and hence 
the sensitivity of the assay. Similarly, there was concern 
about weak unspecific protein binding of substrate which 
would effectively lower the amount of steroid available to 
the enzyme.
d) Aromatization with varying substrate concentrations
Since the substrate concentration varied between 0.029-1.530 nmol, 
incubation tubes were silicone coated to minimize adsorption. This 
was achieved by rinsing each test tube (15 ml) with 5 ml of 
"Repelcote" {1% w/v dimethyldichlorosilane in CCl^), followed by 
washing with CCl^, methanol and water. Tritiated androstenedione 
was dried under ^  in each test tube. A 10 min. pre-incub at ion of 
the mixture was carried out in a conical flask and then, after cooling 
in an ice-bath, aliquots (2.3 ml) were transferred to each tube and 
re-incubated for 15 min at 37° in the presence of the androstenedione.
Freshly prepared placental microsomes were stored overnight at -15°.
In Fig. 5.15, aromatization was found to proceed linearly with 
increasing substrate concentrations. Androstenedione was therefore 
rate-limiting. Placental incubates, carried through the assay with 
no added substrate or isotope dilution, were found not to contain 
measurable quantities of androstenedione, testosterone, oestrone or 
oestradiol-173.
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Fig. 5,15 Effect of substrate levels on aromatization
0.12
0.10
0.08-
0.06 -
0.04 -
0.02 -
0.6 0.9 1.2 1.5 1.80.30
Androstenedione concentration (nmol/2.3ml)
e) Aromatization with varying substrate concentrations
The previous experiment was repeated over the substrate 
range 0.31 nmol-35.7 nmol androstenedione to determine at which 
point the substrate was no longer rate-limiting. In the accompanying 
graph (Fig. 5.17) androstenedione appeared to be the limiting 
factor up to 35.7 nmol. It also seemed that an increased percentage 
of aromatization of the substrate occurred at substrate levels in 
excess of 3.5 nmol. Several explanations were put forward for these 
results, for example, storage of microsomal fractions results in 
a loss of some activity. This was confirmed, and with 0.287 nmol 
substrate the stored preparation of the previous experiment converted 
5.91, whereas with 0.309 nmol substrate, fresh microsomes converted 
22.9% (different placentae). The loss of aromatization with storage 
means that the enzyme to substrate ratio in fresh placental incubates 
would be higher and therefore the possibility of androstenedione
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becoming the rate-limiting step increases. In this experiment, 
the level of substrate was raised to 35.7 nmol, which is over 
a twenty-fold increase on the maximal level used in the previous 
experiment. However, the differences in the rate of conversion 
at the peak substrate level is much greater than twenty-fold, 
being almost 170 higher. Variations in enzyme to substrate 
ratio cannot therefore explain these findings alone. These 
observations are considered in more detail in the next section.
Fig. 5.16 Effect of varying androstenedione concentrations
on human placental aromatization
Substrate nmol oestrone formed/10 mg protein/15 min % Conversion 
(nmol)
0.3 *0.075 ± 0.012 23
0.9 0.28 ± 0.03 29
1.9 0.62 ± 0.17 32
2.6 0.85 ± 0.03 31
3.5 1.04 ±0.19 28
7.8 3.30 ± 0.37 43
21.1 11.0 ± 0.8 52
35.0 17.3 ± 1.0 49
* Mean ± S.D.
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xi) Aromatization with stored human placental microsomal preparations
Differences previously found in the rates of aromatization demanded 
further control of the experimental situation. Variations in the basal 
level of aromatization from placenta to placenta has been reported, which 
is not unreasonable considering the differences in genetic and environmental 
backgrounds (Giles and Griffiths, 1964). To overcome these variations, 
four full-term human placentae were processed and microsomes collected 
during the course of one week. On accumulation of sufficient microsomal 
material, this was resuspended, mixed together and resedimented into 9 
pellets, thus attaining an homogenous enzyme preparation. One microsomal 
pellet was resuspended for each assay. The programme was designed first 
to determine optimal cofactor conditions and then to utilize this information 
for inhibition studies.
Fig. 5.18 Background history regarding the source of human placentae
Placenta 1 (Twins) 2 3 4
Age of mother (yrs) 24 34 23 21
Cigarettes smoked daily 2 - . 2
Drugs administered 
immediately prior to 
delivery
Pethidine
Syntocinon
Pethidine Syntometrine
Marcaine
Long term drug therapy : *“ - Iron Iron \ -■
Addition - . - - -
a) Aromatization with varying substrate concentrations
The influence of androstenedione levels on the stored enzyme 
preparation was examined, as described in the preceding experiments.
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Fig. 5.19 Effect of varying androstenedione concentration on
human placental aromatization
Substrate
(nmol)
nmol oestrone formed/10 mg protein/15 min % Conversion
0.3 0.07 ± 0.01 21
1.6 0.26 ± 0.01 15
1.9 0.38 ± 0.02 19
3.2 0.72 ± 0.09 21
8.6 2.8 ± 0.7 31
36.6 i 8.8 ± 0.4 23
176 11.3 ± 1.1 6.1
351 12.0 ± 0.5 3.2
In Fig. 5.20 and 5.21, aromatization proceeded intially in a 
linear fashion with increasing androstenedione concentrations. When 
the androgen was no longer rate-limiting, the formation of oestrone 
occurred at a decreasing rate. For determining cofactor requirements, 
ten fold the Km, which equalled 0.175 ymol, was employed.
The Lineweaver-Burk plot of these results and those of experiments
x)d. and e. are shown in Fig. 5.22. The plot for this experiment and
x)e. passed through the abscissa and very close to the origin. The
Michaelis constants (K ) were therefore similar. The Linweaver-Burkm
plot of experiment x)d. was not so well defined, though it appeared to
exhibit a K of the same order. The essential difference between the m
Lineweaver-Burk plots was the angle of slope, represented by K
As the Michaelis constants were alike, the variations in slope must
be attributed to differences in Maximal Velocity (V^^). In experiment
x)d. the microsomal enzyme had been stored overnight before use, and
demonstrated the lowest V . In experiment x)e., fresh microsomal
preparations exhibited an elevated Vmax. From these investigations it
appeared that although the substrate affinity for the aromatizing
preparation did not change with storage, the V ' was reduced. In this
experiment, another stored enzyme system was examined and demonstrated
a V and K akin to those found with freshly prepared microsomes. The max m r
variations in are therefore probably due to interplacental 
differences rather than storage. Since aromatization concerns possibly 
three separate enzymic steps, the value is indicative of the overall 
reaction.
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b) Aromatization with varying Mg and G-6-P-dehydrogenase levels
The influence of Mg and G-6-P-dehydrogenase levels were 
assessed independently on a second stored microsomal pellet. The 
incubation mixture consisted of:-
G-6-P (13 ymol) ... ... 0.25 ml
NADP (2.5 ymol) ... ... ... ... ... 0.25 ml
MgCl2 (12.5-100 ymol) ... ... ...... 0.30 ml
G-6-P-dehydrogenase (0.125-1.0 Unit) 0.50 ml
Androstenedione (0.175 ymol) ... ... ... Dried Under
Microsomal preparation (10 mg of protein)... 1.0 ml
Total volume 2.3 ml
In the accompanying graphs (Fig. 5.23, 5.24), it is 
suggested that both Mg concentration and G-6-P-dehydroganse 
levels required further reducing before optimal activity could 
be obtained. The values also suggested a decline in the level 
of aromatization with storage. Over a period of one week the 
rate of biosynthesis had fallen from 10.20 to 6.85 nmol oestrone/
10 mg of protein/15 min. However, by approaching optimal 
G-6-P-dehydrogenase conditions, it was possible to increase 
aromatization to 8.05 nmol oestrone/10 mg protein/15 min.
c) Aromatization with varying Mg** and G-6-P-dehydrogenase levels
In this experiment, MgC^ levels ranged between 1-12.5 ymol
and G-6-P-dehydrogenase levels between 0.01-0.50 Unit. Following
another week of storage at -15°, the control rate of aromatization
had declined to 3.68 nmol oestrone/10 mg of protein/15 min. In
Fig. 5.25 the slope of increasing enzyme activity with the reduction 
++
in Mg levels was comparable to that observed previously and 
suggested a need to lower the concentration of this cofactor still 
further. Ihe optimal G-6-P-dehydrogenase requirement was in the 
region of 0.02-0.04 Unit (Fig. 5.26).
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d) Aromatization with varying NADP and G-6-P levels
As a result of the previous studies, the incubate was 
modified to incorporate only 0.04 unit of G-6-P-dehydrogenase 
and 5 ymol of MgCl^. In determining G-6-P requirements, the 
level was reduced from 13 to 0.050 ymol and for NADP from 2.6 
to 0.010 ymol. The control rate of aromatization equalled 
3.8 nmol oestrone/10 mg protein/15 min.
The accompanying graph (Fig. 5.27)shows that the original 
G-6-P level (13 ymol)was on the plateau of the curve and was 
therefore probably optimal. If this concentration was reduced 
by one quarter, the level was just sufficient for optimal 
aromatization. Since G-6-P did not exert an inhibitory effect 
at high concentrations, the cofactor level was maintained at 
13 ymol. Fig. 5.28 demonstrated that a reduction in NADP levels 
produced a concomitant decline in aromatization.
Fig. 5.27 Effect of G-6-P levels on human placental aromatization
8
■0-
0 2 4 6 8 10 12 14
Concentration of G-6-P (ymol/2.3 ml)
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Fig. 5 .28 Effect of NADP levels on human placental aromatization
8
6
4
2
1.0 1.5 2.5 3.00 0.5 2.0
Concentration of NADP (ymol/2.3 ml)
e) Aromatization with varying NADP, G-6-P and Mg levels
The procedure was as before, the basic incubation consisting 
of MgCl2 (5 ymol), G-6-P (13 ymol), NADP (2.6 ymol), G-6-P- 
dehydrogenase (0.04 unit) and androstenedione (2.5 yCi/0.175 ymol)
Increasing the level of NADP to 26 ymol markedly reduced 
oestrone formation (Fig. 5*29). When the level of activity with 
5.2 ymol (accounting for loss of enzyme through storage) was 
compared to that of experiment xi)d. using 2.6 ymol of NADP, the 
former was marginally lower, though clearly in the region of optimal 
activity. Therefore the NADP requirement was kept at 2.6 ymol.
++
In this experiment, the removal of Mg did not modify the 
rate of oestrone synthesis (Fig. 5.30) and therefore was no longer 
included in the reaction mixtures. The G-6-P-dehydrogenase 
requirement was previously found to be in the region of 0.04 unit. 
Reduction of this enzyme level to 0.01 unit produced a plateau of
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activity equivalent to 4.5 nmol of oestrone/15 min. The G-6-P- 
dehydrogenase level was thus maintained at 0.04 unit.
Fig. 5.29 Effect of NADP levels on human placental aromatization
.3
rH
Concentration of NADP (ymol/2.3 ml)
Fig. 5.30 Effect of Mg on human placental aromatization
LO
rH
rH
0.6 0.8 1.00.4
Concentration of MgCl? (ymol/2.3 ml)
0.2
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The loss of aromatization activity with storage is shown 
in Fig. 5.31. The most marked decline in the capacity for oestrone 
formation occurred during the initial two weeks of storage.
of aromatization activity with storage at -15Fig. 5.31 Loss
Storage of microsomal enzyme at -15° (Weeks)
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f) Aromatization in the presence of metyrapone and
benzo r a] pyrene
Having determined optimal conditions for aromatization, 
the influence of variable concentrations of metyrapone and 
benzo [a] pyrene on this activity was investigated. The reaction 
mixture consisted of:-
NADP (2.6 ymol) ... ...
G-6-P (13.0 ymol)
G-6-P-dehydrogenase (0.04 unit) ... 
Androstenedione (2.5 yCi/0.035 ymol and
0.5 ml 
0.6 ml 
0.1 ml
2.5 yCi/0.350 ymol) ... ...
Inhibitor* ... ... ... ... ...
Microsomal preparation (10 mg of protein)
Dried under ^  
0.1 ml 
1.0 ml
Total volume 2.3 ml
* Aliquots of metyrapone in methanol incubated = 0.082 and 0.815 ymol 
Aliquots of benzo[a]pyrene in acetone incubated = 0.198 and 0.792 ymol
The incubations were completed in three batches. The first 
consisted of benzo [a] pyrene inhibition studies, the second for those 
of metyrapone and the third concerned benzo [a]pyrene hydroxylase 
activity. For inhibition experiments, preincubations in the absence 
of substrate and inhibitor were completed in a conical flask for 
10 min at 37°. On cooling in an ice-bath, aliquots (2.2 ml) were 
removed to test tubes containing substrate and inhibitor. Reaction 
mixtures were then incubated at 37° at one min. intervals. After 
10 min., an aliquot (1 ml) of the incubation was removed to ice- 
cooled ether (10 ml) containing oestrone (500 yg). The remainder of 
the incubate was returned to the water bath for a further 5 min. and 
the reaction was then terminated as previously described. The 
production of oestrone at 10 and 15 min. was determined according 
to standard procedure.
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In measuring microsomal benzo[a]pyrene hydroxylase activity, 
the same incubates were employed as used for the aromatization assay. 
The reactions, carried out in test tubes painted black, were 
terminated after 15 min. at 37° with acetone (3 ml) and by transferring 
samples to an ice-bath. After the addition of n-hexane (9 ml), 
extraction was completed on a rotary mixer for 20 min. A portion 
(1.0 ml) of the organic phase was extracted with 1 M NaOH (10 ml) 
and the fluorescence determined as described in Materials and Methods.
It is clear from the accompanying graph (Fig. 5.32) that 
the presence of methanol or acetone reduced the apparent lag phase 
in aromatization which occurred at low substrate concentrations.
This was presumed to be due to an increased substrate availability 
for the enzyme. At 0.035 ymol androstenedione, non-specific protein 
binding may have produced the lag phase, but at 0. 3 5 ymol of 
substrate was overcome.
Fig- 5.32 Control levels of aromatization
Incubation time (min.)
• = 0.035 ymol substrate ) r . 
&— o = 0.350 ymol substrate )
a— -a = Benzo [a]pyrene Control (0.1 ml acetone)
□— s = Metyrapone control (0.1 ml methanol)
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Metyrapone and benzo[a]pyrene were not found to markedly 
alter the rate of aromatization of androstenedione to oestrone 
(Fig. 5.35, 5.36). At the lowest substrate level (0.035 ymol) 
and highest inhibitor concentrations (0.792 and 0.815 ymol), 
oestrogen biosynthesis proceeded at a comparable rate to that 
of controls. Microsomal hydroxylation of benzo[ a] pyrene 
(0.792 ymol) occurred at low levels (0.197 nmol of 3-hydroxy- 
benzo{a]pyrene/10 mg of protein/15 min) and was reduced by 
M% in the presence of androstenedione (0.35 ymol). As 
benzo [ajpyrene did not affect steroid oxygenation, but 
androstenedione interferred with that of the polycyclic hydro­
carbon, this suggested either different hydroxylation 
processes or possible differences in substrate affinity 
for the enzyme. Competition for NADPH may exist between 
separate oxygenating systems.
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g) Aromatization in the presence of a variety of inhibitors
In contrast to the previous experiment, only one substrate 
and one inhibitor concentration were examined over a set incubation 
time. This allowed the monitoring of a wider range of potential 
inhibitors.
The experiment was completed in three series of incubations.
The reaction media, excluding substrate and inhibitor, was prepared 
in one large solution and then dispensed into one group of test 
tubes. These were preincubated at 1 min intervals for 10 min. at 
37°. Substrate and inhibitor were introduced simultaneously into 
respective test tubes, by means of a Hamilton syringe, and returned 
to the shaking water-bath for a further 15 min. Substrate: and 
inhibitor were prepared in dimethylformamide (50 pi) . Androstenedione 
(2 pCi) was maintained at a level of 0.035 pmol/2.25 ml of incubate, 
and the amount of oestrone used for isotope dilution was reduced 
to 250 pg. All incubations, including batch blanks, were carried 
out in triplicate.
It is apparent from Fig. 5.37 that classical inhibitors of 
hepatic microsomal drug-metabolizing enzymes, such as SKF-525A,
DPEA and Lilly 18947, were without any effect on the steroid ring- 
A aromatizing system. Certain alternate substrates for the hepatic 
system, including $-methosone alcohol, DDT, dieldrin, aldrin and 
endrin, also did not effect the rate of hydroxylation at 4.44 x 10”  ^
However testosterone, an alternative substrate for the aromatizing 
system, reduced the rate of oestrone formation by 891. The thiol- 
blacking reagent, p-hydroxymercuribenzoate lowered aromatization 
by 90%, whereas B-mercaptoethylamine was without effect. The 
high affinity of a,a'-bipyrridyl for iron and zinc did not enable 
this chelating agent to influence oestrone synthesis in vitro.
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Fig. 5.37 Effect of potential inhibitory compounds on placental
aromatization
Inhibitors (4.44 x 10 %) Rate of Aromatization 
(nmol oestrone/lQmg protein/15 min)
% Activity 
of control
Batch 1
Control (No inhibitor) 6.6 ± 0.3 100
SKF-525A 6.8 ± 0.2 103
DPEA 6.2 ± 0.6 94
Lilly 18947 6.1 ± 0.5 92
a,af-Bipyrridyl 6.9 ±0.3 105
Batch 2
Control (No inhibitor) 5.6 ± 0.6 100
3-Mercaptoethylamine 6.4 ± 0.2 113
p-Hydroxymercuribenzoate 0.5 + 0.01 10(in 0.1 M NaOH) V/ • %J mlmV/ • WX
Testosterone 0.3 ± 0.01 11
B-Methosone alcohol 5.6 ± 0.2 99
Batch 3
Control (No inhibitor) 6.6 ± 0.2 100
DDT 6.7 ± 0.2 102
Dieldrin 6.1 ± 0.3 91
Aldrin 6.1 ± 0.3 91
Endrin 6.8 ± 0.2 102
Mean ± S.D.
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h) Aromatization in the presence of a variety of inhibitors
A final assay with the last stored microsomal pellet was completed, 
studying a variety of further potential inhibitors. The experimental 
procedure was as in the previous experiment, except five series of 
incubations were carried out. The findings are tabulated below.
Fig. 5.38 Effect of potential inhibitory compounds on placental
aromatization
Inhibitors . 
(4.44 x 10”4M)
Rate of Aromatization 
(nmol.oestrone/10 mg. 
protein/15 min.)
% Activity 
of Control
Batch 1
Control (no inhibitor) 6.5 + 0.4 100
Metyrapone 6.9 T 0.3 107
Iodoacetamide 5.1 T 0.4 78
Tetracycline 7.0 + 0.3 107
Spironolactone 6.4 T 1.0 99
Batch 2
Control (no inhibitor) 6.2 + 0.7 100
Imipramine 5.8 + 0.2 94
Iproniazid 4.2 ~+ 0.1 67
Glutethimide 6.7 + 0.6 108
Aminoglutethimide 2.4 + 0.1 38
Batch 3
Control (no inhibitor) 6.2 + 0.2 100
Arachidonic acid 4.2 T 0.3 68
Laurie acid 5.2 + 0.4 83
Biphenyl 6.9 T 0.1 110
Ethyl isocyanide 6.2 + 0.8 100
Batch 4
Control* (no inhibitor) 7.7 + 0.9 100
p-Hydroxymercuribenzoate* * 1.3 T 0.3 17
EDTA** 5.9 T 0.4 76
Cholestyramine*** 7.3 T 0.2 94
* = Dimethylformamide (25yl) + 0.1 | glycylglycine buffer, pH 7.5 (25yl).
** = Dimethylfoimamide (25|jl) +0,1 M glycylglycine buffer, pH 7.5 (25yl) 
to dissolve p-hydroxymercuribenzoate and EDTA.
*** = 300yg of cholestyramine/incubate as a dimethylformamide suspension.
Mean + S.D.
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Metyrapone may interfere with mixed function oxidase reactions 
by modifying or obstructing the site of oxygen interaction with 
reduced cytochrome P-450 (Hildebrandt, Leibman and Estabrook, 1969). 
However, the findings here corrobate earlier studies which indicated 
that stored placental microsomes aromatized androstenedione equally 
as effectively in the presence of metyrapone as in its absence.
Inhibitors of hepatic drug-metabolizing enzymes such as ethyl isocyanide, 
and competitive substrates including imipramine and biphenyl, did not 
influence the rate of oestrone synthesis. The monoamine oxidase 
inhibitor, iproniazid caused a 33% reduction in aromatization*
Glutethimide and aminoglutethimide uncouple steroid hydroxylations, 
but only the latter decreased oestrogen formation and to the con­
siderable. extent of 621. The antibiotic, tetracycline and the steroid 
inducer of drug-metabolizing enzymes, spironolactone, were found to 
be without inhibitory effects. Fatty acids appeared to reduce the 
rate of aromatization, the unsaturated arachidonic acid caused a 
32% decrease, and the saturated lauric acid diminished activity 
by 17%. Inhibition of oestrone synthesis by p-hydroxymercuribenzoate 
was confirmed, and a second thiol blocking reagent, iodoacetamide, 
was found to inhibit (22% reduction in rate of aromatization). EDTA, 
in contrast to a,ot"-biprridyl, appeared to diminish oestrone formation 
presumably because of its wider chelating properties. Cholestyramine 
is a strong basis anion exchange resin used to bind bile acids. It was 
without effect on placental aromatization.
The fifth group of incubations were used to measure the progress 
of oestrogen formation over 120 min (Fig. 5.39). After 15 min. of 
incubation, the level of oestrone synthesized declined, possibly suggesting 
further metabolism. This observation had not previously been noted and 
may therefore reflect the special storage conditions of the enzyme 
preparation. Clearly further investigations are necessary.
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Fig. 5.39 Progress of Human Placental Aromatization
6
+->
4
2
12080 10040 60200
Incubation Time (min.)
(xii) Further studies on the effect of metyrapone on aromatization
Using freshly prepared human placental 8,700 g.av. (10 min.) super­
natant, Giles and Griffiths (1964) demonstrated inhibition of oestrone 
formation from testosterone in the presence of metyrapone. Since this 
compound was without effect on stored microsomal arOmarization, the effects 
were measured with freshly prepared subcellular fractions.
a) Metyrapone inhibition studies according to the method of 
Giles and Griffiths (1964)
Placental 8,700 g.av. (10 min.) supernatant was prepared and 
incubated according to the procedure of Giles and Griffiths (1964). 
Androstenedione (2yCi/0.69 pmol) was used in place of testosterone. 
Following a 60 min. incubation at 37°, isotope dilution with oestrone 
250 yg) and oestradiol-178 (250yg) was carried out. Oestrone was 
was isolated and purified in the usual manner. Oestradiol-173,
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isolated on t.l.c. in benzene/ethyl acetate (2:1 V/v), was further 
purified in chloroform/acetone (9:1 V/v) • The rates of oestrone 
and oestradiol-173 formation in the presence of metyrapone are 
shown below.
Fig. 5.40 Effect of metyrapone on placental aromatization
by the 8.700 g.av. supernatant
Incubate nmol, oes trone/h. % control nmol oestradiol- 
17$/h.
% control
Control 107 195
0.44 ymol .metyrapone 119 112 248 127
4.42 " " 98 92 217 Hi
22.10 " 69 65 275 141
Oestrone synthesis was maximally inhibited (351) at a metyrapone 
concentration of 3 x 10 The 50% inhibition observed by Giles
and Griffiths (1964) at 6.14 x 10 %  was not apparent. Concomitant 
with the decline in oestrone formation, oestradiol-17$ synthesis was 
maximally increased at a metyrapone concentration of 3 x 10 The 
degree of inhibition of oestrone production equalled the level of 
enhanced oestradiol-17$ synthesis.
b) Effect of metyrapone on placental aromatization of androstenedione 
and testosterone by particulate fractions
The 10,000 g.av. supernatant, 105,000 g.av. supernatant and 
microsomes (= 177.1 g. resuspended in 35 ml.) were collected in the 
usual manner and incubated in the following reaction mixture, as 
in the previous experiment.
G-6-P (20 ymol) .. .. 0.7 ml
NADP (1 unol) .. .. .. 0.3 ml
G-6-P-Dehydrogenase (1.0 Unit) .. 1.0 ml
Androstenedione or testosterone* 0.1 ml
Enzyme preparation .. 5.0 ml
Metyrapone .. ; 0.1 ml
Total volume 7.2 ml
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* = [7a-Ti ] -Androstenedione (2yCi/0.69 ymol) and [4- C] -Testosterone 
(0.4 yCi/0.69 ymol) were dissolved in methanol (0.1 ml), as was 
metyrapone.
The enzyme preparations were in 0.25 M sucrose (containing 0.04 M 
nicotinamide and 0.05 M phosphate buffer, pH 7.0) and cofactors 
dissolved in 0.05 M phosphate buffer, pH 7.0. Incubations were carried 
out at 37° for 60 min. under air. Following isotope dilution with 
oestrone (250 vg) and oestradiol-173 (250 yg), incubates were extracted 
as previously and steroids resolved on t.l.c. (Hp + 35 )^ in 
benzene/ethyl acetate (2:1 v/v). The oestrone eluate was purified 
on t.l.c. in ethylacetate/cyclohexane (1:1 v/v). Testosterone was 
subjected to further t.l.c. in chloroform/ace tone (9:1 v/v). Separation 
of androstenedione from oestradiol-17$ was effected by t.l.c. in ethyl 
acetate/cyclohexane (1:1 v/v) . Both steroids were further purified 
by t.l.c. in chloroform/acetone (9:1 v/v). Eluted androgens and 
oestrogens were stored in methanol (10 ml).
The androgen recovery was determined by the absorbance at 240 nm 
and by liquid scintillation counting. Oestrogen yield was calculated 
as described in Materials and Methods. From blank incubations, the 
androstenedione recovery was 38.7%, and for testosterone was 44.51.
In the following tables, the amounts of androgens quoted are those 
recovered, and the quantities of oestrogens represent actual yields.
1. 10,000 g.av. Supernatant Incubated with Androstenedione
A (0.145 ymol.)
0.690 ymol.
T (0.043 ymol.)
(0.150 ymol)
-> E2 (0.040 ymol.)
2. 10,000 g.av. Supernatant Incubated with Androstenedione and Metyrapone
A (0.170 ymol)
0.690 ymol.
T (0.024 ymol.)
(0.145 ymol)
(0.033 ymol.)
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10,000 g. av. Supernatant Incubated with Testosterone
A (0.119 ymol) > Ex (0.118 ymol)
0.690 ymol
T (0.057 ymol) ■ ~ V ■■■ —    > E2 (0.041 ymol)
10,000 g.av. Supernatant Incubated with Testosterone and Metyrapone
A (0.140 ymol)
T (0.033 ymol)
-> E1 (0.088 ymol)
0.690 ymol
-> E2 (0.027 ymol)
Microsomal Preparation Incubated with Androstenedione
A (0.223 ymol)
S' ■
-> E1 (0.057 ymol)
0.690 ymol
T (0.061 ymol)— -- - --— ---- — > E2 (0.051 ymol)
Microsomal Preparation Incubated with Androstenedione and Metyrapone
A (0.153 ymol) Ex (0.058 ymol)
0.690 ymol
T (0.027 ymol) ■ • • - -  ) E2 (0.040 ymol)
Microsomal Preparation Incubated with Testosterone
A (0.085 ymol)
T (0.170 ymol)
0.690 ymol
Ep (0.043 ymol)
N
-> E2 (0.079 ymol)
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8. Microsomal Preparation Incubated with Testosterone and Metyrapone
A (0.074 ymol)
T (0.123 ymol)
-) E, (0.049 ymol)
1I\
0.690 ymol
-> E2 (0.064 ymol)
9. 105,000 g.av. Supernatant Incubated with Androstenedione
A (0.105 ymol) 
\'
T (0.215 ymol)
} En (0.043 ymol) 
fr-
0.690 ymol
E2 (0.037 ymol)
10. 105,000 g.av. Supernatant Incubated with Androstenedione and Metyrapone
A (0.197 ymol) 
\
T (0.068 ymol)
0.690 ymol
Ep (0.039 ymol)
N
-> E2 (0.031 ymol)
11. 105,000 g.av. Supernatant Incubated with Testosterone
A (0.059 ymol) 
\
T (0.216 ymol)
Ep (0.030 ymol) 
N
0.690 ymol
-> E2 (0.042 ymol)
12. 105,000 g.av. Supernatant Incubated with Testosterone and Metyrapone
A (0.121 ymol)
T (0.132 ymol)
0.690 ymol
-) Ep (0.032 ymol)
-) E2 (0.035 ymol)
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A = Androstenedione 
T = Testosterone
E^ = Oestrone 
E2 =. Oestradiol - 173
)
) ymol recovered from incubate 
)
)
) ymol produced per incubate 
)
0.69 ymol represents the original substrate pool.
In contrast to the previous experiment, aromatization of 
androstenedione to oestrone by placental 10,000 g.av. supernatant 
(20 min) was not impaired by metyrapone. In agreement with the 
findings of Giles and Griffiths (1964), testosterone conversion to 
oestrone by the same particulate fraction was reduced in the presence
3
of 3 x 10 M metyrapone. The soluble fraction aromatized 
androstenedione and testosterone equally to oestrone and oestradiol-170. 
There was a tendency for androstenedrone to be concentrated, either by 
inhibition of its conversion to testosterone, or enhancement of the 
reverse reaction. The same observation was made with microsomal 
preparations, though testosterone was less effectively converted to 
androstenedione. Thus, androstenedione was converted equally to both 
oestrogens, whereas testosterone was largely aromatized to oestradiol-170. 
The 10,000 g.av. supernatant, which is comprised of the microsomal and 
soluble fractions, also appeared to concentrate androstenedione.
The ratio of oestrone to oestradiol-17$ was not markedly altered 
by the inclusion of high concentrations of metyrapone into the 
incubates. Similarly the total oestrogen yield was not effected, except 
when testosterone was incubated with placental 10,OCX) g.av. supernatant. 
The influence of metyrapone in in vitro oestrogen synthesis appeared 
therefore not to be mediated via aromatization, but through the 
interconversions of androgen substrates which moved the equilibrium 
towards androstenedione. This activity resided essentially in the 
soluble fraction. This explanation* was consistent will all results 
except for the reduction in oestrone synthesis from testosterone. When 
this was considered in conjunction with the results of the previous 
experiment, metyrapone appeared to effectively enhance the hydrogenation 
of androstenedione to testosterone. Irrespective of the mode of action 
of metyrapone, it was clear that high concentrations were necessary to 
achieve marginal changes in oestrogen formation.
(xiii) Androstenedione binding to placental microsomal preparations
Experiments were carried out to investigate whether there was 
any protein(s) in the placental microsomal, preparations with specific 
binding affinity for C-^ steroids, e.g. androstenedione. The presence 
of such a binding protein would have provided a suitable model for 
endogenous steroid-drug interaction studies.
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Fresh human placental microsomes were resuspended in 0.05 y 
phosphate buffer, pH 7.0 to give a protein concentration of 4 mg/ml, 
similar preparations of bovine serum albumin were made. An 
androstenedione range of 10 ng, 100 ng, 1 pg, 10 pg and 100 pg per mg 
of protein was examined i.e. 100 fold either side of the substrate/ 
microsomal protein ratio of 1 pg/mg used in the aromatization assay. 
Androstenedione (1 pCi) was dried under ^  in test tubes and aliquots 
(8 ml) of microsomal and albumin preparations added before incubating 
on a rotary shaker for 20 min at 4°. Samples (6 ml) from each test-tube 
were transferred to dialysis sacs and subjected to ultra-filtration for 
60 min at 5000 r.p.m. (8 x 50 ml rotor,MSE Hi-Speed 18). Aliquots 
(0.1 ml) of the original incubate, dialyzed preparation and ultrafiltrate 
(approx. 0.5 ml) were subjected to liquid scintillation counting, using 
a Triton X100/toluene based scintillator for particulate fractions.
Using this and similar techniques it was not possible to demonstrate any 
appreciable protein binding of androstenedione. The loose, non-specific 
binding could be readily abolished by simple washing procedures.
B. Aromatization in the Wistar/albino rat
Pairs of 8 week-old pregnant rats were pretreated with either 
phenobarbital, 3-methylcholanthrene, saline or ethyl oleate for 3 days prior 
to full-term when they were sacrificed. Placental and hepatic microsomes 
were isolated as described for the aromatization assay and incubated in the 
following reaction mixture for 60 min at 37°, following a 10 min preincubation 
in the absence of androstenedione.
NADP (2.6 pmol)
G-6-P (13.0 pmol)
G-6-P-Dehydrogenase (0.1 Unit)
Androstenedione (1 pCi/0.035 pmol)
Microsomal preparations (10 mg of prot
ein)
Total Volume =
The substrate was dissolved in dimethylformamide, and cofactors and enzymes 
prepared in 0.05 M phosphate buffer, pH 7.0.
0 .5 ml 
0.6 ml 
0.1 ml 
0.025 ml
1.0 ml 
2.225 ml
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Incubations, completed in triplicate, were carried out under at CO/C^ 
(1:1 v/v) mixture. Preincubations were completed in air. Following isotope 
dilution with oestrone (250 yg) and oestradiol-173 (250 yg), incubates were 
extracted and steroids purified in the usual manner. Oestrogens were 
methylated and the Specific activity redetermined. No aromatization was 
apparent when either placental or hepatic microsomal preparations were 
incubated. Phenobarbital and 3-methylcholanthrene did not induce measurable 
activity. Preliminary studies indicated that rat liver and placenta was 
deficient in measurable levels of oestrogen synthesis.
C. Aromatization in the New Zealand white rabbit
(i) Metabolism of androstenedione by the 600 g.av. supernatant.
Maternal liver and placentae of full-term rabbit were 
homogenized according to Materials and Methods and the 600 g.av.
(for 10 min) supernatant incubated in the following reaction mixture.
NADP (1.5 ymol) 0.25 ml
G-6-P (12 ymol) 0.25 ml
G-6-P-Dehydrogenase (0.5 Unit) 0.50 ml
MgCl2 (25 ymol) 0.30 ml
Androstenedione (5 yCi/0.35 ymol) 0.10 ml
600 g.av. Supernatant 1.00 ml
Total Volume = 2.4 ml
Androstenedione was dissolved in methanol, and cofactors prepared in 
0.05 M phosphate buffer, pH 7.0.
Following a 15 min preincubation at 37° in the absence of substrate, 
a 60 min incubation was carried out under 0^ . After isotope dilution 
with oestrone (500 yg), steroids were extracted as usual and resolved on 
t.l.c. (Hp 254+366^  benzene/ethylacetate (2:1 v/v). Bands (1 cm) 
were eluted with methanol (2 x 5 ml) and aliquots removed for liquid 
scintillation counting. No tritium was found in association with bands 
exhibiting Rp values comparable to those of classical oestrogens. The 
radioactivity, apart from that of androstenedione, was found in 
association with a A^-3-oxo steroid with an Rp akin to that of 
testosterone. Further t.l.c. purification in chloroform/ethyl acetate
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(4:1 v/v) further indicated that the major metabolite of androstenedione 
by maternal liver and placental 600 g.av. supernatant was testosterone.
(ii) Effect of 3-methylcholanthrene pretreatment on androstenedione
metabolism in the full-term rabbit.
Placentae, ovaries, adrenals, uterus and maternal livers of 
control and 3-methylcholanthrene-treated rabbit were homogenized in 
2 volumes of 0.25 M sucrose (refer to rabbit benzo [a] pyrene 
hydroxylase studies). Whole homogenates of ovaries, adrenals and uterii, 
and 10,000 g.av. (20 min) supernatants of placentae and maternal liver 
were incubated in duplicate in the following reaction mixture.
NADP (2.6 ymol) 0.5 ml
G-6-P (13.0 ymol) 0.6 ml
G-6-P-Dehydrogenase (0.1 Unit) 0.1 ml
Androstenedione (1 yCi/0.035 ymol) 0.025 ml
Enzyme preparation* 1.0 ml
Total Volume = 2.225 ml
* = Protein Concentrations Incubated (mg/ml)
Control 3-MC Treated 
Placenta 16.5 16.5
Liver 36.4 33.0
Uterus 21.0 12.2
Ovary 3.75 8.75
Adrenal 13.0 13.5
Cofactors were prepared in 0.05 M phosphate buffer, pH 7.0 and 
androstenedione dissolved in dimethylfoimamide.
Following a 15 min preincubation in the absence of substrate, 
samples were incubated for 30 min at 1 min intervals in a shaking water- 
bath at 37°. After isotope dilution with oestrone (250 yg) and 
oestradiol-173 (250 yg), steroids were extracted with ether and resolved 
on t.l.c. (Hp 254+366  ^ benzene/ethyl acetate (2:1 v/v). Oestradiol-173 
was further purified on t.l.c. in chloroform/acetone (9:1 v/v). Tritium 
was not associated in significant amounts with the purified oestrone and
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oestradiol-173 extracts, even from ovarian and uterine incubates. The 
major metabolite was a A^-3-oxo steroid with an Rp of 0.25. A minor 
3-oxo steroid with an Rp of 0.10 was apparent with adrenal incubates 
only.
Silica gel containing the major metabolite was transferred to 
liquid scintillation vials and counted. The tritium content is shown 
in Fig. 5.41. Ovarian homogenates converted approximately 10% of 
androstenedione into the major metabolite, considered to be testosterone. 
Placenta, liver, uterus and adrenal produced the metabolite in that 
order of magnitude. The "testosterone fraction" of the duplicate 
placental incubate was eluted with methanol (3 ml), diluted with 
unlabelled testosterone (500 yg) and dried under N2- Pyridine 
(5 drops of a pasteur pipette) and then acetic anhydride (5 drops) were 
added to the residue and left overnight in a stoppered test-tube.
After the addition of ethanol (1 ml), the extract was again reduced in 
volume under N2 and then resolved on t.l.c. (Hp 254+366  ^ in benzene/ 
ethyl acetate (1:1 V/v), along with testosterone and testosterone acetate 
standards. The radioactivity associated with testosterone acetate
Fig. 5.41 Tritium associated with the "testosterone fraction"
Tissue Incubated Total Content (dpm x 10 )^
Control 3-Methyl cholanthrene
Placenta 121 (5.46) 106 ( 4.35)
1 Liver 56 ( 2.54) 70 (3.16)
Uterus 25 ( 1.11) 13 ( 0.61)
Ovary 286 (12.85) 282 (12.72)
Adrenal 3.7 ( 0.17) 5.8 (0.26)
Figures in parenthesis represent percentage conversions.
was identical to that of the original "testosterone fraction". It was 
tentatively deduced, therefore, that the major metabolite in these 
incubations was testosterone. The admins tr at ion of 3-methylcholanthrene 
did not markedly influence the production of testosterone in any of the 
tissues studied.
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The second A^-3-oxo steroid metabolite found with adrenals, after
preliminary investigations, was considered to be possibly
11-hydroxyandros tenedione. The level produced by control adrenals
(39 x 10 dpm) was comparable to that found in 3-methylcholanthrene
3treated animals (48 x 10 dpm).
(iii) Effect of 3-methylcholanthrene and phenobarbital pretreatment
on androstenedione metabolism in the rabbit at midpregnancy.
Rabbits were sacrificed on day 23 of pregnancy, following either 
phenobarbital or 3-methylcholanthrene pretreatment. Microsomal 
preparations of placentae and maternal livers were processed and 
incubated according to the aromatization assay described in Materials 
and Methods. No evidence of oestrone or oestradiol-173 formation from 
androstenedione was obtained.
D. Aromatization in the full-term pig placenta
Microsomal pellets, prepared according to the aromatization assay, were 
collected from a portion (303 g) of pig placenta (2.9 kg) and stored at 
-10° for three days. Tissue (10.6 mg of protein) was incubated, as described 
in Materials and Methods, for up to 100 min. The progress of oestrone formation 
is shown in Fig. 5.42. The low rate of aromatization may reflect suboptimal 
incubation conditions, or may be a consequence of storage.
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SUMMARY
The potential of placentae from different species to aromatize androgens 
to oestrogens was determined, and characterized where possible. Using the 
assay procedure described in Materials and Methods, human placenta was found 
to readily convert androstenedione into oestrone. Alternate metabolic routes 
yielding oestradiol-173 were limited with stored microsomal preparations.
Marker enzymes suggested that aromatization was associated essentially with 
the microsomal fraction, though there was evidence for low activity with other 
particulate fractions. The ommision of nicotinomide from the homogenizing 
media markedly reduced the subsequent rate of aromatization, though the reaction 
remained linear for 60 min. The Mg++ requirement for optimal aromatization 
was 10 mM.
Aromatization was readily reduced in the presence of surfactants such 
as sodium deoxycholate, Triton WR-1339, lipase, papain or sonication. Deoxy- 
cholate treatment did solubilize extraneous microsomal protein which produced 
an increase in the rate of aromatization of 571 on a mg of protein basis.
The formation of oestrone was not influenced by the degradation of cytochrome 
P-450 to P-420, or by the apparent absence of cytochrome b^ . Exposure to 
CO up to 90! in the presence of 5! 0  ^did not uncouple oestrone synthesis.
Preliminary studies, which indicated that aniline, zoxazolamine and 
cytochrome c reduced androstenedione aromatization, also suggested that the 
existing reaction mixture was not suitable for inhibition studies. As a 
consequence, the incubate size was reduced by one half and the microsomal 
protein concentration maintained at 10 mg. A 10 min preincubation, in the 
absence of androstenedione, was introduced to generate NADPH and metabolize 
endogenous substrates. The primary incubation was reduced from 60 min to 
15 min, having previously dried androstenedione under N^ . The point at 
which the substrate was no longer the rate-limiting factor in aromatization 
was found to be dependent on the storage of microsomal preparations.
To minimize inter-placental differences in aromatization, the micro­
somal content of four full-term human placentae was collected, pooled and 
stored as 9 pellets at -15°. Lineweaver-Burk plots indicated differences
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in placental oestrone formation were not due to variations in Km but to 
Vmax* Once an homogenous enzyme preparation was attained, individual 
pellets were resuspended and the optimal incubation conditions redetermined;
• |*4*
a Mg requirement was no longer apparent. Loss of enzyme activity was 
greatest during the first two weeks of storage. Inhibition studies 
characterizing human placental aromatization were completed on the 
remaining microsomal preparations.
Inhibition studies (4.44 x 10  ^M) with classical inhibitors of hepatic 
drug-hydroxyl ating enzymes (SKF 525-A, DPEA, Lilly 18947, ethyl isocyanide), 
competitive inhibitors of these enzymes (imipramine, glutethimide, biphenyl, 
DDT, dieldrin, aldrin, endrin), inhibitors of steroid hydroxylation 
(spironolactone, B-methasone alcohol, metyrapone), and a chelating agent 
(a,a'-bipyrridyl) were without effect on the stored aromatizing system. 
However, inhibition did occur at this concentration (4.44 x 10"  ^M) with 
testosterone (89V), aminoglutethimide (62%) a desmolase inhibitor, and 
with the sulphydryl reagents p-hydroxymercuribenzoate (83%), iodoacetamide 
(22%) but not with B-mercaptoethylamine. Slight inhibition also occurred 
with the fatty acids, arachidonic acid (32%) and lauric acid (17%), and 
with EDTA (24%), iproniazid (33%) but not with tetracycline. Whereas 
androstenedione appeared to reduce benzo[a]pyrene hydroxylation, the latter 
did not influence aromatization.
Aromatization in the presence of metyrapone by freshly prepared human
placental 8,700 g.av. (10 min), 10,000 g.av. (20 min) and 105,000 g.av.
(60 min) supernatants and with microsomal preparations suggested no marked
-3inhibition in concentrations as high as 3 x 10 M. The mode of action 
was unclear, though there was evidence for enhanced conversion of testosterone 
to androstenedione, and inhibition of androstenedione to testosterone by the 
soluble fraction. Aromatization itself was not markedly influenced by 
metyrapone.
Attempts at binding androstenedione to its possible sites of metabolism 
using microsomal preparations were not successful. Only weak, non-specific 
binding was apparent.
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Maternal liver and placentae of full-term Wistar/albino rats were 
unable to aromatize androstenedione to oestrone in measurable amounts. 
Pretreatment with phenobarbital and 3-methylcholanthrene was without 
effect. Similar observations were noted with New Zealand white rabbits 
at mid-gestation and at full-term. The major metabolite of androstenedione 
with placental, ovarian, adrenal, uterine and hepatic homogenates was 
suggested to be testosterone.
Adrenal homogenates appeared to yield 11-hydroxyandros tenedione in 
readily detectable amounts. Pretreatment with 3-methylcholanthrene did , 
not influence these alternate routes of oxygenation.
Stored microsomal fractions of full-term placenta of sow demonstrated • 
a modest capacity to fom oestrone from androstenedione. The release of 
oestrogen proceeded linearly for 100 min.
Aromatization in the placenta, of human and pig, involves an 
oxygenation process, which is independent of cytochrome P-450, and has 
as yet to be solubilized. A variety of compounds were found not to alter 
the in vitro oestrogen synthesis indicating that biological oxygenation 
of steroids and drugs in different organs may involve different enzyme 
systems.
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Introduction
The liver microsomal enzyme system which catalyzes the co-hydroxylation 
of fatty acids (Lu and Coon, 1968; Coon and Lu, 1969; Lu et al, 1969;
Lu, Junk and Coon, 1969), has recently been obtained in a soluble form and 
resolved into three fractions, namely cytochrome P-450, NADPH-cytochrome P-450 
reductase, and a heat-stable component identified as phosphatidylcholine 
(Strobel et al, 1970). The reconstituted enzyme system was found to catalyze 
not only the w-hydroxylation of fatty acids but also demethylation of drugs; 
the latter resulting from the hydroxylation of N- or 0-methyl groups and 
the liberation of formaldehyde (Lu, Strobel and Coon, 1970).
The human placenta is a tissue active in lipid metabolism. It has 
been reported to contain all the enzymes necessary for the synthesis of fatty 
acids and triglycerides (Roux and Villee, 1960; Hosoya et al, 1960;
Kleine, 1967), and also is a source of foetal plasma phospholipids and perhaps 
other lipid compounds (Biezenski et al, 1971). However, little is known 
about the catabolism of lipids in the placenta and therefore investigations 
into placental w-hydroxylation of fatty acids were undertaken. It was further 
anticipated that such a study might elucidate the role of cytochrome P-450 in 
the placenta and whether, like hepatic cytochrome P-450, it is involved in 
the hydroxylation of fatty acids and the biotransfoimation of drugs.
Results
A. (d-Hydroxylation in the Wistar/albino rat at full-term
i) Subcellular distribution of the w-hydroxylase activity
(jo-Hydroxylase activity was investigated in particulate fractions 
of rat liver and placenta at full-term. Following homogenization of 
these tissues, the 600 g.av. (for 10 min.) supernatant and the 
microsomal and mitochondrial fractions were collected as for the steroid 
aromatization assay (page 49 ) and diluted to 1 mg protein/ml. 
Incubations of 1-^C lauric acid (0.4 ymol) were carried out according 
to the procedures described in Materials and Methods (page 88). 
■^C-Lauric acid was purified on silicic acid columns by eluting with 
benzene/ether (9:1 v/v) and collecting the first seven 2 ml fractions 
(page 89). Hydroxylated derivatives formed in the incubation
271
procedures were similarly collected in the next five fractions (2 ml) 
of benzene/ether (1:1 v/v) eluates (Lu, Junk and Coon, 1969) . Aliquots 
(0.2 ml) of each sample were removed for liquid scintillation counting, 
as for the aromatization assay (page 85), using a Packard Model 3320 
Tri-Carb (Gain = 16, Window = 40-1000). The elution pattern of 
/^C-lauric acid and its metabolites produced by liver are shown in 
Fig. 6.1.
Silicic acid chromatography of lipid extracts from incubation 
mixtures of ^C-lauric acid with liver reveals the presence of 
hydroxylated metabolites equivalent to 10-20% of the incubated substrate. 
Placental homogenate did not yield any radioactive material identical 
with the hydroxylated metabolites. Only ^C-lauric acid, unchanged, 
was eluted from the columns and it is concluded that no co-hydroxylation 
of lauric acid occurred on incubation with placental tissue fractions. 
Hepatic co-hydroxylase activity was associated with only the 600 g.av. 
supernatant and the sedimented microsomal preparations, each producing 
comparable amounts of metabolites. With placenta, neither these, nor 
the mitochondrial fraction, showed any co-hydroxylase activity, and the 
mean recovery of ^ C  as unchanged lauric acid was 94-100%.
ii) Effect of CO on hepatic microsomal co-hydroxylation
Freshly prepared hepatic microsomes were incubated in the presence 
of 50% (v/v) CO in air. Gassing of reaction mixtures was completed as 
described in Chapter Five (page 219), however, the CO/air was fed in 
and out of the test-tubes (10 ml) via syringe needles inserted through 
rubber bungs. Incubations, placed in an ice-bath, were preflushed 
for 15 min. with the gaseous mixture prior to a 30 min. incubation at 
37°. The elution patterns of ^C-lauric acid and its hydroxylated 
metabolites from the silicic acid columns, determined as the mean of 
triplicate incubations, are shown in Fig. 6.2. The yield of 
■^C-labelled metabolites was reduced by 45% in an atmosphere of 50% CO 
in air but not with 50% ^  in air.
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Fig. 6.1 Chromatography of qj-oxidation products in lauric acid produced
by rat liver subcellular fractions
Benzene/Ether (9:1 v/v) Benzene/Ether (1:1 V/v)
30-
10
Fraction nunher
•— — • = Hepatic 600 g.av. supernatant
*---- ▲ = Hepatic mitochondrial preparation
*— ---■ = Hepatic microsomal preparation
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Fig. 6.2 Effect of CO on hepatic microsomal oxidation of lauric
acid in the rat
Benzene/Ether (1:1 /v)Benzene/Ether (9:1 /v)
601
50-
1 40
§30-
*3
20-
Fraction nunber
•---- • = Control incubation
■ ■ = Incubation under ^ A i r  (1:1)
a— — -a = Incubation under CO:Air (1:1)
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B. (jo-Hydroxylation in the New Zealand White rabbit at full-term
i) Hepatic and placental w-hydroxylation
Hepatic and placental microsomal preparations were incubated as 
described in Materials and Methods. In Fig. 6.3 it was clear, 
following incubations of ^C-lauric acid with placental microsomal 
preparations, that no oxygenated derivatives were eluted from silicic 
acid columns. co-Hydroxylation of '^C-lauric acid is therefore not 
effected by placental microsomal enzymes.
ii) Effect of 3-methylcholanthrene administration on
oj-hydroxylation in steroidogenic tissues at full-term
w-Hydroxylation of lauric acid was examined in the placenta, 
liver, ovary, adrenal and uterus of control and 3-methylcholanthrene- 
treated rabbits. Aliquots (0.25 and 0.50 ml) of whole homogenates and, 
in the case of placenta and liver, microsomal preparations (10 mg 
protein/ml) were incubated with "^C-lauric acid as before. 
oo-Hydroxylation was detected only with hepatic preparations (Fig. 6.4) . 
Administration of 3-methylcholanthrene did not markedly alter the yield 
of oxygenated metabolites of ^C-lauric acid incubated with liver 
preparations. The recovery of ^C-lauric acid and its metabolites from 
these incubations, where a higher than normal protein level was employed, 
was however significantly reduced by 30-401.
C. (jj-Hydroxylation in the full-term human placenta
The capacity for lauric acid w-hydroxylation was examined in 
six full-term human placentae. Cytochrome P-450 was apparent in all 
samples, although these were of differing backgrounds regarding 
medication, cigarette smoking and race. Despite modification of the 
incubation conditions and the incubation of various subcellular fractions 
for up to 2 hours, it was not possible to detect u)-hydroxylation.
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Fig. 6.3 Chromatography of o>-oxidation products of lauric acid produced
by rabbit liver and placental microsomal preparations
Benzene/Ether (9:1 /v) Benzene/Ether (1:1 /v)
421 3 5 6 7
Fraction nunber
8 9 10 1211
Placental incubation 
Liver incubation
276
Ra
di
oa
ct
iv
it
y 
of 
Su
bs
tr
at
e
Fig* 6.4 Effect of 3-methylcholanthrene on hepatic microsomal oxidation
of lauric acid in the full-term rabbit
Benzene/Ether (1:1 /v)Benzene/Ether (9:1 /v)
30-
20-
10-
Fraction nunber
Control liver
3-methylcholanthrene treated liver
5 mg of microsomal 
protein incubated
277
Summary
Hepatic co-hydroxylation of lauric acid is mediated via a microsomal 
enzyme system involving cytochrome P-450. The subcellular site of activity 
(Fig. 6.1) and the CO sensitivity (Fig. 6.2) was demonstrated with the rat 
liver enzyme complex, co-Hydroxylation appeared to occur more readily in the 
presence of rabbit hepatic microsomal preparations (Fig. 6.3) than with those 
of rat. 3-Methylcholanthrene administration did not alter the yield of 
oxygenated derivatives, though increasing the concentration of rabbit enzyme 
in the incubation mixtures significantly reduced the recovery of labelled 
material (Fig. 6*4).
co-Hydroxylation was not detectable in any particulate fraction of 
placentae of rat, rabbit and human, though mitochrondrial and microsomal 
cytochrome P-450 was readily demonstrated in human placentae. The pretreatment 
with 3-methylcholanthrene did not induce measurable levels of w-hydroxylase 
activity in rabbit placenta, nor in the adrenals, ovary and uterus.
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CHAPTER 7
DISCUSSION
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One of the tenets of modem biochemistry is that the structure and 
function of any tissue is the end result of the activity of the enzymes 
contained in that tissue. These enzymes are a protein expression of genetic 
information contained in and transmitted by deoxyribonucleic acid, with 
modifications introduced by the process of cellular differentiation. From 
this proposition it is deduced that a complete and detailed understanding 
of the enzyme constituents of any tissue should lead directly to a complete 
and detailed understanding of the structure and function of that tissue.
Thus through the present studies of placental enzymology, it has been 
possible to gain an insight into the organ’s functions, particularly with 
regard to xenobiotics.
Since the important discovery of placental cytochrome P-450 (Meigs 
and Ryan, 1968) , studies have been undertaken to determine its biochemical 
function. As with the adrenal cortex and corpus luteum, the CO-binding 
haemoprotein was found to be in association with both the mitochondrial 
and microsomal preparations. The total cytochrome P-450 content of full- 
term human placenta was about one tenth those calculated by Harding et al 
(1964) for the adrenals and paralleled those reported for the corpus 
luteum (Yohro and Horie, 1967) . The human placental cytochrome P-450 
concentration in mitochondria was several times that found in microsomes, 
whereas the low content of rat placenta was associated only with the 
microsomes. Rabbit placenta exhibited an equal distribution between these 
two subcellular components.
The CO-binding pigment of human placenta may be identified with that 
of liver microsomes in its response to storage, its conversion to cytochrome 
P-420 by deoxycholate and its binding of metyrapone when previously reduced 
with dithionite. The presence of cytochrome b,. in placental particulate 
fractions was not apparent. However, Gillette et al (1972) question whether 
cytochrome b^ has a role in the oxygenation of drugs since a) antibodies 
against cytochrome b^ do not inhibit the metabolism of either aniline or 
aminopyrine, and b) in the presence of substrate the rate of cytochrome 
reduction by NADPH in liver microsomes is at least an order of magnitude 
faster than either the rate of cytochrome P-450 reduction in CO, or the 
rate of NADPH-oxidation in air.
280
The nature of rat and rabbit placental cytochrome P-450 was 
unclear since the CO-difference spectrum was ill-defined and not 
readily detectable. Similarly the administration of enzyme inducing 
agents produced conflicting results. In rat placental microsomes, the 
CO-binding pigment was apparent at full-term only after 3-methylchol­
anthrene pretreatment, yet human placentae exposed to polycylic hydro­
carbons from cigarette smoke did not show elevated haemoprotein levels.
In the rabbit, phenobarbital administration reduced both placental 
mitochondrial and microsomal cytochrome P-450 levels. This may be 
analagous to the diminished placental weight and drug-metabolizing 
activity observed occasionally following such pretreatment. Since 
concentrated particulate fractions were necessary to secure a CO-difference 
spectrum, the possibility that the spectrum represented only an artefact 
cannot be ruled out. Certainly the reduced ethyl isocyanide difference 
spectrum was most probably a consequence of binding to haemoglobin.
It is important to understand that the cytochrome P-450 concentrations 
quoted here are based on the original molar extinction coefficient as 
determined by Qmura and Sato (1964b). However, since the recent awareness 
of different types of cytochrome P-450-C0, a variety of new values, often 
conflicting, for each of these species have appeared (Gillette et al, 1972).
An indication of placental cytochrome P-450 function may have been 
obtained through spectral binding studies. Evidence of spectral binding 
is not however a prerequisite for metabolism, nor necessarily will 
metabolism follow binding. The failure to elicit spectral changes with 
placental cytochrome P-450 in the presence of a variety of substrates 
probably reflected the low content of the CO-binding haemoprotein, the 
presence of haemoglobin and the observation of Ullrich (1969) that not 
all cytochrome P-450 is available for substrate binding. Access of 
the substrate to the active site may possibly be impeded by a particular 
conformation which the placental membrane takes on as a consequence of 
homogenization. Such a phenomena would seem peculiar to the placenta.
The failure to bind drugs to placental cytochrome P-450 corresponded with 
the inability to bind fatty acids and steroids, and in particular 
andros tenedione.
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In comparison, rat testicular cytochrome P-450 was found only to 
be associated with microsomes (though a trace amount was located with the 
mitochondria from ferret testes) and represented only 3.31 of that of 
liver on a unit weight basis. This is in agreement with Machino et al 
(1969). Phenobarbital pretreatment, as in the placenta, did not increase 
the cytochrome P-450 content. Similarly, the only binding demonstrated, 
other than with CO, was the reduced metyrapone difference spectrum.
What might the function of cytochrome P-450 in the placenta 
therefore be? Since the organ has major metabolic capabilities with 
regard to endogenous substrates (Hagerman, 1964), it may also be expected
to metabolize foreign substrates. Because of its unique role as a
physical barrier between two genetically different individuals, and its 
purported function as an auxiliary foetal liver, the cytochrome P-450 
of placenta, unlike that of the adrenal cortex, may exhibit a low
substrate specificity accommodating drugs, steroids and fatty acids. It
had therefore become necessary to clearly define the drug-metabolizing 
capacity of the placenta, and investigate whether cytochrome P-450 has 
a role to play here.
Systematic studies of the biotransformation of xenobiotics in the 
placenta indicated an organ of diverse catalytic activity but the extent 
to which any one reaction was carried out was for the most part minimal.
The fungistat, biphenyl, was poorly hydroxylated in the placenta, testes 
and foetal liver as suggested by Creaven and Parke (1965). Placental 
biphenyl-4-hydroxylase activity was possibly associated with light micro­
somes since it could not be sedimented at 104,000 g.av. (60 min) or may 
genuinely be present in the soluble fraction. As the 4-hydroxylation 
of biphenyl in adult rat liver is inhibited by SKF-525A and a,a'-bipyrridyl 
and enhanced following phenobarbital induction, the reaction has been 
regarded as a typical drug-metabolizing enzyme which is possibly cytochrome 
P-450 mediated (Creaven, Parke and Williams, 1965).
Biphenyl-4-hydroxylase activity proceeded at a comparable rate in 
placentae of rats and humans but was not detectable in that of rabbits. 
Whereas phenobarbital and 3-methylcholanthrene markedly increased
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para-hydroxylation in the rat maternal liver, they slightly reduced 
the placental activity. Phenobarbital was also without effect on the 
rabbit placental system. The modest bipheny 1 -4-hydroxylase activity 
of human placenta appeared to marginally increase with the period of 
gestation. Foetal liver biphenyl hydroxylation in all three species 
was at least comparable to that of corresponding placentae.
Practical observations and the results of the dialysis experiment 
indicated that the human placental system responsible for biphenyl 
hydroxylation was gradually inactivated at 4° or lower. Protein 
denaturation also abolished activity. Dialysis of human placental 
microsomes did not enhance biphenyl hydroxylase activity. If the 
hypothesis that the higher affinity and high concentration of endogenous 
steroid substrates saturate the enzyme systems and prevents access of 
drugs to the enzyme site is correct , then clearly dialysis was insufficient 
to disrupt such binding.
Biphenyl-2-hydroxylase activity was apparent only with placentae 
from humans. Induction experiments with phenobarbital in the rabbit, 
and phenobarbital and 3-methylcholanthrene in the rat failed to stimulate 
placental biphenyl ortho-hydroxylation. In the liver, biphenyl 2- and 
4-hydroxylase activity are almost certainly mediated via separate enzymic 
pathways, the former paralleling more the systems involved in the 
oxygenation of polycyclic hydrocarbons.
: ' ! ;
In contrast to the studies of Dixon and Willson (1968) concerning
zoxazolamine metabolism in rabbit placenta, no such activity was detectable 
with human placental preparations. Juchau, Niswander and Yaffe (1968) 
studied zoxazolamine metabolism (largely aromatic hydroxylation) employing 
the whole homogenate and soluble fraction of human placental tissue 
obtained during therapeutic abortion at 9-12 weeks of gestation. Initial 
data obtained from disappearance of substrate did indicate the occurrence 
of zoxazolamine metabolism by placental homogenates. However it was 
subsequently shown that similar quantities of this substrate were not 
recoverable from incubation mixtures when they were incubated in the 
absence of cofactors or incubated with boiled homogenates. The experiments 
performed tended to indicate that zoxazolamine may bind strongly to
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proteins or other substances present in placental homogenates and thus 
were not fully recoverable by extraction procedures following incubation. 
Similarly, in the present study it was noted that the zoxazolamine 
recovered from placental incubations was less than with liver samples, 
but this may reflect differences in protein concentration. It is 
interesting to note that the quantities of zoxazolamine not recovered 
due to the binding effect per g per h reported by Juchau, Niswander and 
Yaffe (1968) closely approximates to the levels of metabolism reported 
for rabbit placenta. It is not known whether Dixon and Willson (1968) 
employed the standard zoxazolamine recovery assay for their investigations.
If this is the case, however, the low levels of activity noted were 
probably at the limit of sensitivity of the assay.
The advantage of recovery experiments, particularly when studying 
organs not noted for their detoxicating capacity, is that they may 
indicate unique routes of biotransformation leading to unusual metabolites. 
For this reason it can always be argued that using assay procedures, 
developed for liver enzymes, cannot be employed for other tissues simply 
because the mode of metabolism may be quite distinct.
Zoxazolamine hydroxylase is thought to closely resemble the enzymes 
which metabolize benzo[a]pyrene and 3-methyl-4-monomethylaminobenzene 
(Dixon and Willson, 1968) , since they are all inducible by polycyclic 
hydrocarbons. Subjects who provided placentae for the present study 
had no record of prolonged drug therapy or of cigarette smoking during 
pregnancy. This may account for the apparent deficiency in zoxazolamine 
metabolism since it exists only following enzyme induction.
In agreement with previous findings (Welch et al, 1969), benzo[a]pyrene 
hydroxylase activity appeared to be induced to readily detectable levels 
by cigarette smoking. From the brief study undertaken, there seemed an 
individual variation in the extent of enzymic induction, as also observed 
by Conney et al (1971). The inductive effect of polycyclic hydrocarbons 
inhaled in cigarette smoke may be further influenced by the period of 
gestation since no hydroxylation was apparent at 8-10 weeks irrespective 
of maternal smoking habits (Juchau, 1971). Schlede and Merker (1972) also
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found that benzo[a]pyrene induction of hydroxylase activity in the rat 
placenta was dependent on the age of the tissues, i.e. on the distribution 
of different cell populations and on the process of differentiation of 
these cell types. The administration of 3-methylcholanthrene to pregnant 
rats and rabbits in this study, surprisingly, stimulated benzo[a]pyrene 
hydroxylase activity only slightly and by no means to the levels observed 
in maternal liver.
Placental benzo[a]pyrene hydroxylase activity differs from that of 
liver in its subcellular distribution, being mainly associated with the 
1000 g (av.) (10 min) pellet rather than with microsomes. Cytochrome 
P-450 cannot, therefore, participate in the placental hydroxylation of 
benzo[a]pyrene as it does in the liver. The physiological significance 
of the placental hydroxylating system is questionable since its activity 
may readily be inhibited by steroids synthesized in the organ, including 
oestradiol-17$, oestrone and progesterone (Juchau, 1971), which are 
present in great abundance (DiczfaEhsy and Troen, 1961). Those substrates 
which serve for other mixed function oxidase systems, including steroid 
ring-A aromatization, exhibited comparatively minor inhibitory effects, 
though in this study the rate of hydroxylation of benzo[a]pyrene 
(0.792 pmol) in the human placenta was reduced by 471 in the presence 
of androstenedione (0.35 ymol). In contrast, the aromatization of 
androstenedione proceeded unaltered in the presence of benzo[a]pyrene. 
Conney et al (1971) reported that in vitro oestrogen biosynthesis was 
not subject to maternal smoking habits.
Gelboin and Weibel (1971) studied benzo[a]pyrene hydroxylase in 
cell culture and concluded it may be responsible for the activation of 
polycyclic hydrocarbons to cytotoxic or carcinogenic forms. Huberman 
et al (1971) reported a correlation between the cytotoxicity of 3-methyl­
cholanthrene and the production of its water soluble metabolites.
Schlede and Conney (1970) have suggested that inhibitors of polycyclic 
hydrocarbon-metabolizing systems may prevent the formation of carcinogenic 
metabolites of compounds like 7,12-dimethylbenz[a]anthracene; The 
inhibition of placental benzo[a]pyrene hydroxylase activity by steroids 
may therefore serve to prevent activation of polycyclic hydrocarbons to 
more toxic forms.
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There are several reports of placental N-demethylase activity, 
particularly following cigarette smoking (Welch et al, 1969) and 
phenobarbital pretreatment (Fahim et al, 1970; Bertd et al, 1969), but 
there is no evidence that it corresponds to the cytochrome P-450 
mediated systems of the liver. Modifications of the assay procedure j
of Holtzman et al (1968) failed to produce measurable rates of human 
placental ethylmoiphine N-demethylation. Since placental drug-metabolizing 
activity, in general, varied little over the period of gestation, the 
results may indicate that N-demethylation of ethylmorphine does not .
occur earlier in pregnancy. This is supported by the findings that 
rabbit placenta at mid-gestation was unable to N-demethylate ethylmorphine. 
The findings are also consistent with the knowledge that morphine-like 
drugs administered maternally during labour traverse the placentae in 
sufficient quantities to depress the breathing of the new bom child.
The lack of response of the rabbit placental N-demethylating 
system towards phenobarbital and 3-methylcholanthrene induction contrasted 
this dealkylation to others reported in the literature. Human placental 
N-demethylation was not detectable despite readily measurable levels 
of mitochondrial and microsomal cytochrome P-450.
The findings regarding rat placental JN-demethylation of £-chloro- 
N-methylaniline agree in part with those of Fahim et al (1970), though 
it was necessary to modify considerably the assay procedure of Kupfer 
and Bruggeman (1966). Despite differences in placentation, full-term 
human (haemo-chorial) and pig (epithelio-chorial) placentae were both 
deficient in N-demethylase activity. Pelkonen et al (1971b) found a ! 
modest rate of £-methylaniline ^ N-demethylation in human placentae from 
early gestation, whereas other workers were unable to demonstrate 
aminopyrine demethylation at 9-12 weeks and at full-term. In the liver, 
the metabolism of aminopyrine and N-methylaniline are probably mediated 
through separate pathways (Kato, 1966; Kato et al, 1969). The full- 
term human placenta may thus be largely deficient in both these systems. 
Analogous to the recent report of Pelkonen et al (1972), cigarette 
smoking did not promote placental N-demethylation of £-chloro-N-methyl- 
aniline. As ejected, however, the hepatic enzyme of rat is markedly 
stimulated by polycyclic hydrocarbons (Kato et al, 1969). The
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N-demethylation of p-chloro-N-methylaniline is inhibited by oestrogens 
in male rats, and to a lesser degree in female rats (Fahim, Hall and 
Jones, 1971). In this respect the position of placental benzo[a]pyrene 
hydroxylase and p-chloro-N-methy1aniline N-demethylase systems is 
comparable. It is also of interest that the placenta of rat was the 
only one of three species examined which exhibited N-demethylase 
activity but could not aromatize androgens to oestrogens.
These investigations, unlike the studies of Fahim et al, (1970), 
did not involve chronic phenobarbital pretreatment, which may explain 
the lack of induction of rat placental p-chloro-N-methylaniline 
N-demethylase activity. A 97V increase in microsomal protein per g 
wet weight placenta was, however, noted. This proliferation of endo­
plasmic reticulum was not associated with increased drug-metabolizing 
activity but rather countered by a reduction in pooled placental 
weight. At the phenobarbital doses employed, no gross foetal aberrations 
were observed as were in the studies of Fahim et al (1970). The effects 
of phenobarbital, therefore, appear to be related both to the period 
of gestation and to the dose administered (Pecile et al, 1968).
The N-dealkylation of p-chloro-N-methylaniline in rat testes 
proceeded at a rate comparable to that observed in placentae. It also 
was insensitive to enzyme induction. No proliferation of the endoplasmic 
reticulum was found after 3-methylcholanthrene or isosafrole treatment.
Chtsuji et al (1972) reported dissimilarities between hepatic O^- 
and N-demethylation reactions. Only O-dealkylation of codeine is 
reported to take place in the human placenta, and at 9-12 weeks of gestation 
this is at a minimum (Juchau, Niswander and Yaffe, 1968). Employing the 
sensitive assay procedure of Netter and Seidel (1964), no evidence for 
p-nitroanisole O-demethylase activity in the full-term placenta was 
found. This is despite one subject admitting to have smoked approximately 
20 cigarettes a day during pregnancy. The livers of foetal and newborn 
pigs exhibit only modest O-dealkylation which is insensitive to inducing 
agents (Short and Davis, 1970). This suggests, therefore, that the foeto- 
placental unit may possibly be susceptible to the effects of drugs such 
as phenacetin and codeine. Cytochrome P-450 was present in both human
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placentae which were deficient in O-demethylase activity.
In a comparative study, rat testes were shown to O-demethylate 
p-nitroanisole at modest rates (4.71 of that of liver/mg microsomal 
protein). Whereas phenobarbital caused a three fold increase in 
hepatic O-demethylation per mg microsomal protein, the testicular 
system was unchanged by this treatment and there was no proliferation 
of the endoplasmic reticulum. These observations could reflect the 
amount of barbiturate which reached the testes.
In accord with the studies of Van Petten et al (1968) and Juchau 
(1969), minimal reduction of p-nitrobenzoic acid was found to occur in 
the foeto-placental unit. On a unit weight basis, the rate of nitro- 
reduction exhibited by rat placenta was less than 101 of that found in 
maternal liver at full-term, though this ratio is dependent on the amount 
of flavin used. Nitroreduction occurred more readily, under the 
experimental conditions, with human placental preparations than with 
those from rat and rabbit, though the omission of FMN reduced the 
former*s activity the most.
The subcellular distribution studies in the rat indicated that 
placental nitroreductase activity was to be found associated with the 
soluble fraction. The modest rate of reduction was considered to be 
due to the apparent low concentration of G-6-P-dehydrogenase, and hence 
the inadequate provision of NADPH. However, such enzyme deficiency does 
not have unanimous acceptance. Measurements by Beaconfield et al (1964), 
Ginsburg and Jeacock (1964), and Sakurai et al (1969) showed that human 
placenta contains the hexose monophosphate shunt pathway of carbohydrate 
metabolism early in gestation and that its magnitude decreases as 
gestation proceeds. Whether the observed decrease is the result of 
reduced rates of biosynthesis, as the authors concluded, or is the cause 
of diminished biosynthesis or is simply one of many time-dependent 
variables observable in placental development, is as yet unknown.
However, the relevant two dehydrogenases of this pathway, phospho- 
gluconate dehydrogenase (Hagerman, 1969) and G-6-P-dehydrogenase (Betz 
and Warren, 1965) are reported to be present in extracts of human full- 
term placenta at concentrations nearly as high as occur in erythrocytes.
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These enzymes have been partially characterized, and the G-6-P-dehydrogenase 
of placenta is reported to be inhibited in vitro by a variety of steroid 
hormones at high concentrations.
Juchau (1972) indicated that placental homogenates contain relatively 
high concentrations of substrates for enzymes of the hexose monophosphate 
shunt pathway such that, by virtue of what is described as a highly active 
placental pathway, comparatively large quantities of NADPH can be generated 
or regenerated during the course of an in vitro incubation. Enhanced 
azo-linkage reduction was shown to depend entirely upon this mechanism:
NADPH + Neoprontosil— r—> NADP + sulphanilimide (spontaneous)
Thus through repeated recycling, large quantities of neoprontosil could 
be converted to sulphanilimide in placental tissues because of the high 
capacity of this organ to regenerate suitable reducing equivalents. In 
these studies, human placental soluble fraction has been used successfully 
as a G-6-P-dehydrogenase source to support steroid ring-A aromatization.
In repeating the work of Van Petten et al (1968), it was shown that 
the rat hepatic 105,000 g.av. (60 min) supernatant did indeed stimulate 
placental 10,000 g.av. (20 min) supernatant nitroreductase activity.
.However, in agreement with Fouts and Brodie (1957) and Kato, Oshima and 
Takanaka (1969), the hepatic soluble fraction was shown to readily reduce 
p-nitrobenzoic acid, and by the same amount in which the placental activity 
was enhanced. Curiously, Van Petten et al (1968) did not observe any 
nitroreduction with rat liver soluble fraction.
The mixing of a variety of placental and hepatic subcellular 
fractions indicated that the former was not devoid of a component which 
the latter could provide. The hepatic system for the reduction of 
aromatic nitro compounds appeared associated largely with the soluble 
fraction, whereas the microsomal routes, involving either cytochrome 
P-450 or cytochrome c reductase, were very much dependent on the NAD(P)H 
generating systems of the former. The possible inhibitory effect of 
placental 105,000 g.av. (60 min) supernatant on the nitroreductase 
activity of hepatic microsomes may have been due to haemoglobin bound
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O2, since Kato, Oshima and Takanaka (1969) have indicated that the 
microsomal reductases are the more sensitive. The influence of 
maternal liver 105,000 g.av. (60 min) supernatant on the foetal liver 
10,OCX) g.av. (20 min) supernatant incubation indicated that the latter 
was probably not deficient in G-6-P-dehydrogenase, which Pelkonen,
Arvela and Khrki (1971) also concluded (human foetal liver G-6-P- 
dehydrogenase was found to be the same or even higher than in adult 
liver of rat or human), but that the enzymes responsible for £-nitro- 
benzoic acid reduction are not sufficiently developed to utilize the 
NADPH made available. Thus as in the placenta, the full-term rat 
foetal liver may rely on the non-enzymatic route for the reduction 
of aromatic nitro groups, which would explain its lack of response to 
inducing agents. Pelkonen et al (1971a) suggested, however, that human 
foetal liver nitroreductase activity belongs to the same class of NADPH- 
dependent mixed function oxidases found in the livers of adult humans 
and animals.
It is improbable that the placental nitroreductase activity was in 
any way associated with cytochrome P-450, as it is, in part, in the liver. 
Juchau (1970) postulated that CO inhibition in the placenta might 
represent a chemical interaction with certain electron donors necessary 
for nitroreduction. Similarly, O2 is though: to reoxidize the reduced 
flavins and bring about autoxidation of the hydroxylamine intermediate.
A decrease in human placental nitroreduction with length of pregnancy 
may be due to the elevated blood content, and hence haemoglobin bound 
©2, which progressively inhibits the reaction (Juchau, 1970). Such a 
phenomena was also observed in this study. By contrast, the reverse 
findings were found with rat placenta. As yet this observation is not 
understood. Possible explanations are a) the rat placenta is more 
intimately associated with the endometrium such that no marked changes 
in blood content late in gestation occur, b) the flavin content may 
increase in the rat placenta corresponding with the period of maximal 
foetal growth, c) intensified hexose monophosphate shunt activity as 
gestation progresses and therefore elevated dehydrogenase activity, 
d) an increase of the protein-bound heat stable intermediate, necessary 
for placental nitroreduction, towards full-term.
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Pregnancy may reduce the capacity of the rat maternal liver to 
reduce £-nitrobenzoic acid to its amino analogue, but the effect 
appeared to be only a marginal one. The situation regarding the rabbit 
system was less clear, except that nitroreduction appeared to occur 
more readily than in rat liver. Similarly, following phenobarbital 
pretreatment, the rabbit foetal liver at full-term exhibited active 
nitroreductase activity. Although aromatic nitro compounds are rarely 
used as drugs, a variety of aromatic hydroxyamino compounds are 
recognized as proximate carcinogens which clearly require detoxicating.
It is well established that the placenta is active in hydrolyzing 
glucuronide conjugates. Contractor and Shane (1972) indicated that the 
placenta has no part in the increase in plasma $-glucuronidase levels 
observed during pregnancy. Therefore, what may the function of this 
enzyme be in the placenta? Clearly, such hydrolytic reactions are 
utilized to release conjugated steroid precursors for its own biosyntheses. 
Steroids are, however, inducers of this enzyme, and therefore possibly 
the hydrolytic activity is maintained at a maximum. If the hydrophilic 
steroid glucuronides are capable of entering placental cells for 
subsequent hydrolysis, then it is not unreasonable to assume that xeno- 
biotic conjugates might also undergo the same reaction. The release of 
phenolphthalein from its glucuronide indicated a low substrate specificity. 
The fate of liberated xenobiotics in the placenta is unknown. They may 
undergo limited phase I or II metabolism, though as will be indicated 
the placental capacity for glucuronidation is very limited. Alternately, 
by virtue of the probable increase in the hydrophobic nature and the 
diminished molecular weight, the xenobiotic may permeate through the 
placenta. Drug metabolites have been found in the foetal circulation 
(Moya and Thorndike, 1962) and they would appear unlikely to be derived 
from foetal origin.
The foetus is also active in hydrolysing glucuronides but not in 
forming them. Since the placenta is impervious to glucuronides, then 
foetal 3-glucuronidase activity is unlikely to be primarily concerned 
with the release of precursors, but possibly concerned with the 
degradation of oligosaccharides or the provision of ascorbic acid.
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The placental enzyme also probably shares other functions. As the
3-glucuronidase activity declines in the developing mouse neonate, this 
may reflect involvement in special processes associated with rapid 
developmental growth.
The function of placental 3-glucuronidase cannot be fully clarified 
until its subcellular distribution has been agreed upon. When considering 
the prospect of the placenta releasing potentially toxic aglycones into 
the foetal circulation, the intracellular source of the enzyme is of 
some inportance. If the lysosomal theory is correct, it is possible that 
glucuronides would not normally be available substrates for such intra­
cellular scavengers. The findings in this brief study together with 
those of Contractor and Shane (1972) would, however, indicate large 
quantities of 3-glucuronidase activity in association with the endoplasmic 
reticulum and cytosol. Under these circumstances, the penetration of 
glucuronides into placental cells would result in almost immediate 
hydrolysis. Nevertheless, since the pH optimum of this enzyme is very 
much in the acid region, under normal physiological pH the reaction would 
be inhibited. This could be interpreted to imply the existence of a 
micro environment where such an acid pH could, for a transient period, 
be maintained. The hydrolytic enzymes of lysosomal particles all exhibit 
acid pH optima and it is perhaps easier to conceive a pocket of endo­
plasmic reticulum maintaining the necessary acid conditions for hydrolysis. 
This kind of speculation could most satisfactorily be resolved with the 
aid of perfusion studies. By exposing the maternal surface of the 
placenta to a perfusion media containing conjugated xenobiotics, the 
possible release of aglycones into the foetal circulation could be 
monitored. Any physiological significance from a study of this nature 
would then be readily apparent.
As previously indicated, placental particulate fractions exhibited 
minimal UDP-glucuronyl transferase activity. The transfer of the glucuronic 
acid moiety of UDPGA to 4-methylunibelliferone did not occur spontaneously, 
nor in the presence of boiled placental 10,000 g.av. (20 min) supernatant. 
The incubation of a whole homogenate of rat placenta, if anything, 
marginally reduced conjugation suggesting that the component(s) responsible
292
for the reaction was not associated with nuclear or mitochondrial 
particles. Since UDPGA is incorporated in the reaction mixture, a 
deficiency of UDP-glucose dehydrogenase would not influence the 
measurement of UDP-glucuronyl transferase activity (Brown et al,
1958 claim UDPG dehydrognase is present in human placenta). However, 
the presence of an active 3-glucuronidase enzyme or the presence of 
competitive substrates might interfere with measurements of glucuronide 
formation. Hagerman (1969) indicated that placenta is an abundant 
source of 3-glucuronidase activity, though the pH optima would be very 
different from that of UDP-glucuronyl transferases. Similarly Hsia 
et al (1963) reported the in vitro inhibition by steroids of UDP- 
glucuronyl transferase activity. Despite these factors, the use of a 
fluorescent substrate provided an assay of high sensitivity.
Studies with rat placenta suggested that increasing amounts of 
UDP-glucuronyl transferase activity became available with progression 
of the gestation. This pattern conflicts with that observed by Bertd 
et al (1969) who found rabbit placental glucuronidation of oxazepam 
highest at day 14 of gestation. This may be a species difference. The 
same group of workers were able to induce conjugation with subcutaneous 
administration of phenobarbital, as was also the case with 4-methylumbelliferone 
conjugation in rabbit placenta in this study. By contrast, rat placental 
activity was diminished by such pretreatment. Therefore in this respect, 
the rabbit placental UDP-glucuronyl transferase activity was more akin to 
that of liver than was that of rat placenta, though the latter was more 
active on a unit weight basis. The rat foetal liver UDP-glucuronyl 
transferase activity was also unusually high at full-term (Dutton, 1966).
Foetal livers of all species examined exhibited considerably 
higher, or at least comparable, UDP-glucuronyl transferase activity to 
that found in the placentae of the corresponding animals. In the rat, 
for example, foetal liver conjugation occurred at a rate over thirteen 
fold that observed in placenta on a unit weight basis. Dutton (1959) 
demonstrated that at pH 7 or above, glucuronides were not more rapidly 
attacked in perinatal liver homogenates than in similar homogenates of 
foetal liver, despite the higher 3-glucuronidase activity there. The 
human foetal liver activity was the lowest, but the observations were 
recorded at relatively earlier stages of pregnancy. The values for
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conjugation suggested there may be a gestational pattern. The relatively 
high rate of 4-methylumbelliferone glucuronide formation in the rat 
foetal liver at full-term could not be stimulated with 3-methylcholanthrene 
or phenobarbital pretreatment. This was also the case with the placental 
system. Thus the hope that phenobarbital might, in part, stimulate 
glucuronide formation in the foeto-placental unit and thereby reduce 
bilirubin levels in the blood, hence preventing kemicterus, could be 
unfounded. However, it has already been indicated that the rat responds 
differently to enzyme inducers when compared to the rabbit, and therefore 
the human foeto-placental unit may also respond in a separate way.
Though the rate of foetal liver UDP-glucuronyl transferase is greater 
than that observed in the placenta, it does not nearly approach that of 
the maternal liver. In the rat, on a g wet weight basis, the reaction in 
foetal liver proceeded at only about 6-81 of that observed in the mother, 
and the total capacity for forming the glucuronide was only approximately 
1%. However, at full-term the foetal liver was capable of synthesizing 
4-methylumbelliferorie glucuronide at 401 the rate of the 5 day old neonate 
(Basu, Dickerson and Parke, 1971). In the phenobarbital-treated rabbit, 
the rates of glucuronide formation in the foetal and maternal livers at 
full-term were comparable. The position of the basal state is unknown, 
though it might be considered that foetal liver would respond more markedly 
to enzyme induction. The finding that the human foetus cannot effectively 
conjugate a foreign compound with glucuronic acid is comparable to studies 
using bilirubin (Dutton, 1966).
It is held that during pregnancy the elevated levels of steroid 
hormones may extend the glucuronic acid corij ugating capacity of the 
mother. Neale (1970) demonstrated that the UDP-glucuronyl transferase 
activity per unit weight decreased with increasing gestation. There was 
also a simultaneous increase in liver weight. The consequences of these 
two effects was that the overall capacity of the animal to conjugate 
with glucuronic acid was not markedly altered. The increased levels 
of steroid hormones present during pregnancy means, however, that the 
mother may not effectively cope with a sudden influx of exogenous 
substances which require conjugating, e.g. as may occur during drug 
therapy. It may therefore be possible to overload the organism’s 
capacity for glucuronide conjugation.
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In this study, the ability of the rat maternal liver to form
4-methylumbelliferone glucuronide, on a unit weight basis, was indeed 
found to decline towards full-term. The total capacity of liver for 
glucuronide conjugation was not markedly changed. In the rabbit, 
insufficient data was available to draw any conclusions. The administration 
of enzyme inducers considerably elevated rat UDP-glucuronyl transferase 
activity but was less effective in the rabbit. 3-Methylcholanthrene 
appeared to stimulate conjugation to a greater extent than was observed 
with phenobarbital. One possible explanation for this might be differences 
in the rate of metabolism of these compounds to their inactive metabolites.
The modest levels of placental and foetal liver UDP-glucuronyl 
transferase activity observed in the Study supports the theory that such 
a capacity would be deleterious to the developing organism, in as much 
as harmful glucuronides would tend to accumulate to toxic proportions in 
the foetal circulation.
The in vitro studies discussed here clearly establish the presence 
of placental detoxicating mechanisms, though the nature and rates of 
reaction differ considerably from those of liver. From investigations 
cited in the literature and those reported here, placental cytochrome 
P-450 does not mediate in the metabolism of drugs. Its role may therefore 
be restricted to the metabolism of endogenous substrates as in the adrenals, 
and perhaps also testes. This may be due to the manner in which the 
haemoprotein is associated with the microsomal and mitochondrial membranes, 
or differences in individual components of the monooxygenase system or 
perhaps even due to separate species of cytochrome P-450.
It has been argued that the low placental drug metabolism is possibly 
a consequence of the modest cytochrome P-450 content. This must depend 
to a large degree on the relative affinity of the xenobiotic for the 
enzyme site. Dialysis of placental microsomes did not enhance biphenyl-
4-hydroxylation suggesting possibly that saturation of the enzyme sites 
by, for example, steroids exhibiting a higher affinity and present in 
greater concentrations, is not valid. Indeed it is clear that for the 
ubiquitous benzo[a]pyrene hydroxylase system of extra-hepatic tissues, 
including the placenta, cytochrome P-450 is not involved in the oxygenation. 
It may even give rise to carcinogenic metabolites.
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Gillette et al (1972) reported that "since drugs have widely 
different structures, it is not surprising that virtually every enzyme 
in the body may be considered as a drug-metabolizing enzyme". This 
statement perhaps characterizes extra-hepatic sites of detoxication 
being well demonstrated by the placental nitroreductase system. The 
liver, in contrast, has developed a highly organized and sophisticated 
system for the biotransformation of xenobiotics in readiness for their 
excretion. These differences may account for the individual responses 
observed with enzyme inducing agents. Though not readily demonstrable 
in the placenta, with the exception of the benzo [a]pyrene hydroxylase 
system, extra-hepatic tissues seem to respond more to induction with 
polycyclic hydrocarbons than to barbiturates. This may be related to 
a steroid-like configuration seen with polycyclic hydrocarbons such as 
3-methylcholanthrene. However, phenobarbital pretreatment was found 
to increase the microsomal protein content of placenta, but no parallel 
increase in £-chloro-N-methylaniline N-demethylase activity was noted. 
Similarly enzyme inducing agents do not appear to influence steroid 
ring-A aromatization.
It was originally postulated that placental detoxication might be
at a maximum during the first trimester when the embryo was most
susceptible to the effects of drugs. This has since been disproved, 
and most drug-metabolising activity reaches a peak at full-term.
The latter is subject, however, to steroid concentrations which tend 
to inhibit detoxication. It has since been indicated, however, that 
placental drug-metabolism may be disadvantageous as it would tend to 
concentrate metabolites to toxic levels in the foetus. The latter was 
shown to possess a low but comparable drug-metabolizing activity to 
that of the placenta, but in contrast, the foetal hepatic cytochrome P-450 
could be induced by phenobarbital. The foetus late in gestation may 
therefore have an equal capacity to metabolize drugs as the placenta.
The brief study of maternal liver detoxication processes during 
pregnancy indicated the overall capacity was not greatly impaired.
In summarizing the drug metabolism studies, one can assess the 
role of the placenta in the aetiology of foetal toxicity. The majority
of anutrients to which pregnant women are exposed are taken in by 
ingestion. Not all will be absorbed from the gastro-intestinal tract,
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and those which are will be converted in the main by the liver, into 
less toxic, hydrophilic metabolites which can be readily excreted. The 
concentration of a drug (or its metabolites) reaching the placenta 
depends on its plasma half-life, and the percentage capable of penetrating 
the placenta depends on the physico-chemical factors discussed in 
Chapter 1. Placental detoxication may occur during diffusion. However 
drugs can disrupt foeto-placental homoestasis by influencing placental 
function, e.g. serotonin and trypan blue reduce placental blood flow.
The placenta possesses no organized nerve elements. Thus the final 
concentration to which the foetus is finally exposed to may in many 
cases be quite low. To exert a pharmacological effect, however, the 
drug receptor sites need to be sufficiently developed to elicit a 
response. At the same time, the foetus exhibits a limited capacity for 
detoxication, and this may conceivably be induced by a toxic build-up 
of drug. With regard to barbiturates, the inducibility of the compound 
appears to be very much dependent on its plasma half-life.
In order to further characterize placental oxygenases, particularly 
those involving cytochrome P-450, the hydroxylation of several endogenous 
substrates was examined. Meigs and Ryan (1968) indicated mitochondrial 
cytochrome P-450 might participate in cholesterol side-chain cleavage, 
a metabolic route unlike that of ovaries and testes which is not subject 
to gonadotrophic regulation (Macome et al, 1972). The identification 
of Billiar and Little (1969) of an andrenodoxin-like substance from
■ I
human placental mitochondria, capable of supporting steroid 113-hydroxy- 
lation in the adrenals, substantiates this hypothesis. Since experimentally 
microsomal cytochrome P-450 is difficult to detect, it was proposed to 
quantitatively determine a reaction in which it is involved and use it 
as a measure of placental hydroxylating activity. It was therefore 
decided to investigate the aromatization of ring A of androgens involved 
in oestrogen biosynthesis.
In agreement with the literature, the human placenta readily 
aromatizes androstenedione to oestrogens. The assignment of the intracellular 
localization of the placental enzymes involved in steroidogenesis and other 
biochemical reactions has usually been made on the basis of methods of 1 
differential centrifugation originally developed for other organs and
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applied to the placenta without the necessary ultras true tural documentation. 
Thus as with the findings of Aleem et al (1970), subcellular fractions 
of human placenta which were satisfactorily homogenous were not obtained. 
However, a bimodal distribution of microsomal and mitochondrial (including 
lysosomal) aromatizing activity has been proposed (Aleem et al, 1970).
The present results generally agree with this suggestion. The mitochondrial 
aromatization was found to reside largely with the lysosomal fraction.
Aleem et al (1970) believe that if all the aromatizing activity associated 
with the mitochondrial fraction were due to microsomal contamination, 
repeated washing would be ejected to decrease aromatization. in the same 
proportion as the glucose-6-phosphatase activity used as a microsomal 
marker. Such was not the case in their studies nor in this. However, 
the centrifugation pattern must depend on the effectiveness of tissue 
disruption to produce homogenous subcellular fractions of discrete and 
well-defined particle size. Clearly, where there is considerable 
connective tissue to contend with, as in the human placenta, this cannot 
always be achieved. Nevertheless, irrespective of the subcellular 
distribution of the aromatizing complex, the microsomes were found to 
be a major site of such activity.
The major metabolite of androstenedione with human placental 
preparations was oestrone, there normally being less amounts of 
oestradiol-173 and the C-19 oxygenated intermediates. Macome et al 
(1972) suggest that the different ratios of these metabolites quoted 
in the literature stems from differences in experimental conditions.
The inclusion of nicotinamide in the homogenizing media appeared 
necessary to prevent marked losses of NADP by pyridine nucleotidase 
activity. When the conventional in vitro assay conditions were employed, 
a Mg++ requirement of 10 mM was found optimal in agreement with Hollander 
and Hollander (1960). However, when the incubation size was reduced for
*4*"^
kinetic studies, Mg was no longer found necessary, possibly as a 
consequence of using a stored enzyme preparation or the new cofactor 
conditions.
The aromatization of neutral steroids to oestrogens is a complex 
conversion involving both demethylation and desaturation via a multistep
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reaction sequence. Probably for this latter reason it has proved 
impossible to bring the system into solution. Even employing 
sonication, the only method reported to effect a partial solubilization 
(Hollander and Hollander, 1960), did not work. The procedure of 
Gaylor and Mason (1968) for solubilizing an oxidative sterol demethyl- 
ating system of liver, a non-cytochrome P-450 mediated reaction, did 
not bring the aromatization complex into solution. The deoxycholate 
treatment did effect a purification, however, by solubilizing extraneous 
lipid and protein. Aromatization was found to proceed in the absence 
of detectable levels of cytochrome P-450 and bg, but in the presence 
of cytochrome P-420. Agents such as Triton WR-1339, lipase and 
papain did not solubilize the aromatizing complex, and sonication was 
found only to release microsomally bound haemoglobin.
Incubations of human placental microsomes with androstenedione 
in the presence of up to 901. CO, when that of O2 was maintained at 5%, 
indicated that the overall aromatization sequence in vitro was CO 
insensitive and that cytochrome P-450 was unlikely to be involved in 
the rate limiting step. More recently, Meigs and Ryan (1971) have 
put forward evidence for three mixed function oxidases active in 
steroid aromatization, one of which may be a form of cytochrome P-450.
The aromatization of androstenedione and 19-hydroxyandrostenedione 
were partially inhibited in the presence of limiting O2 (5%), while that 
of 19-oxoandrostenedione was not. The inclusion of CO in these reactions 
did not alter aromatization. In contrast, the aromatization of 19-nor- 
androstenedione and 1,4-androstadienedione were both found to be CO 
sensitive, as was hydroxylation of ring A of the former. It may be 
argued, however, that the aromatization of C^g and C^g steroids may be 
distinct metabolic processes and share no common mechanism or catalyst. 
This is supported by the fact that the enzyme system which aromatizes 
testosterone is not involved in the aromatization of epitestosterone 
(Horn and Finkelstein, 1971) .
The association of aromatizing activity with crude lysosomal 
fraction suggested the possibility of peroxisome participation. Jocelyn 
(1970) has shown that the oxidation of glutathione could be linked to 
xanthine oxidase and urate oxidase activity, in conjunction with that of
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glutathione peroxidase. Such a mechanism seems unlikely in aromatization 
since cannot replace NADPH, and neither catalase or cyanide has any 
effect in vitro. It would also be necessary to postulate a substrate 
for an oxidase linked to the "aromatization peroxidase" which is normally 
present in placental incubates as an source.
Preliminary studies in the presence of aniline, zoxazolamine and 
cytochrome c indicated inhibition of androstenedione aromatization. 
Hatakeyama et al (1971) reported a considerable depletion of steroidogenic 
enzymes in the corpora lutea of rats following aniline pretreatment. The 
nature of the inhibition with placental microsomal preparations could 
not be ascertained using the conventional steroid incubation of large 
volume. For this reason a new set of incubation conditions were 
developed to further control the experimental situation. However, 
considerable interplacental differences in aromatization were still 
apparent, probably as a consequence of differences in storage, and of 
the genetic and environmental backgrounds. Thus to still further control 
the experimental situation, it became necessary to collect a sufficient 
quantity of the stored enzyme preparation to enable optimal cofactor 
conditions to be determined, before inhibition studies were undertaken 
on the same homogenous fraction. This allowed valid comparisons to be 
drawn between different experiments. Storage of human placental micro- 
somes did not appear to significantly alter the overall Km, which was 
consistently very close to the origin of the axes on a Lineweaver-Burk 
plot, and the Vmax appeared to be effected mainly by the source of 
placentae. The loss of aromatization during the first two weeks of 
storage at -18° was untypically high.
The presence of thiol groups would appear important for the 
aromatization of androstenedione since both p-hydroxymercuribenzoate 
and iodoacetamide inhibit activity, though 3-mercaptoethylamine was 
without effect. p-Hydroxymercuribenzoate was the second most effective 
inhibitor studied and this may be related to its wider spectrum of 
activity, since it can also cause structural damage of enzymes by, for 
example, causing dissociation. Though a,a'-bipyrridyl is a strong 
iron and zinc chelating agent, capable of uncoupling many haem and 
non-haem iron mediated reactions, it was without effect on aromatization.
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In contrast to the work of Ryan (1959), EDTA was found to reduce the 
rate of oestrone synthesis by 24! presumably due to its wider chelating 
properties. The lack of inhibition in the presence of ethyl isocyanide 
strongly indicated no cytochrome P-450 involvement in androstenedione 
aromatization.
Testosterone was utilized as a positive control in these experiments 
and as to be expected was a most potent competitive inhibitor. A number 
of xenobiotic substrates which the hepatic monooxygenase system can 
detoxicate were found not to interact with in vitro oestrogen biosynthesis.
The potentially competitive substrates included benzO[a]pyrene, betamethosone, 
DDT, dieldrin, endrin, aldrin, tetracycline, spironolactone, glutethimide, 
imipramine and biphenyl. Differences between the hepatic and placental 
mixed function oxygenases were further apparent when classical inhibitors 
such as SKF525A, DPEA and Lilly 18947, which competitively inhibit both 
the hydroxylation of drugs, steroids and fatty acids in the liver, did 
not modify the rate of androstenedione aromatization.
The majority of these competitive inhibitors normally act upon the 
hepatic terminal oxygenase, cytochrome P-450. The steroid inducer, 
spironolactone, exhibits a biphasic effect, first causing inhibition as 
it blocks the active site of cytochrome P-450, and then causing de novo 
synthesis of new haemoprotein. Spencer (1972) found that oestradiol-173 
and benzo[a] pyrene inhibited each others hydroxylation by competition 
for cytochrome P-450. However, following benzanthracene treatment, 
oestradiol-173 was largely without inhibitory effects since unlike 
benzo[a]pyrene, it could not interact with the newly induced cytochrome 
P-448. Pesticides like those employed in these studies also interact 
with cytochrome P-450 forming type I binding spectra (Mailman and 
Hodgson, 1972). The failure to elicit binding spectra with placental 
cytochrome P-450 using xenobiotic substrates may explain the present 
findings, though it was anticipated that endogenous steroids would bind.
Aminoglutethimide inhibits C-20 hydroxylation in the adrenals, a 
reaction mediated via mitochondrial cytochrome P-450. The mechanism 
of this inhibition could be that the non-polar molecule has some 
stereo-specific similarity, probably residing in the ethyl glutarimide
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portion, with the hydrophobic portion of the cholesterol molecule which 
is normally bound by the 20-hydroxyoxygenase. The presence of an amino 
group may enhance the fit between the enzyme and inhibitor, through 
electrical interaction or salt formation, and may account for the 
difference in potency between aminoglutethimide and glutethimide. This 
may also be related to the fact that aminogluthimide binds cytochrome 
P-450 in the type II position wheieas glutethimide elicits an essentially 
type I spectrum. The 621 inhibition of aromatization in the presence 
of aminoglutethimide may implicate a role for cytochrome P-450, though 
this is contrary to most available information.
Iproniazid is a monoamine oxidase inhibitor though originally 
intended as an anti-tubercular drug. It was investigated as an inhibitor 
of non-microsomal drug metabolism. Further studies are necessary to 
clarify the mode of action of iproniazid on androstenedione aromatization.
It is well documented that metyrapone uncouples drug and steroid 
hydroxylations by interacting at the site of substrate binding to 
cytochrome P-450 (Kahl and Netter, 1970). Giles and Griffiths (1964) 
found the conversion of testosterone to oestrone by human placental 
8,700 g.av. (10 min) supernatant was markedly inhibited by metyrapone 
and suggested the site of uncoupling was 19-hydroxylation. The present 
studies indicated, however, that high concentrations of metyrapone 
exerted only a marginal effect on aromatization. Since metyrapone was 
bound by placental cytochrome P-450, this was interpreted as further 
evidence that the latter was not involved in this reaction. Isurugi 
et al (1971) found the placental soluble fraction contained activity of 
the 17$-hydroxysteroid dehydrogenase which specifically converted 
oestrone into oestradiol-17$, whereas the microsomal preparation was 
practically deficient in this enzyme activity. The microsomal fraction, 
however, retained the 17$-hydroxysteroid dehydrogenase which catalyzed 
the oxido-reduction between androstenedione and testosterone. From 
the present investigation, it might be postulated that metyrapone does 
not influence the activity of the aromatization complex but rather 
that of 173-hydroxysteroid dehydrogenase, effecting in particular the 
interconversion of androstenedione with testosterone. The effects of 
metyrapone may be related to gestational period since the 176-hydroxy- 
steroid dehydrogenase activity increases towards full-term (Sybulski, 1970).
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Little is known of lipid metabolism in the placenta, and therefore 
the inhibitory effects of lauric acid and arachidonic acid on steroid 
ring-A aromatization is of some interest. In the liver, lauric acid 
undergoes aj-hydro:xylation by a cytochrome P-450 mediated mixed function 
oxidase reaction also involved in the oxygenation of drugs and steroids. 
Verkade (1938) proposed co-oxidation, followed by 3-oxidation to give 
shorter chain dicarboxylic acids, as an alternative pathway to the direct 
3-oxidation of fatty acids. Robertson et al (1971) have recently shown 
that, concomitant with the high levels of free fatty acids, the human 
placenta can oxidize such compounds extensively. This activity was not 
influenced by oestradiol-173, oestriol, progesterone or DDT, but was 
inhibited in the presence of polychlorinated biphenyls. Using the 
assay procedure of Lu, Junk and Coon (1969), w-hydroxyl at ion of lauric 
acid was not apparent in placentae from rats, rabbits and humans.
Orrenius (personal communication) believes co-hydroxylation may occur 
in the rabbit placenta but this was not borne out by these studies, 
even when animals were pretreated with 3-methylcholanthrene. Similarly 
no such activity was present in rabbit adrenals, ovaries and uterus.
It was anticipated that placental oi-hydroxylation might take a 
form similar to that of rat kidney cortex microsomes which involves 
cytochrome P-454 (Jakobsson et al, 1970). In contrast to the hepatic 
w-hydroxylase system, that of kidney cortex microsomes catalyzes the 
oxidative demethylation of aminopyrine at a very slow rate and reveals 
no measurable testosterone hydroxylating activity. Whereas laurate 
gives rise to a type I spectral change when added to either kidney 
cortex or liver microsomes, testosterone produces a type II spectral 
change with kidney cortex microsomes. There exists further dissimilarities 
in substrate specificity as well as in response to enzyme inducing 
agents. Since placental cytochrome P-450 appeared not to participate 
in the hydroxylation of drugs, it may have been involved in fatty acid 
w-hydroxylation.
How might fatty acids therefore inhibit placental androstenedione 
aromatization? It would seem unlikely that neutral steroids and fatty 
acids might compete for the same enzyme site because of the low substrate
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specificity required. Similarly it is not known how lauric acid might 
call upon the reducing equivalents of NADPH other than by undergoing 
ou-hydroxylation. The inhibitory effects of the fatty acid may 
therefore have resulted from its slight surface-acting properties 
disturbing the integrity of the endoplasmic reticulum or even due 
to a pH effect.
One of the predominating free fatty acids in the placenta is 
arachidonic acid (Robertson et al, 1971). This is a precursor of 
the prostaglandin PGf^ . Prostaglandins are readily diversified 
through mono- and dioxygenases, and it has recently been suggested 
that the placenta may be a site of such biosynthesis (Jarabak, 1972). 
Arachidonic acid reduced the rate of aromatization by 32%, compared 
'to. 17% with lauric acid. The mode of inhibition may be the same 
as that of the latter, or reflects a separate mixed function oxidase 
reaction also utilizing NADPH.
In agreement with the studies of Rembiesa et al (1972) and 
Sybulski (1970), rat placenta was deficient in steroid ring-A aromatization 
activity suggesting it cannot take over the endocrine functions of the 
ovaries. There is evidence, however, that the rat placenta may provide 
the ovaries with oestrogen precursors. The synthesis of oestrogens 
was not detectable in placenta of rabbit, even following pretreatment 
with phenobarbital and 3-methylcholanthrene. Conney et al (1971) 
reported human placental steroid ring-A aromatization was not elevated 
in placentae from cigarette smoking mothers.
To conclude, the present study has clarified our understanding of 
placental function. Clearly the placentae of those species examined 
exhibit minimal drug-metabolizing activity and can therefore provide 
little protection for the foetus by their detoxicating mechanisms alone.
It is questionable, however, whether the existence of placental drug- 
metabolizing activity would be beneficial to the foetus; it could even 
lead to a selective accumulation of xenobiotic metabolites in the 
foetus and foetal fluids. In pregnancy, the total detoxicating capacity 
of the maternal liver does not appear to be significantly depressed, 
and similarly, the foetus has been shown to possess a certain ability
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to cope with toxic anutrients; so there is no dire need for another 
detoxicating system to protect the foetus. The placental mixed function 
oxidase system associated with cytochrome P-450 appears to function, 
as in other steroidogenic organs, only with the metabolism of endogenous 
substrates, most probably steroids. It appears not to participate in 
the aromatization of ring A of androstenedione or in the oa-hydroxylation 
of lauric acid. Though certain placental functions may be susceptible 
to the pharmacological and toxicological effects of xenobiotics, the 
steroid aromatizing system appears to be remarkably resilient to 
interference by such agents.
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